etoposide has been researched along with mitoxantrone in 593 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 36 (6.07) | 18.7374 |
| 1990's | 232 (39.12) | 18.2507 |
| 2000's | 205 (34.57) | 29.6817 |
| 2010's | 103 (17.37) | 24.3611 |
| 2020's | 17 (2.87) | 2.80 |
| Authors | Studies |
|---|---|
| Allison, DL; Glaser, R; Holliday, JE; Kamat, PL; Liebowitz, SM; Moeschberger, ML; Schaller, JP; Witiak, DT | 1 |
| Barrows, LR; Clardy, J; Concepción, GP; Eldredge, GS; Foderaro, TA; Ireland, CM; Lobkovsky, E | 1 |
| Barrows, LR; Eldredge, GS; Ireland, CM; McDonald, LA | 1 |
| Chen, AY; Cheng, CC; Chou, TC; Dong, Q; Liu, DF; Liu, LF; Luo, YL; Savaraj, N; Yu, C | 1 |
| Barrows, LR; Ireland, CM; Kokoshka, JM | 1 |
| Barzi, A; Cecchetti, V; Fravolini, A; Miao, H; Nocentini, G; Sabatini, S; Sissi, C; Tabarrini, O | 1 |
| Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
| Akiyama, S; Baba, M; Furukawa, T; Nitanda, T; Okamoto, M; Sugimoto, Y; Wang, X | 1 |
| Baguley, BC; Deady, LW; Denny, WA; Rodemann, T; Zhuang, L | 1 |
| Allen, JD; Buitelaar, M; Schinkel, AH; Van Dort, SC; van Tellingen, O | 1 |
| Gibbons, S; Kaatz, GW; Zloh, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Chan, YL; Chen, HW; Chen, WR; Guh, JH; His, CP; Hsin, LW; Kao, PH; Lee, CH; Lee, O; Li, TK; Wang, HP; Yang, MS | 1 |
| Austin, CA; Curtis, H; Gilroy, KL; Jobson, A; López-Lázaro, M; Padget, K; Willmore, E | 1 |
| Guziec, FS; Guziec, LJ; Hasinoff, BB; Liang, H; Marshall, K; Wu, X; Yalowich, JC | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Bailly, C; Baldeyrou, B; Garcin, D; Goossens, JF; Hénichart, JP; Houssin, R; Lansiaux, A; Ryckebusch, A | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Ghosh, I; Manoharlal, R; Prakash, O; Prasad, R; Puri, N; Sharma, M | 1 |
| Ahn, G; Bailly, C; Baldeyrou, B; Couture, A; Goossens, JF; Grandclaudon, P; Lansiaux, A; Ryckebusch, A; Schifano-Faux, N | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Ahn, G; Baldeyrou, B; Couture, A; Goossens, JF; Grandclaudon, P; Lansiaux, A; Ryckebusch, A; Schifano-Faux, N | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Aridoss, G; Bleeker, NP; Hermanson, DL; Xing, C; Zhou, B | 1 |
| Burckhardt, G; Flörl, S; Hagos, Y; Kühne, A; Marada, VV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, JN; Li, X; Lu, CH; Wu, XK | 1 |
| Aversa, SM; Bianco, A; Chiarion-Sileni, V; Contu, A; Endrizzi, L; Fiorentino, MV; Olmeo, N; Salvagno, L; Schintu, GM; Sorarù, M | 1 |
| Sumner, AT | 3 |
| Glisson, BS; Killary, AM; Merta, P; Ross, WE; Siciliano, J; Siciliano, MJ | 1 |
| Cowan, KH; Dixon, KH; Horton, J; Kelley, K; Morrow, C; Nakagawa, M; Schneider, E | 1 |
| Higuchi, S; Itoh, T; Kishibe, T; Sakata, Y; Seino, Y; Sohma, N; Sugimoto, N; Suzuki, H | 1 |
| Birck, C; Charcosset, JY; Laval, F; Muller, C; Soues, S | 1 |
| Aoki, K; Nose, H; Okada, S; Okazaki, N; Yoshimori, M | 1 |
| Chiba, S; Hanazono, Y; Hirai, H; Miura, Y; Miyagawa, K; Miyazono, K; Piao, YF; Sakamoto, S; Taketazu, F; Yazaki, Y | 1 |
| Mizoguchi, H; Saito, H | 1 |
| Cabanillas, F | 2 |
| Bosanquet, AG; Chapman, CS; Hutchinson, RM; Parker, AN | 1 |
| Belin, T; Champlin, R; Gajewski, J; Lee, M; Nimer, S; Schiller, G; Territo, M | 1 |
| Kimura, F; Mizukami, H; Motoyoshi, K; Nagata, N; Ohtsuki, T; Takagi, S; Takemura, Y; Yamamoto, K | 1 |
| Baglin, TP; Flavell, DJ; Flavell, SU; Lim, SH; Marcus, RE; Wimperis, JZ | 1 |
| Oguro, M; Sakai, C; Takagi, T | 1 |
| Cold, S; Pfeiffer, P; Rose, C | 1 |
| O'Connor, BM; Spaulding, MB; Ziegler, P | 1 |
| Gray, RG; Rees, JK | 1 |
| Carbone, A; De Cicco, M; Errante, D; Monfardini, S; Serraino, D; Talamini, R; Tirelli, U; Zagonel, V | 1 |
| Almadrones, L; Barakat, R; Curtin, J; Hakes, T; Hoskins, W; Jones, W; Lewis, JL; Markman, M; Reichman, B; Rubin, S | 1 |
| Wiernik, PH | 1 |
| Björkman, S; Roth, B | 1 |
| Ito, T; Ito, Y; Kitaori, K; Nagai, T; Ohno, R; Okumura, M; Sugiura, I; Takeo, T; Yano, K; Yokomaku, S | 1 |
| Hausamen, TU; Loeffler, TM; Weber, FW | 1 |
| Gilbert, KS; Griswold, DP; Harrison, SD; Laster, WR; Waud, WR | 1 |
| Bastida Vila, P; Giralt López, J; Javier Manchón, G; Olivé Oliveras, T; Ortega Aramburu, JJ; Sánchez, C | 1 |
| Beran, M; Estey, E; Kantarjian, H; Keating, M; Koller, C; McCredie, K; O'Brien, S | 1 |
| Bertino, J; Crown, JP; Gulati, S; Heelan, R; Kolitz, J; Lee, BJ; O'Brien, J; Portlock, C; Straus, DJ | 1 |
| Granada, I; Las Heras, G; Millá, F; Ribera, JM | 1 |
| Baccarani, M; Cenacchi, A; Damiani, D; Fanin, R; Fogli, M; Gamberi, B; Revignas, G; Russo, D; Tura, S; Visani, G | 1 |
| Ho, AD; Hunstein, W; Knauf, WU; Körbling, M | 1 |
| Björkholm, M; Ideström, K; Johansson, B; Kimby, E; Lindemalm, C; Merk, K; Osby, E | 1 |
| Farhi, DC; Rosenthal, NS | 1 |
| Archimbaud, E; Cordonnier, C; Devaux, Y; Dreyfus, F; Fenaux, P; Fiere, D; Jaubert, J; Leblond, V; Michallet, M; Travade, P | 1 |
| Amadori, S; Arcese, W; Isacchi, G; Mandelli, F; Meloni, G; Monarca, B; Petti, MC; Testi, AM | 1 |
| Calabró, F; Daniele, O; Fiore-Donati, L; Fiorentino, MV; Fornasiero, A; Ghiotto, C; Piazza, M; Rea, F | 1 |
| Buzdar, A; Dunphy, F; Ewer, M; Holmes, F; Hortobagyi, G; Huan, S; Spitzer, G; Theriault, R; Wallerstein, R; Yau, J | 1 |
| Ehninger, G; Fackler-Schwalbe, E; Freund, M; Heil, G; Henke, M; Hoelzer, D; Hoffmann, R; Kurrle, E; Link, H; Lösch, A | 1 |
| Austein, J; Diedrich, H; Fackler-Schwalbe, E; Freund, M; Henke, M; Hoffmann, R; Link, H; Schlimok, G; Wandt, H; Wilke, H | 1 |
| Andersen, J; Bennett, JM; Cassileth, PA; Hines, JD; Mazza, JJ; Oken, MM; Rowe, JM | 1 |
| Davis, RB; Holland, JF; Martelo, O; Paciucci, PA; Schiffer, CA | 1 |
| Cawley, JC; Davies, JM; Hay, CR; Nash, JR; Parry, H; Phillips, JK; Spearing, RL | 1 |
| Björkholm, M; Björnsdottir, J; Grimfors, G; Stenke, L | 1 |
| Kühn, B; Löffler, H; Polchau, H; Rister, M; Suttorp, M | 1 |
| Broustet, A; Cony, P; Duclos, F; Marit, G; Puntous, M; Reiffers, J | 1 |
| Choi, KE; Daley, KM; Kaminer, LS; Larson, RA | 1 |
| Auzanneau, G; Gisselbrecht, C; Gratecos, N; Harousseau, JL; LeBlond, V; Michallet, M; Milpied, N; Sebban, C; Troussard, X; Witz, F | 1 |
| Ito, T; Komatsu, M; Saito, Y; Takahashi, H; Toyota, T; Uzuka, Y | 1 |
| Markman, M | 1 |
| Cole, SP; Gerlach, JH; Mirski, SE | 1 |
| Chan, HS; Estrov, Z; Freedman, MH; Weitzman, SS | 1 |
| Davies, SL; Davies, SM; Harris, AL; Hickson, ID | 1 |
| Ellis, AL; Gewirtz, DA; Povirk, LF; Randolph, JK; Swerdlow, PS; Yalowich, JC; Yanovich, S | 1 |
| Hamada, H; Ishida, Y; Minato, K; Ohtsu, T; Shimoyama, M; Sugimoto, Y; Tobinai, K; Tsuruo, T | 1 |
| Furukawa, Y; Im, T; Inoue, T; Kishida, T; Park, K; Sasaki, A; Tatsumi, N; Yamane, T | 1 |
| Kyo, T; Maehama, S | 1 |
| Hakes, T; Hoskins, W; Jones, W; Lewis, JL; Markman, M; Reichman, B; Rubin, S | 1 |
| Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Inverardi, D; Lazzarino, M; Merante, S; Morra, E; Orlandi, E; Pagnucco, G | 1 |
| Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Caldera, D; Lazzarino, M; Merante, S; Morra, E | 1 |
| Bernasconi, C | 1 |
| Cowan, KH; Hill, BT; Hosking, LK; Townsend, AJ; Whelan, RD | 1 |
| Epstein, RJ; Smith, PJ | 1 |
| Phillips, JK | 1 |
| Nishizaki, H; Sumida, M | 1 |
| Berger, NA; Lazarus, HM | 1 |
| Ehninger, G; Freund, M; Ho, AD; Illiger, HJ; Körbling, M; Lipp, T; Meyer, P | 1 |
| Amadori, S; Avvisati, G; Mandelli, F; Meloni, G; Petti, MC; Tafuri, A | 1 |
| Ehninger, G; Freund, M; Ho, AD; Hunstein, W; Illiger, HJ; Lipp, T; Meyer, P | 1 |
| Ehninger, G; Freund, M; Ho, AD; Hunstein, W; Lipp, T; Meyer, P | 1 |
| Ehninger, G; Ho, AD; Kaboth, W; Körbling, M; Lipp, T; Meyer, P; Rückle, H; Steinke, B | 1 |
| Hayashi, K; Kimura, I; Murashima, M; Ohnoshi, T; Tada, A; Ueno, K; Ueoka, H; Yamane, T; Yoshida, M | 2 |
| Ogawa, M | 2 |
| Cheng, YC; Ferguson, PJ | 1 |
| Hiraki, S; Kimura, I; Miyamoto, H; Murashima, M; Ohnoshi, T; Toyata, K; Ueno, K; Ueoka, H; Yamane, T | 1 |
| Gahrton, G | 1 |
| Brunner, KW; Cavalli, F; Goldhirsch, A; Joss, RA; Mermillod, B | 1 |
| Akbulut, H; Arican, A; Cay, F; Demirkazik, A; Dinçol, D; Içli, F; Karaoğuz, H | 1 |
| Björkholm, M; Gruber, A; Liliemark, E; Liliemark, J; Paul, C; Peterson, C; Tidefelt, U | 1 |
| Cabanillas, F; Hagemeister, FB; Lee, MS; McLaughlin, P; Pate, O; Rodriguez, MA; Romaguera, J; Sarris, A; Swan, F; Younes, A | 1 |
| Avilés, A; Díaz-Maqueo, JC; García, EL; Nambo, MJ; Talavera, A | 1 |
| Clark, RE; Creagh, MD; Shlebak, AA | 1 |
| Brandi, M; De Lena, M; Ditonno, P; Lorusso, V; Marzullo, F; Pellecchia, A; Timurian, A; Ventrella, V | 1 |
| Cabanillas, F; Cortes, JE; Kurzrock, R; Seymour, JF; Talpaz, M | 1 |
| Aoyagi, A; Arimura, H; Furusawa, S; Koike, T; Noguchi, M; Saito, K; Sakuma, H; Waga, K; Yamada, K; Yamato, H | 1 |
| Fuchsberger, P; Lakota, J | 1 |
| Arneson, M; Blumenschein, G; Dicke, JA; Dicke, KA; Fulbright, L; Hanks, S; Hood, DL; Vaughan, M | 1 |
| Anastasi, J; Hayashi, Y; McGavran, L; Nucifora, G; Roulston, D; Rowley, JD; Rudinsky, R; Tsuchida, M; Zeleznik-Le, N | 1 |
| Iigo, M; Sagawa, K; Shimamura, M; Tsuda, H | 1 |
| Bezwoda, WR; Dansey, RD; Seymour, L | 1 |
| Cabanillas, FC; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Romaguera, JE; Swan, F; Velasquez, W | 2 |
| Björkholm, M; Gahrton, G; Grimfors, G; Gruber, A; Hast, R; Järnmark, M; Juliusson, G; Killander, A; Kimby, E; Liliemark, J | 1 |
| Amadori, S; Avvisati, G; Cedrone, M; Cimino, G; Mancini, F; Mandelli, F; Moleti, ML; Testi, AM; Todisco, E | 1 |
| Aster, JC; Inhorn, RC; Roach, SA; Slapak, CA; Soiffer, R; Stone, RM; Tantravahi, R | 1 |
| Abe, T; Hirao, A; Kawano, Y; Okamoto, Y; Saito, S; Sato, J; Shimizu, T; Suzue, T; Takaue, Y; Watanabe, T | 1 |
| Hayashi, K; Kawashima, K; Matsutomo, S; Mizuta, J; Ohnoshi, T; Saito, S; Tada, A; Tagawa, S; Ueno, K; Yoshino, T | 1 |
| Ezoe, A; Fujisaki, Y; Hayashi, S; Kohda, K; Nakazawa, O; Takayanagi, N; Takeda, M; Takimoto, R; Tsuji, A; Tsuji, Y | 1 |
| Bosly, A; Coiffier, B; Gisselbrecht, C; Haioun, C; Herbrecht, R; Lepage, E; Morel, P; Reyes, F; Sebban, C; Tilly, H | 1 |
| Ballestrero, A; Basta, P; Brema, F; Ferrando, F; Ghio, R; Gobbi, M; Moraglio, L; Patrone, F; Sessarego, M; Valbonesi, M | 1 |
| Cimoli, G; De Sessa, F; Mazzoni, A; Noviello, E; Parodi, S; Rovini, E; Russo, P; Valenti, M | 1 |
| Calvert, L; Claxton, D; Durett, A; Giralt, S; Hamer, J; Kantarjian, H; Khouri, I; Liang, J; Talpaz, M; Tibbits, P | 1 |
| Bout, M; Brémond, JL; Dayan, A; Delain, M; Domenech, J; Gihana, E; Linassier, C; Petit, A; Petitdidier, C; Truglio, D | 1 |
| Archim-Baud, E; Castaigne, S; Chastang, C; Chomienne, C; Degos, L; Fenaux, P; Fey, M; Link, H; Löwenberg, B; Sanz, M | 1 |
| Archimbaud, E; Cordonnier, C; Dreyfus, F; Fenaux, P; Jaubert, J; Leblond, V; Michallet, M; Thomas, X; Travade, P; Troussard, X | 1 |
| Azuno, Y; Fujita, N; Kaku, K; Kaneko, T; Matsumoto, N; Okubo, M | 1 |
| Cabanillas, F; Hagemeister, FB; Hill, D; McLaughlin, P; Moore, DF; Rodriguez, MA; Romaguera, JE; Sarris, AH; Swan, F; Younes, A | 1 |
| Bajetta, E; Buzzoni, R; Colleoni, M; Nelli, P; Nolè, F | 1 |
| Fridborg, H; Killander, A; Kristensen, J; Larsson, R; Liliemark, J; Nygren, P; Oberg, G; Simonsson, B | 1 |
| Archimbaud, E; Auzanneau, G; Bordessoule, D; Castaigne, S; Dupriez, B; Fenaux, P; Legros, M; Simon, M; Tertian, G; Tilly, H | 1 |
| Cimoli, G; Conte, P; De Sessa, F; Mazzoni, A; Parodi, S; Russo, P; Valenti, M | 1 |
| Carstensen, J; Malmström, H; Simonsen, E | 1 |
| Carbone, A; Errante, D; Monfardini, S; Sorio, R; Talamini, R; Tirelli, U; Zagonel, V | 1 |
| Burkes, R; Chow, W; Crump, M; Davidson, M; Goss, PE; King, M; Myers, R; Poldre, P; Rudinskas, L; Sutton, D | 1 |
| Cabanillas, F; Rodriguez, MA | 1 |
| Attal, M; Canal, P; Huguet, F; Laurent, G; Pris, J; Schlaifer, D | 1 |
| Bastie, JN; Baumelou, E; Casassus, P; Coloma, F; Delmas-Marsalet, B; Delmer, A; Faussat Suberville, AM; Leroux, G; Marie, JP; Rio, B | 1 |
| Asbury, RF; Cnaan, A; Haller, DG; Harris, J; Johnson, L; Zaentz, SD | 1 |
| Cimoli, G; De Sessa, F; Parodi, S; Russo, P; Valenti, M | 1 |
| Berdel, WE; Ho, AD; Knauf, WU; Kreuser, ED; Thiel, E | 1 |
| Cortes, JE; Estey, E; Hirsh-Ginsberg, C; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Robertson, LE; Stass, S | 1 |
| Nakane, S; Suzuki, H | 1 |
| Ballester, OF; Elfenbein, GJ; Fields, KK; Foody, MC; Hiemenz, JW; Janssen, WE; Kronish, LE; Perkins, JB; Zorsky, PE | 1 |
| Perilov, AA; Poddubnaia, IV | 1 |
| Björkholm, M; Gruber, A; Liliemark, EK; Liliemark, J; Peterson, C; Pettersson, B | 1 |
| Ariad, S; Bezwoda, MA; Bezwoda, WR; Dansey, R; Seymour, L | 1 |
| Attal, M; Canal, P; Chatelut, E; Dezeuze, A; Huguet, F; Laurent, G; Payen, C; Pris, J; Schlaifer, D | 1 |
| Daenen, S; Huijgens, PC; Löwenberg, B; Sonneveld, P; van Putten, WL; van Veldhoven, M; Verdonck, LF; Verhoef, G | 1 |
| Del Valle, F; Döhner, H; Ehrhardt, R; Fischer, JT; Haas, R; Ho, AD; Huberts, H; Hunstein, W; Kaplan, E; Witt, B | 1 |
| Abe, Y; Hatanaka, T; Ito, T; Kamiya, O; Nagata, K; Ohara, K; Ono, Y; Saito, M | 1 |
| Fukazawa, M; Hashimoto, S; Ishii, A; Kawano, E; Kogure, K; Matsuura, Y; Nakamura, H; Nishimura, M; Oh, H; Okuyama, Y | 1 |
| Kobayashi, K; Kyohda, K; Matano, S; Matsuda, T; Nakamura, S; Ohtake, S; Okabe, Y; Okumura, H; Yoshida, T | 1 |
| Gajewski, J; Lee, M; Nimer, S; Schiller, G; Territo, M | 1 |
| Kuroume, T; Shitara, T; Sotomatsu, M; Yugami, S | 1 |
| Delmer, A; Marie, JP; Suberville, AM; Thevenin, D; Zittoun, R | 1 |
| Gondo, H; Harada, M; Matsuishi, H; Omori, F; Otsuka, T; Shibuya, T; Taniguchi, S; Teshima, T; Yamano, Y; Yamazaki, K | 1 |
| Archimbaud, E; Auzanneau, G; Cordonnier, C; Fenaux, P; Leblond, V; Marie, JP; Reiffers, J; Tilly, H; Travade, P; Troussard, X | 1 |
| Ansell, SM; Falkson, G | 1 |
| Aloe Spiriti, MA; Arcese, W; Avvisati, G; Fazi, P; Latagliata, R; Meloni, G; Petti, MC; Spadea, A; Testi, AM; Vegna, ML | 1 |
| Barnett, MJ; Klingemann, HG; Nantel, SH; Phillips, GL; Reece, DE; Shepherd, JD; Sutherland, HJ | 1 |
| Chisesi, T | 1 |
| Béhar, C; Benoit, Y; Bertrand, Y; Boutard, P; Ferster, A; Lutz, P; Manel, AM; Otten, J; Robert, A; Solbu, G; Suciu, S; Tokaji, E; Vilmer, E | 1 |
| Hirakawa, K; Horiike, S; Kaneko, H; Kashima, K; Misawa, S; Nakai, H; Nakao, M; Taniwaki, M; Ueda, Y | 1 |
| Berman, E; Golde, DW; Maslak, PG; Scheinberg, DA; Tyson, D; Weiss, MA; Yao, TJ | 1 |
| Bow, EJ; Cheang, MS; Loewen, R; Schacter, B | 1 |
| Dann, EJ; Gillis, S; Rund, D | 1 |
| Burkes, R; Chow, W; Crump, M; Davidson, M; Goss, P; King, M; Myers, R; Poldre, P; Rudinskas, L; Sutton, D | 1 |
| Amadori, S; Cenacchi, A; Latagliata, R; Mandelli, F; Manfroi, S; Petti, MC; Spadea, A; Tosi, P; Tura, S; Visani, G | 1 |
| Elfenbein, GJ; Fields, KK; Moscinski, LC; Perkins, JB | 1 |
| Ahmed, T; Akhtar, T; Chun, H; Feldman, E; Grima, K; Helson, L; Lake, D; Mittelman, A; Puccio, C; Seiter, K | 1 |
| Elonen, E; Jokipii, A; Lautenschlager, I; Lyytikäinen, O; Ruutu, P; Tiittanen, L | 1 |
| Chau, WK; Chiu, CF; Ho, CH; Hsu, HC; Tan, TD; Tseng, CS | 1 |
| Chubachi, A; Endo, K; Kuriya, S; Maruyama, Y; Meguro, K; Narigasawa, Y; Sasaki, H; Sato, S; Shiga, T; Takami, H | 1 |
| Blume, KG; Chao, NJ; Hoyle, CF; Kusnierz-Glaz, CR; Long, GD; Negrin, RS; Schriber, JR | 1 |
| Döhner, H; Flentje, M; Goldschmidt, H; Haas, R; Hunstein, W; Möhle, R; Moos, M; Murea, S; Wannenmacher, M; Witt, B | 1 |
| Errante, D; Gastaldi, R; Magnani, G; Nigra, E; Nosari, AM; Spina, M; Tirelli, U; Vaccher, E | 1 |
| Fey, MF; Hardegger, TP; Tobler, A; von Rohr, A | 1 |
| Bow, EJ; Clinch, JJ; Kilpatrick, MG; Rubinger, M; Schacter, BA; Shore, TB; Sutherland, JA; Williams, GJ | 1 |
| Chiusolo, P; Di Mario, A; Leone, G; Micciulli, G; Salutari, P; Sica, S; Tommasi, M | 1 |
| Araki, K; Arima, N; Chiyoda, S; Hosokawa, T; Ikeda, S; Kawano, F; Kikuchi, H; Kinoshita, KI; Kohno, H; Matsuzaki, H; Miyoshi, I; Momita, S; Nishimura, H; Taguchi, H; Takahashi, H; Takatsuki, K; Tamura, K; Tomonaga, M; Tsuda, H; Uozumi, K; Yamada, O | 1 |
| Atkins, HL; Curtis, JE; Lipton, JH; Messner, HA; Minden, MD | 1 |
| Huismans, DR; Klumper, E; Loonen, AH; Ossenkoppele, GJ; Pieters, R; Rottier, A; Veerman, AJ; Westra, G | 1 |
| Cowan, KH; Gudas, JM; Li, T; Nguyen, H; Robey, R; Sadzewicz, L; Wosikowski, K | 1 |
| Nishikawa, K | 1 |
| Taguchi, H | 1 |
| Doi, T; Kobayashi, D; Koike, K; Kougo, Y; Matsunaga, T; Muramatsu, H; Niitsu, Y; Sakamaki, S; Sato, T; Watanabe, N | 1 |
| Appelbaum, FR; Bensinger, WI; Buckner, CD; Chauncey, T; Demirer, T; Fefer, A; Lilleby, K; Petersen, FB; Rowley, S; Sanders, J; Storb, R | 1 |
| Bonini, A; Carotenuto, M; Cascavilla, N; D'Arena, G; Di Mauro, L; Greco, MM; Melillo, L; Minervini, MM; Musto, P; Sajeva, MR; Scalzulli, P | 1 |
| Alterini, R; Bellesi, G; Bernardi, F; Di Lollo, S; Ferrini, PR; Fusco, II; Innocenti, F; Longo, G; Rigacci, L; Stefanacci, S | 1 |
| Bhalla, K; Fang, G; Huang, Y; Ibrado, AM; Liu, L | 1 |
| Gonzalez-Gonzalez, A; Pinilla, J; Requena, A; Velasco, JG | 1 |
| Arvizu, C; Conzen, SD; Kaufman, PA; LeMarbre, P; Maurer, LH; Mills, LE; Mott, LA | 1 |
| Ezaki, K; Hirano, M; Ino, T; Kojima, H; Maruyama, F; Matsui, T; Miyazaki, H; Nomura, T; Okamoto, M; Tsuzuki, M; Wakita, M; Yamaguchi, T | 1 |
| Archimbaud, E; Auzanneau, G; Cony-Makhoul, P; Cordonnier, C; Dombret, H; Dreyfus, F; Fenaux, P; Ffrench, M; Leblond, V; Marie, JP; Thomas, X; Tilly, H; Troussard, X | 1 |
| Chubachi, A; Hashimoto, K; Hayashi, Y; Miura, AB; Miura, I; Nimura, T; Ohshima, A; Seto, M; Takahashi, N; Ueda, R; Utsumi, S | 1 |
| McMillan, R; Meisenberg, BR; Miller, WE | 1 |
| Ganapathi, R; Grabowski, D | 1 |
| Falkson, CI; Nel, JS | 1 |
| Amadori, S; Andrizzi, C; Meloni, G; Moleti, ML; Orsini, E; Petti, MC; Pinto, RM; Vignetti, M | 1 |
| Flexner, JM; Goodman, S; Greer, JP; Stein, RS; Wolff, SN | 1 |
| Ando, T; Ariyoshi, K; Hikiji, K; Kobayashi, M; Shinohara, K; Toyosawa, M | 1 |
| Rodriguez, MA | 1 |
| Dekker, AW; Haak, HL; Huijgens, PC; Löwenberg, B; Ossenkoppele, G; Schouten, HC; Sizoo, W; Sonneveld, P; van der Lelie, J; van Putten, WL; van't Veer, MB; Verdonck, LF; Willemze, R | 1 |
| Barbui, T; Bertini, M; Botto, B; Cinieri, S; Cortellazzo, S; Falda, M; Freilone, R; Grignani, F; Levis, A; Liberati, AM; Locatelli, F; Lovisone, E; Marmont, F; Pizzuti, M; Resegotti, L; Rossi, A; Viero, P; Vitolo, U | 1 |
| Ezaki, K; Hirano, M; Ino, T; Kojima, H; Maruyama, F; Matsui, T; Miyazaki, H; Nomura, T; Okamoto, M; Tsuzuki, M; Yamaguchi, T | 1 |
| Hanada, R; Hongo, T; Horikoshi, Y; Sakurai, M; Yajima, S | 1 |
| Hizawa, Y; Itoh, J; Kawamura, S; Munakata, A; Nakui, Y; Saitoh, S; Satoh, T; Taka-mi, H; Tamura, Y; Tsushima, K | 1 |
| Brodsky, AL; Melero, MJ; Minissale, CJ; Sánchez Avalos, JC | 1 |
| Bezwoda, WR; Dansey, R; Davidge-Pitts, M | 1 |
| Andreeff, M; Consoli, U; Estey, E; Kantarjian, H; Keating, M; Kornblau, SM; Madden, T; Newman, RA; Sanchez-Williams, G; Snell, V; Tran, HT; Zhao, S | 1 |
| Aitini, E; Bendandi, M; Falini, B; Fattori, PP; Gentilini, P; Gherlinzoni, F; Gobbi, M; Guardigni, L; Lauta, VM; Leone, G; Liso, V; Magagnoli, M; Moretti, L; Pavone, E; Storti, S; Tabanelli, M; Tura, S; Venturi, S; Zinzani, PL | 1 |
| Barakat, RR; Brown, C; Curtin, JP; Fennelly, D; Pizzuto, F; Venkatraman, ES | 1 |
| Brinch, L; Evensen, SA; Hedenus, M; Hörnsten, P; Oberg, G; Simonsson, B; Wahlin, A | 1 |
| el-Yazigi, A; Ezzat, A | 1 |
| Cabanillas, F; Rodriguez-Monge, EJ | 1 |
| Archimbaud, E; Thomas, X | 1 |
| Azuma, E; Higashigawa, M; Hirayama, M; Hori, H; Ido, M; Kawasaki, H; Sakurai, M | 1 |
| Borg, AG; Burgess, R; Fisher, A; Grey, M; Wood, P; Yin, JA | 1 |
| Akashi, K; Eto, T; Fujisaki, T; Gondo, H; Harada, M; Harada, N; Hayashi, S; Hirota, Y; Kinukawa, N; Makino, S; Matsuishi, E; Miyamoto, T; Mizuno, S; Murakawa, M; Nagafuji, K; Niho, Y; Ohno, Y; Okamura, T; Shibuya, T; Takamatsu, Y; Takenaka, K; Taniguchi, S; Tanimoto, K; Teshima, T; Yamasaki, K | 1 |
| Hoskin, PJ | 1 |
| Akan, H; Aydogdu, I; Beksac, M; Gurman, G; Ilhan, O; Koc, H; Konuk, N; Ozerol, E; Uysal, A | 1 |
| Bron, D; Errante, D; Kluin-Nelemans, JC; Noordijk, EM; Rosti, G; Somers, R; Teodorovic, I; Thomas, J; Tirelli, U; Van Glabbeke, M; Zagonel, V | 1 |
| Bukh, A; Clausen, N; Hokland, P; Langkjer, ST; Nørgaard, JM; Palshof, T | 1 |
| Allen, SL; Amrein, PC; George, SL; Lee, EJ; Paciucci, PA; Schiffer, CA | 1 |
| Goi, K; Iijima, K; Inukai, T; Kagami, K; Kinoshita, A; Kojika, S; Mori, T; Nakazawa, S; O-Koyama, T; Sugita, K; Suzuki, T; Tezuka, T | 1 |
| Chen, CL; Horng, YY; Kao, YL; Kuo, JH; Ou, YC; Yang, CR; Yang, CS; Yean, SY | 1 |
| Gray, RG; Hann, IM; Stevens, RF; Wheatley, K | 1 |
| Ballester, OF; Elfenbein, GJ; Fields, KK; Goldstein, SC; Heimenz, JW; Kronish, LA; Partyka, JS; Perkins, JB; Saez, RA; Sullivan, DM | 1 |
| Dissing, M; Le Beau, MM; Pedersen-Bjergaard, J | 1 |
| Bender-Götze, C; Creutzig, U; Körholz, D; Niemeyer, C; Ritter, J; Stollmann-Gibbels, B; Zimmermann, M | 1 |
| Bairey, O; Blickstein, D; Epstein, O; Gabbay, U; Lahav, J; Prokocimer, M; Shaklai, M; Stark, P | 1 |
| Apel, D; Maj, S; Mariańska, B; Seferyńska, I | 1 |
| Ariyoshi, K; Kameda, N; Shinohara, K; Takeda, K | 1 |
| Colomer, R; Gómez, H | 1 |
| Cabanillas, F; Dong, K; Hagemeister, FB; McLaughlin, P; Moon, T; Rodriguez, MA; Rodriguez-Diaz Pavón, J; Romaguera, JE | 1 |
| Catovsky, D; Killick, S; Matutes, E; Swansbury, J | 1 |
| Barişta, I; Celik, I; Firat, D; Güler, N; Hayran, M; Kars, A; Ozyilkan, O; Tekuzman, G | 1 |
| Furukawa, Y; Kitani, T; Tsukaguchi, M | 1 |
| Bernasconi, C; Castagnola, C; Corso, A; Dabusti, M; Lazzarino, M; Lunghi, M; Tajana, M; Zappasodi, P | 1 |
| Astori, C; Bernasconi, C; Bernasconi, P; Lazzarino, M; Orlandi, E | 1 |
| Baak, JP; Broxterman, HJ; Eekman, CA; Feller, N; Klumper, E; Kuiper, CM; Ossenkoppele, GJ; Pieters, R; Schuurhuis, GJ; van Heijningen, TH | 1 |
| Bhalla, K; Bullock, G; Huang, Y; Maria Ibrado, A; Miyashita, T; Ray, S; Reed, J | 1 |
| Adam, Z; Hájek, R; Hejlová, N; Klabusay, M; Korístek, Z; Krahulcová, E; Král, Z; Mayer, J; Müllerová, I; Navrátil, M; Penka, M; Tomíska, M; Vásová, I; Vodvárka, P; Vorlícek, J | 1 |
| Akan, H; Arat, M; Arslan, O; Beksaç, M; Gürman, G; Ilhan, O; Koç, H; Konuk, N; Ozcan, M; Uysal, A | 1 |
| De La Rubia, J; Gomis, F; González-García, Y; Jarque, I; Martín, G; Pérez-Sirvent, M; Sanz, MA; Sempere, A; Senent, L | 1 |
| Avramis, VI; Carcich, S; Ortega, JA; Ozkaynak, MF | 1 |
| Lehman, S; Löfgren, C; Möllgård, L; Paul, C; Sundman-Engberg, B; Tidefelt, U | 1 |
| Feliu, E; Hernández, JA; Millá, F; Navarro, JT; Oriol, A; Pujol, M; Ribera, JM; Sancho, JM | 1 |
| Cavalli, F; Ghielmini, M; Sanna, P; Van den Bosch, S | 1 |
| Hande, KR | 1 |
| Advani, R; Davis, E; Dugan, K; Greenberg, PL; Litchman, M; Lum, B; Paietta, E; Ramek, J; Rowe, JM; Saba, HI; Sikic, BI; Tallman, MS; Villena, J; Wiernik, PH | 1 |
| Bennett, JM; Lee, S; Paietta, E; Rowe, JM; Sikic, BI; Tallman, MS; Wiernik, PH | 1 |
| Bachier, C; Cabanillas, F; Hagemeister, FB; McLaughlin, P; Preti, H; Rodriguez, MA; Romaguera, JE; Sarris, AH; Weber, D; Younes, A | 1 |
| Curti, A; Lemoli, RM; Leopardi, G; Motta, MR; Rizzi, S; Testoni, N; Tura, S; Visani, G | 1 |
| Aguado, MJ; Arrieta, R; Bustos, JG; Canales, MA; Hernández-García, C; Hernández-Navarro, F | 1 |
| Boerman, RH; Mattijssen, V; Mulder, AH; Raemaekers, JM | 1 |
| Cabanillas, F; Fayad, L; Hagemeister, FB; Hess, M; McLaughlin, P; Rodriguez, J; Rodriguez, MA; Romaguera, J; Santiago, M | 1 |
| Chillón, C; García, JL; González, M; Gutiérrez, NC; Hernández, JM; Muntión, S | 1 |
| Altés, A; Brunet, S; Guardia, R; Martino, R; Sierra, J; Sureda, A | 1 |
| Chiba, S; Hirai, H; Honda, H; Kanda, Y; Yazaki, Y | 1 |
| Readett, D; Richards, M; Vora, AJ; Watmore, A; Welch, J | 1 |
| Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Caldera, D; Colombo, A; Malcovati, L; Martinelli, G; Pagnucco, G; Salvaneschi, L | 1 |
| Amadori, S; Archimbaud, E; Belhabri, A; De Cataldo, F; Fillet, G; Jehn, U; Martin, C; Peaud, PY; Thomas, X; Willemze, R | 1 |
| Aitini, E; Bendandi, M; Bocchia, M; De Renzo, A; Falini, B; Fattori, PP; Gentilini, P; Gherlinzoni, F; Gobbi, M; Guardigni, L; Lauta, VM; Leone, G; Magagnoli, M; Mazza, P; Moretti, L; Pavone, E; Storti, S; Tabanelli, M; Tura, S; Volpe, E; Zaccaria, A; Zaja, F; Zinzani, PL | 1 |
| Ehninger, G; Illmer, T; Neubauer, A; Nowak, R; Oelschlägel, U; Renner, U; Schaich, M; Subat, S; Ziegs, B | 1 |
| Archimbaud, E; Bordessoule, D; Cony-Makhoul, P; Cordonnier, C; de Revel, T; Delair, S; Dombret, H; Dreyfus, F; Fenaux, P; Ffrench, M; Janvier, M; Leblond, V; Marie, JP; Nicolini, F; Rousselot, P; Simon, M; Stoppa, AM; Thomas, X; Tilly, H; Troussard, X; Vekhoff, A | 1 |
| Gherlinzoni, F; Isidori, A; Lemoli, R; Leopardi, G; Martinelli, G; Motta, M; Pastano, R; Piccaluga, P; Ricci, P; Rizzi, S; Testoni, N; Tosi, P; Tura, S; Visani, G | 1 |
| Hidaka, E; Ito, S; Koike, K; Koike, T; Komiyama, A; Kurokawa, Y; Matsuura, H; Miki, J; Nakazawa, T; Sakashita, K; Sawai, N | 1 |
| Advani, R; Covelli, A; Davis, E; Dugan, K; Greenberg, P; Litchman, M; Lum, B; Milligan, D; Paietta, E; Ramek, J; Rowe, JM; Saba, H; Sikic, B; Tallman, M; Villena, J; Visani, G; Wiernik, PH | 1 |
| Austin, CA; Baguley, BC; Errington, F; Li, G; Li, L; Li, W; Tilby, MJ; Willmore, E | 1 |
| Joseph, CD; Kuttan, G; Kuttan, R; Praveenkumar, V | 1 |
| Asbury, R; Dutcher, JP; Haller, DG; Novik, Y; Ryan, LM; Schutt, A | 1 |
| Abgrall, JF; Audhuy, B; Casassus, P; Deconinck, E; Delain, M; Desablens, B; Guilhot, F; Guyotat, D; Harousseau, JL; Hunault-Berger, M; Le Prise, PY; Lioure, B; Solary, E; Tournilhac, O; Vilque, JP; Witz, B | 1 |
| Bashey, A; Corringham, RE; Corringham, S; Garrett, J; Gilpin, EA; Ho, AD; Lane, TA; Law, P | 1 |
| Cotter, TG; Knox, KA; McGahon, AJ; McKenna, SL; O'Gorman, DM | 1 |
| Caracciolo, D; Corradini, P; Cuttica, A; Gavarotti, P; Ladetto, M; Novero, D; Pileri, A; Rossi, G; Tarella, C; Zallio, F | 1 |
| Aloe Spiriti, MA; Betrò, P; Breccia, M; D'Elia, GM; Latagliata, R; Luzi, G; Montefusco, E; Petti, MC; Pulsoni, A; Spadea, A | 1 |
| Arceci, RJ; Brophy, N; Chang, M; Dahl, GV; Dunussi-Joannopoulos, K; Lacayo, NJ; Sikic, BI; Weinstein, HJ | 1 |
| Baguley, BC; Finlay, GJ | 1 |
| Ahmed, T; Ali, MF; Bar, M; Chun, HG; Durrani, H; Farley, T; Goldberg, R; Kancherla, R; Lake, D; Lipshutz, M; Mannancheril, A; Mittelman, A; Preti, R; Puccio, C; Qureshi, Z; Seiter, K | 1 |
| Ahmed, T; Baskind, P; Darzynkiewicz, Z; Feldman, EJ; Goff, H; Pozzuoli, M; Santos, S; Seiter, K; Traganos, F | 1 |
| Berthou, C; Buzyn, A; Cahn, JY; Chomienne, C; Cordonnier, C; de Revel, T; Degos, L; Dombret, H; Fegueux, N; Fenaux, P; Gardin, C; Gratecos, N; Guerci, A; Huguet, F; Kotoucek, P; Maloisel, F; Naccache, P; Pigneux, A; Reman, O; Sadoun, A; Stamatoullas, A; Thomas, X; Travade, P; Vekhoff, A; Vilque, JP | 1 |
| Döhner, H; Döhner, K; Schlenk, RF; van der Reijden, BA | 1 |
| Anderson, JE; Appelbaum, FR; Chauncey, TR; Chen, I; Godwin, JE; Head, DR; Kalaycio, ME; Kopecky, KJ; Kraut, EH; Leith, CP; Luthardt, FW; Moore, DF; Petersdorf, SH; Rankin, C; Shurafa, MS; Willman, CL | 1 |
| Avvisati, G; Barbui, T; Bernasconi, C; Bolufer, P; Colomer, D; Díaz-Mediavilla, J; Esteve, J; Ferrara, F; Fioritoni, G; González, JD; Gonzalez, M; Liso, V; Lo Coco, F; Mandelli, F; Martín, G; Petti, MC; Rayón, C; Ribera, JM; Rodeghiero, F; Sanz, MA | 1 |
| Budel, L; Doorduijn, JK; Löwenberg, B; Sonneveld, P; Spruit, P; van Der Holt, B; van't Veer, M | 1 |
| Ballestrero, A; Clavio, M; Ferrando, F; Garuti, A; Ghio, R; Gobbi, M; Gonella, R; Patrone, F; Sessarego, M | 1 |
| Huismans, DR; Pieters, R; Schuurhuis, GJ; Styczynski, J; Veerman, AJ; Wysocki, M | 1 |
| Blume, KG; Hoppe, RT; Horning, SJ; Hu, WW; Johnston, LJ; Negrin, RS; Stockerl-Goldstein, KE | 1 |
| Archimbaud, E; Cambier, N; Ecstein-Fraïssé, E; Leblond, V; Pautas, C; Reman, O; Soler-Michel, P; Taksin, AL; Thomas, X; Vekhoff, A | 1 |
| Bajwa, RP; Reid, MM; Skinner, R; Wariyar, UK; Windebank, KP | 1 |
| Anami, K; Ayukawa, H; Eguchi, H; Hara, T; Ikuno, Y; Inada, H; Ishii, E; Matsuzaki, A; Miyazaki, S; Nibu, K; Okamura, J; Sugimoto, T; Yanai, F | 1 |
| Balaguer-Martínez, JV; Castillo-Pallarés, FJ; Ferrer Albiach, C; Pallardó-Calatayud, J; Romero-de-Avila, C; Ruiz Hernández, G | 1 |
| Kancherla, R; Nair, JS; Seiter, K; Traganos, F; Tse-Dinh, YC | 1 |
| Chen, S; Lu, D; Ren, H | 1 |
| Weiss, M | 1 |
| Hsieh, TS; Hu, T; Liu, LF; Mao, Y; Wang, H; Zhou, N | 1 |
| Buckley, DA; du Vivier, AW; Hopster, D; Keane, FM; Mufti, GJ; Munn, SE | 1 |
| Ancín, I; Berlanga, JJ; Ferrá, C; Gallardo, D; González, JR; Grañena, A; Marín, D; Muñoz, J; Peris, J; Sarrá, J | 1 |
| Chisesi, T; Congiu, AM; Contu, A; Coser, P; Indrizzi, L; Leoni, P; Majolino, I; Polistena, P; Porcellini, A; Rizzoli, V; Salvagno, L; Santini, G; Zambaldi, G | 1 |
| Cunningham, D; Gregory, W; Hancock, B; Hoskin, P; Hudson, GV; Linch, D; MacLennan, K; Mainwaring, PN; Norton, AJ; Smith, P | 1 |
| Hokland, P; Langkjer, ST; Nørgaard, JM; Palshof, T; Pedersen, B | 1 |
| Chang, J; Covelli, A; Isidori, A; Kelsey, S; Leoni, F; Litchman, M; Malagola, M; Marcus, R; Mayer, H; Milligan, D; Pfister, C; Piccaluga, PP; Powles, R; Schey, S; Visani, G | 1 |
| Daibata, M; Hatakeyama, N; Hiroi, M; Kamioka, M; Miyoshi, I; Nemoto, Y; Taguchi, H | 1 |
| Cabanillas, FF; Cox, JD; Ha, CS; Hess, MA; Rodriguez, MA; Tucker, SL; Wilder, RB | 1 |
| Fletcher, BD; Harrison, PL; Kaste, SC; Kennedy, W; Neel, MD; Pui, CH; Razzouk, BI; Relling, MV; Ribeiro, RC; Rubnitz, JE; Sandlund, JT | 1 |
| Bernasconi, P; Boni, M; Castoldi, GL; Ciolli, S; Clavio, M; Cox, MC; Cuneo, A; Del Poeta, G; Dini, D; Falzetti, D; Fanin, R; Gobbi, M; Isidori, A; Leoni, F; Liso, V; Malagola, M; Mandelli, F; Martinelli, G; Mecucci, C; Petti, MC; Piccaluga, PP; Rondelli, R; Russo, D; Sessarego, M; Specchia, G; Testoni, N; Torelli, G; Tura, S; Visani, G | 1 |
| Ahmed, T; Feldman, EJ; Kancherla, R; Liu, D; Papageorgio, C; Pozzuoli, M; Seiter, K; Sreekantaiah, C; Weisberger, J; Weiss, M | 1 |
| Glimelius, B; Kimby, E; Nygren, P | 1 |
| Bonifazi, F; Bonini, A; Castellani, S; Gugliotta, L; Isidori, A; Lemoli, RM; Malagola, M; Martinelli, G; Motta, MR; Piccaluga, PP; Rizzi, S; Tura, S; Visani, G | 1 |
| Cernilová, I; Doubek, M; Klabusay, M; Korístek, Z; Mayer, J; Navrátil, M; Petráková, K; Vásová, I; Vodvárka, P; Vorlícek, J | 1 |
| Avigan, D; Giallombardo, N; Hurley, D; Joyce, RM; Kraser, CN; Levine, J; McDermott, D; Regan, M; Tetrealt, JC; Uhl, L; Umiel, T | 1 |
| Burnett, AK; Clark, RE; Goldstone, AH; Hutchinson, RM; Smith, AG; Wheatley, K | 1 |
| Hudes, GR; Obasaju, C | 1 |
| Boulware, D; Dalton, WS; Hazlehurst, LA; Storey, JA; Sullivan, DM; Valkov, N; Wisner, L | 1 |
| Gralow, JR; Livingston, RB | 1 |
| Fojo, T; Matsumoto, Y; Nagao, S; Takano, H | 1 |
| Amadori, S; Archimbaud, E; Aul, C; Boogaerts, M; de Witte, T; Ferrant, A; Gratwohl, A; Hagemeijer, A; Jehn, U; Labar, B; Mandelli, F; Muus, P; Selleslag, D; Suciu, S; Verhoef, G; Wijermans, P; Willemze, R; Zittoun, R; Zwierzina, H | 1 |
| Cady, J; de Gramont, A; Dehni, N; Lejeune, V; Louvet, C; Marpeau, L; Molitor, JL; Pigne, A; Sezeur, A; Tournigand, C | 1 |
| Hosomi, Y; Shibuya, M | 1 |
| Eguchi, M; Hayashi, Y; Hibi, S; Hongo, T; Imaizumi, M; Ishii, E; Isoyama, K; Kamada, N; Kawasaki, H; Kinukawa, N; Kosaka, Y; Mizutani, S; Nishimura, S; Oda, M; Oda, T; Okamura, T; Okawa, H; Tsukimoto, I | 1 |
| Creutzig, U; de Vries, E; Hählen, K; Huismans, DR; Janka-Schaub, GE; Jansen, G; Kaspers, GJ; Peters, GJ; Pieters, R; Rots, MG; van Zantwijk, CH; Veerman, AJ; Zwaan, CM | 1 |
| Akiba, M; Bessho, M; Hirashima, K; Itoh, K; Itoh, Y; Kashimura, T; Kawai, N; Kishimoto, K; Matsuda, A; Murohashi, I; Sakata, T; Suzuki, T; Takahashi, T; Tominaga, K; Wakao, D; Yagasaki, F; Yoshida, K | 1 |
| Bendix, K; Hokland, P; Kjeldsen, E; Kristensen, JS; Meyer, K; Nørgaard, JM; Olesen, G; Olesen, LH; Pedersen, B | 1 |
| Hara, T; Hattori, H; Ishii, S; Matsuzaki, A; Suminoe, A | 1 |
| Bordessoule, D; Bosly, A; Coiffier, B; Deconninck, E; Divine, M; Dupriez, B; Fillet, G; Gaulard, P; Gisselbrecht, C; Herbrecht, R; Lepage, E; Nouvel, C; Tilly, H | 1 |
| Alloisio, M; Balzarotti, M; Bertuzzi, A; Castagna, L; Compasso, S; Nozza, A; Quagliuolo, V; Santoro, A; Siracusano, L; Soto Parra, H | 1 |
| Chen, S; Gomez, SP; Mainwaring, MG; McCarley, D | 1 |
| Becton, DL; Bomgaars, L; Chang, MN; Dahl, GV; Lacayo, NJ; Lauer, SJ; Lum, BL; Ravindranath, Y; Sikic, BI; Weinstein, H | 1 |
| Andresen, S; Elson, P; He, XY; Hussein, M; Kalaycio, M; Lichtin, A; Pohlman, B | 1 |
| Balleari, E; Ballestrero, A; Clavio, M; Ferrando, F; Garuti, A; Ghio, R; Gobbi, M; Gonella, R; Grasso, R; Miglino, M; Patrone, F | 1 |
| Chisesi, T; Deliliers, GL; Federico, M; Gobbi, PG; Levis, A; Linfomi, MB; Luminari, S; Santini, G | 1 |
| Kowalski, P; Lage, H; Scheffer, GL; Stein, U | 1 |
| Brighton, T; Kwan, YL; Manoharan, A; Trickett, A | 1 |
| Hon, C; Liang, R; Shek, TW | 1 |
| Hernandez, H; Kohlhagen, G; Laurent, G; Lautier, D; Plo, I; Pommier, Y | 1 |
| Kylmä, J; Nazhat, SN; Rich, J; Seppälä, J; Tanner, KE; Tuominen, J | 1 |
| Gibson, AD | 1 |
| Handa, H; Isozumi, K; Komatsumoto, S; Motohashi, S; Nara, M | 1 |
| Braylan, R; Chen, SF; Fieniewicz, KJ; Gomez, SP; Kahn, S; Leather, H; Lynch, J; Mainwaring, MG; May, WS; Moreb, J; Reddy, V; Rimsza, LM; Rowe, TC; Weeks, FW; Wingard, JR | 1 |
| Aulitzky, W; Bodenstein, H; Clemens, M; Ehninger, G; Illmer, T; Neubauer, A; Repp, R; Schaich, M; Schäkel, U; Soucek, S; Wandt, H | 1 |
| Aitini, E; Alinari, L; Baccarani, M; Ciccone, F; De Renzo, A; Falini, B; Fattori, PP; Gentilini, P; Gherlinzoni, F; Guardigni, L; Lauria, F; Lauta, VM; Mannina, D; Mazza, P; Moretti, L; Pavone, E; Stefoni, V; Storti, S; Tani, M; Tura, S; Volpe, E; Zaccaria, A; Zaja, F; Zinzani, PL | 1 |
| Axdorph, U; Björkholm, M; Carneskog, J; Grimfors, G; Hansen, J; Linder, O; Ljungman, P; Löfvenberg, E; Malm, C; Simonsson, B; Stenke, L; Turesson, I; Udén, AM; Vilén, L | 1 |
| Baccarani, M; Benni, M; Cavo, M; Cellini, C; Fiacchini, M; Gozzetti, A; Ronconi, S; Tosi, P; Tura, S; Zamagni, E | 1 |
| Amir, G; Cohen, Y; Da'as, N; Gillis, S; Polliack, A; Rund, D | 1 |
| Büchler, T; Ferra, C; Grañena, A; Montanya, E; Virgili, N | 1 |
| Aricò, M; Egeler, RM; Elinder, G; Filipovich, AH; Gadner, H; Henter, JI; Imashuku, S; Janka, G; Komp, D; Ladisch, S; Samuelsson-Horne, A; Webb, D | 1 |
| Anderson, JE; Appelbaum, FR; Balcerzak, SP; Chen, IM; Head, D; Johnson, DB; Kopecky, KJ; Luthardt, FW; Norwood, TH; O'Donnell, MR; Willman, CL | 1 |
| Ayala, A; Cabanillas, F; Hagemeister, FB; Hess, M; Lee, MS; McLaughlin, P; Preti, A; Rodriguez, MA; Romaguera, J; Sarris, A; Smith, TL; Tsimberidou, AM; Yang, Y; Younes, A | 1 |
| Emmanouilides, C; Grody, W; Lill, M; Rosen, P; Rosenfelt, F; Telatar, M; Territo, M | 1 |
| Borker, A; Ode, D; Yu, L | 1 |
| Andersson, PO; Brune, M; Gustavsson, B; Stockelberg, D; Wadenvik, H; Wernstedt, P | 1 |
| Alterini, R; Bellesi, G; Bernardi, F; Bosi, A; Carpaneto, A; Carrai, V; Longo, G; Rigacci, L; Rossi Ferrini, P | 1 |
| Adamczyk-Cioch, M; Dmoszynska, A; Holowiecki, J; Jamroziak, K; Konopka, L; Kuliczkowski, K; Maj, S; Marianska, B; Mazur, G; Robak, T; Wierzbowska, A; Wrzesien-Kus, A; Zawilska, K | 1 |
| Alinari, L; Baccarani, M; Stefoni, V; Tani, M; Zinzani, PL | 1 |
| Fedier, A; Fink, D; Haller, U; Lenherr, L; Schwarz, VA; Steiner, RA | 1 |
| Avigan, D; Giallombardo, N; Hurley, D; Joyce, RM; Lamontagne, D; Levine, J; McDermott, D; Ottaway, J; Regan, M; Smith, T; Tetreault, JC; Uhl, L; Umiel, T | 1 |
| He, XY; Kalaycio, M; Lichtin, A; Pohlman, B; Rybicki, L | 1 |
| Barbui, T; Boccadoro, M; Cortelazzo, S; Coser, P; Cuttica, A; De Crescenzo, A; Di Nicola, M; Di Renzo, N; Federico, M; Gallamini, A; Gallo, E; Gianni, AM; Levis, A; Liberati, M; Musso, M; Pavone, E; Pescarollo, A; Pileri, A; Pregno, P; Romano, R; Rosanelli, C; Rosato, R; Santini, G; Tarella, C; Vitolo, U | 1 |
| Greco, FA; Hainsworth, JD; Lamb, MR; Litchy, S; Rodriguez, GI; Scroggin, C | 1 |
| Adams, MT; Alonzo, TA; Arceci, RJ; Buckley, J; Buxton, AB; Dusenbery, K; Gamis, A; Masterson, M; Vik, T; Warkentin, P; Wells, RJ; Whitlock, JA | 1 |
| Chelghoum, Y; Elhamri, M; Le, QH; Michallet, M; Revesz, D; Thomas, X | 1 |
| AULAGNE, L | 2 |
| ORR, TG | 1 |
| KUSCHINSKY, G; LUELLMANN, H; MOSLER, KH | 1 |
| Austin, CA; Errington, F; Leontiou, C; Tilby, MJ; Willmore, E | 1 |
| Alinari, L; Baccarani, M; Stefoni, V; Vianelli, N; Zinzani, PL | 1 |
| Amadori, S; Buccisano, F; Coco, FL; Consalvo, MI; Cudillo, L; De Fabritiis, P; Del Poeta, G; Del Principe, MI; Franchi, A; Lo-Coco, F; Maurillo, L; Mazzone, C; Picardi, A; Tamburini, A; Venditti, A | 1 |
| Creutzig, U; Kaiser, J; Klingebiel, T; Lehrnbecher, T; Reinhardt, D; Varwig, D | 1 |
| Adamo, F; Ambrosetti, A; Angelucci, E; Anselmo, AP; Bertini, M; Boccadoro, M; Cavalieri, E; Gallo, E; Gavarotti, P; Genua, A; Levis, A; Liberati, M; Mandelli, F; Pavone, V; Pietrasanta, D; Ricetti, MM; Salvi, F; Scalabrini, DR; Vitolo, U | 1 |
| Kondo, T; Mikami, M; Nakanishi, H; Otsuki, T; Suemori, S; Suetsugu, Y; Sugihara, T; Tsujioka, T; Wada, H; Yamamori, S | 1 |
| Aström, M; Björkholm, M; Hast, R; Hedenius, M; Lerner, R; Liliemark, J; Löfgren, C; Nilsson, I; Paul, C; Rödjer, S; Simonsson, B; Stockelberg, D; Tidefelt, U | 1 |
| Advani, R; Bennett, JM; Chin, DL; Dewald, G; Dugan, K; Greenberg, PL; Lee, SJ; Letendre, L; Lum, B; Paietta, E; Rowe, JM; Sikic, BI; Tallman, MS | 1 |
| Kitanishi, T; Kitano, H; Kouzaki, H; Suzuki, M | 1 |
| Dalton, WS; Engel, R; Gump, JL; Hazlehurst, L; Sullivan, DM; Valkov, NI | 1 |
| Batlle, M; Besalduch, J; Brunet, S; Bueno, J; Carreras, E; Esteve, J; Feliu, E; Guàrdia, R; Julià, A; Llorente, A; Montserrat, E; Oriol, A; Pedro, C; Ribera, JM; Sánchez, JM; Sierra, J; Tormo, M; Vilà, JM; Vivancos, P | 1 |
| Furukawa, Y; Kitani, T; Shibano, M; Tsukaguchi, M | 1 |
| Daenen, S; Ferrant, A; Huijgens, PC; Kramer, MH; Löwenberg, B; Schouten, HC; Sonneveld, P; Steijaert, MM; van den Berg, E; van der Holt, B; van Marwijk Kooy, R; Verdonck, LF; Verhoef, GE; Wijermans, PW | 1 |
| Abrams, J; Al-Katib, A; Ibrahim, D; Karanes, C; Lai, P; Millenson, M; Pemberton, P; Smith, MR; Varterasian, M; Yeslow, G | 1 |
| BURGOS, M | 1 |
| Isaksson, O; Tarkowski, A; Verdrengh, M | 1 |
| Creutzig, U; Dworzak, M; Lehrnbecher, T; Reinhardt, D; Stary, J; Zimmermann, M | 1 |
| Baer, MR; Block, AW; Bloomfield, CD; Carroll, AJ; Farag, SS; Koduru, PR; Kolitz, JE; Larson, RA; Mayer, RJ; Moore, JO; Mrózek, K; Pettenati, MJ; Powell, BL; Ruppert, AS; Schiffer, CA; Stamberg, J; Stone, RM; Vardiman, JW | 1 |
| Kalaycio, M | 1 |
| Chaoui, D; Legrand, O; Marie, JP; Peffault De Latour, R | 1 |
| Hausmaninger, H; Heilmann, V; Huebner, G; Nitsch, T; Possinger, K; Schippinger, W; Schmid, P; Schultze, W; Wischnewsky, M | 1 |
| Alterini, R; Bernardi, F; Bosi, A; Carrai, V; Longo, G; Nassi, L; Rigacci, L | 1 |
| Fujino, H; Hayashi, K; Hirai, M; Hirose, A; Ishii, K; Katsurada, T; Kitajima, H; Kitayama, H; Mugitani, A; Ohta, T; Shigeki, T; Teshima, H; Urase, F; Yagi, T; Yamamoto, Y | 1 |
| Naito, K; Ohnishi, K | 1 |
| Seiter, K | 1 |
| Kluin, PM; Kluin-Nelemans, HC; Kramer, MH; MacKenzie, MA; Meulendijks, LA; Ossenkoppele, GJ; Raemaekers, JM; Schouten, HC; Sonneveld, P; van 't Veer, MB; van der Holt, B; van Imhoff, GW; van Marwijk Kooy, M; van Oers, MH; Verdonck, LF; Wijermans, PW | 1 |
| Kluin, PM; Kluin-Nelemans, HC; Mackenzie, MA; Ossenkoppele, GJ; Schouten, HC; Sonneveld, P; Steijaert, MM; van der Holt, B; van Imhoff, GW; Van't Veer, MB; Verdonck, LF; Wijermans, PW | 1 |
| Adès, L; Blair, IA; Cassinat, B; Chomienne, C; Cross, NC; Felix, CA; Fenaux, P; Grimwade, D; Lafage-Pochitaloff, M; Mason, A; Mistry, AR; Osheroff, N; Parry, A; Peniket, AJ; Reiter, A; Segal, MR; Solomon, E; Walz, C; Whitmarsh, RJ; Wiemels, JL | 1 |
| Borkhardt, A; Bruch, J; Fuchs, U; Metzler, M; Perez, AV; Wilda, M; Woessmann, W | 1 |
| Aksu, S; Güven, GS; Koçak, T; Ozçakar, L | 1 |
| Allen, K; Barth, NM; Beutel, LD; Chico, S; Dillman, RO; VanderMolen, LA | 1 |
| Brandwein, J; Brown, R; Chopra, R; De Angelo, D; Ehmann, WC; Feldman, EJ; Frankel, SR; Jurcic, JC; Kalaycio, M; Miller, C; Moore, J; O'Connor, J; Roboz, GJ; Scheinberg, D; Schulman, P; Stone, R; Wedel, N | 1 |
| Botton, Sd; Chelghoum, Y; Dhedin, N; Dombret, H; Dreyfus, F; Elhamri, M; Fenaux, P; Guerci, A; Le, Q; Michallet, M; Pautas, C; Pigneux, A; Raffoux, E; Reman, O; Revel, Td; Thiebaut, A; Thomas, X; Travade, P; Troncy, J; Vekhoff, A | 1 |
| Kara, B; Kara, IO; Paydas, S; Sahin, B | 1 |
| Agoliati, G; Ahmed, T; Arshad, M; Galvin-Parton, P; Liu, D; Qureshi, A; Seiter, K | 1 |
| Chi, HS; Choi, SJ; Jang, S; Kim, WK; Lee, JH; Lee, JS; Lee, KH; Lee, YS; Park, CJ; Ryu, SG; Seol, M | 1 |
| Chin, WW; Dantzig, AH; Iversen, PW; Jin, S; Krishnan, V; Lesoon, A; Moore, RE; O'Brien, KA; Peek, VL; Perry, WL; Rolfe, M; Sampath, J; Shepard, RL; Shyjan, A; Tighe, M; Williamson, M; Yaden, B | 1 |
| Chamorey, E; Delwail, V; Fabbro, M; Foussard, C; Gressin, R; Harrousseau, JL; Lepeu, G; Maisonneuve, H; Peyrade, F; Richard, B; Rossi, JF; Thyss, A; Vilque, JP | 1 |
| Bloomfield, CD; Carroll, AJ; Edwards, CG; Kolitz, JE; Larson, RA; Maharry, K; Marcucci, G; Mayer, RJ; Moore, JO; Mrózek, K; Pettenati, MJ; Powell, BL; Ruppert, AS; Schiffer, CA; Sterling, LJ; Vardiman, JW | 1 |
| Cabanillas, F; Cox, JD; Ha, CS; Lee, MS; McLaughlin, P; Mesina, OM; Rodriguez, MA; Romaguera, JE; Tucker, SL; Younes, A | 1 |
| Albarello, A; Ballerini, F; Balocco, M; Canepa, L; Canepa, P; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Varaldo, R | 1 |
| Lemez, P; Urbánek, V | 1 |
| Döhner, H; Döhner, K; Eiwen, K; Fröhling, S; Schlenk, RF; Scholl, C | 1 |
| Austin, CA; Ayuso, MJ; Azrak, SS; Cortés, F; López-Lázaro, M; Pastor, N | 1 |
| de Graaf, SS; Gibson, BE; Hann, IM; Hills, RK; O'Marcaigh, A; Rao, A; Stiller, C; Webb, DK; Wheatley, K | 1 |
| Burton, C; Cunningham, D; Dyer, MJ; Hancock, B; Hoskin, P; Jack, A; Linch, D; MacLennan, K; Milligan, D; Mouncey, P; Qian, W; Smith, P; Webb, A | 1 |
| Aung, L; Kirk, RC; Liang, S; Quah, TC; Tan, RM; Yeoh, AE | 1 |
| Hasegawa, H; Miyagi, T; Nagasaki, A; Nakachi, S; Shinzato, O; Taira, N; Takasu, N; Tomoyose, T | 1 |
| Kageyama, Y; Kihara, K; Kobayashi, T; Kubo, Y; Yokoyama, M | 1 |
| Belch, A; Gluck, S; Larratt, L; Robinson, KS; Sheridan, D; Shustik, C; Stewart, K; Van Der Jagt, R; Wells, G; Yetisir, E | 1 |
| Hanada, R; Kigasawa, H; Kinoshita, A; Tabuchi, K; Tomizawa, D; Tsuchida, M; Tsukimoto, I | 1 |
| Salonen, JH | 1 |
| Adamo, F; Amadori, S; Beeldens, F; Berneman, Z; de Witte, T; Fazi, P; Fillet, G; Jehn, U; Lefrère, F; Leone, G; Mandelli, F; Marie, JP; Montanaro, M; Muus, P; Nobile, F; Ricciuti, F; Rizzoli, V; Suciu, S; Thomas, X; Willemze, R | 1 |
| Ambudkar, SV; Chearwae, W; Limtrakul, P; Phisalphong, C; Shukla, S | 1 |
| Kansu, E; Kars, A; Koc, Y; Oyan, B; Ozdemir, E; Tekuzman, G; Turker, A | 1 |
| Martin, PL; McLean, TW; White, MS | 1 |
| Dörken, B; Dreyling, M; Forstpointner, R; Freund, M; Ganser, A; Hiddemann, W; Hoster, E; Huber, C; Ludwig, WD; Nickenig, C; Trümper, L; Unterhalt, M | 1 |
| Ahmad, I; André, M; Bennani, J; Bron, D; Dargent, JL; Meuleman, N; Ngirabacu, MC; Ravoet, C; Ysebrant, L | 1 |
| Alvarez, C; Bolufer, P; Brunet, S; Colomer, D; Díaz-Mediavilla, J; Escoda, L; Esteve, J; González San Miguel, JD; González, M; Martín, G; Rivas, C; Rubio, V; Sánchez Godoy, P; Sanz, MA; Sayas, MJ; Tomás, JF; Tormo, M | 1 |
| Darzynkiewicz, Z; Halicka, HD; Seiter, K; Tanaka, T; Traganos, F | 1 |
| Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kirito, K; Mano, H; Matsuo, Y; Odgerel, T; Sato, Y; Tsunoda, S; Vu, HA | 1 |
| Chen, H; Han, W; Huang, XJ; Liu, DH; Liu, KY; Xu, LP | 1 |
| Balleisen, L; Buss, EC; Emmerich, B; Fischer, T; Fruehauf, S; Hehlmann, R; Ho, AD; Hochhaus, A; Müller, MC; Ottmann, OG; Schuld, P; Topaly, J | 1 |
| Franklin, EE; Robertson, JD | 1 |
| Bakshi, A; Gujral, S; Gupta, S; Nair, R; Parikh, P; Prabhash, K; Sengar, M | 1 |
| Awan, F; Devine, S; Hamadani, M | 1 |
| Amadori, S; Buccisano, F; Consalvo, MI; De Fabritiis, P; Del Poeta, G; Del Principe, MI; Fraboni, D; Maurillo, L; Mazzone, C; Neri, B; Ottaviani, L; Panetta, P; Sarlo, C; Spagnoli, A; Tamburini, A; Venditti, A | 1 |
| Allen, WL; Galligan, L; Johnston, PG; Longley, DB; Rogers, KM; Sakai, H; Thomas, M; Wilson, TR | 1 |
| Boccadoro, M; Bregni, M; Cabras, A; Calvi, R; Caracciolo, D; Comino, A; Corradini, P; Devizzi, L; Di Nicola, M; Fornari, A; Gallamini, A; Gianni, AM; Ladetto, M; Magni, M; Majolino, I; Mirto, S; Novero, D; Patti, C; Pescarollo, A; Ponzoni, M; Remotti, D; Rosato, R; Stella, M; Tarella, C; Zanni, M; Zoli, V | 1 |
| Baxter, H; Di Iulio, J; Juneja, S; Leahy, M; Manoharan, A; Matthews, J; Reynolds, J | 1 |
| Hait, WN; Nayak, MS; Yang, JM | 1 |
| Aikawa, K; Arima, F; Fukuda, H; Hanada, S; Hotta, T; Kasai, M; Kobayashi, T; Masanori, S; Mukai, K; Ogura, M; Shirakawa, S; Sueoka, E; Tajima, K; Takeyama, K; Tobinai, K | 1 |
| Fukao, M; Isogai, R; Kawada, A | 1 |
| Hasumi, H; Izumi, K; Kanno, H; Mikata, K; Nagashima, Y; Osada, Y; Otai, J; Tsuchiya, F; Umemoto, S | 1 |
| Alinari, L; Baccarani, M; Bacci, F; Derenzini, E; Fina, M; Marchi, E; Musuraca, G; Pellegrini, C; Pileri, S; Stefoni, V; Tani, M; Zinzani, PL | 1 |
| Fujiwara, M; Higashimura, M; Izumi, N; Koike, T; Satou, N; Shibasaki, Y; Tsukada, N | 1 |
| Balzarotti, M; Boiardi, A; Calatozzolo, C; Ciusani, E; Croci, D; de Grazia, U; Salmaggi, A | 1 |
| Böttger, S; Jerszyk, E; Low, B; Walker, C | 1 |
| Marik, PE; Vahid, B | 1 |
| Darzynkiewicz, Z; Halicka, HD; Schmuck, G; Smart, DJ; Traganos, F; Williams, GM | 1 |
| Kell, J | 1 |
| Aversa, SML; Bianco, A; Errante, D; Salvagno, L | 1 |
| Birkmann, J; Bodenstein, H; Clemens, M; Fuchs, R; Hänel, M; Hensel, M; Peter, N; Pfreundschuh, M; Reiser, M; Zeynalova, S; Ziepert, M; Zwick, C | 1 |
| Advani, A; Kalaycio, M; Pohlman, B; Rybicki, L; Sekeres, M; Sobecks, R; Tripp, B | 1 |
| Chi, HS; Jang, S; Kang, YA; Kim, DY; Kim, SH; Lee, JH; Lee, KH; Lee, SS; Lee, YS; Lim, SN; Park, CJ; Ryu, SG; Seol, M; Yun, SC | 1 |
| Jonathan, F | 1 |
| Berlanga, JJ; Besalduch, J; Brunet, S; Bueno, J; Esteve, J; Gallardo, D; Guardia, R; Heras, I; Hoyos, M; Llorente, A; Nomdedeu, J; Pérez-García, A; Ribera, JM; Sierra, J; Tormo, M | 1 |
| Mavridis, K; Scorilas, A; Talieri, M; Thomadaki, H | 1 |
| Karp, J | 1 |
| Brown, AW; McGregor, BA; Osswald, MB; Savona, MR | 1 |
| Chandacham, A; Charoenkwan, K; Cheewakraingkrai, C; Khunamornpong, S; Kietpeerakool, C; Phongnarisorn, C; Siriaree, S; Srisomboon, J; Suprasert, P; Tantipalakorn, C | 1 |
| Li, Y; Mi, Y; Qiu, L; Wang, J; Zhao, Y; Zou, D | 1 |
| Clarke, SJ; Cunningham, D; Dent, O; Robertson, G; Sharma, R; Smith, P | 1 |
| Hu, NP; Hu, XM; Li, L; Liu, C; Liu, F; Ma, R; Wang, HZ; Xiao, HY; Xu, YG; Yang, XH; Zhang, SS; Zheng, CM | 1 |
| Bhartia, S; Proctor, SJ; Sieniawski, M; Wilkinson, J | 1 |
| de Bont, ES; Kamps, WA; Koetse, HA; Rings, EH; Stellaard, F; Tissing, WJ; van Vliet, MJ | 1 |
| Akbulut, H; Buyukcelik, A; Demirkazik, A; Dincol, D; Dogan, M; Icli, F; Onur, H; Samur, M; Senler, FC | 1 |
| Amadori, S; Baila, L; de Witte, T; Di Raimondo, F; Fazi, P; Ferrara, F; Labar, B; Liso, V; Mandelli, F; Marie, JP; Marmont, F; Meloni, G; Muus, P; Petti, MC; Stasi, R; Suciu, S; Thomas, X; Vignetti, M; Willemze, R; Zittoun, R | 1 |
| Batteux, F; Debray, M; Hirt, D; Laurent, A; Pavlovic, S; Poupon, J; Richardet, JP; Sogni, P; Treluyer, JM; Urien, S; Weill, B | 1 |
| Kepp, O; Kroemer, G; Martins, I; Métivier, D; Michaud, M; Perfettini, JL; Schlemmer, F; Senovilla, L; Séror, C; Tesniere, A; Zitvogel, L | 1 |
| Agha, M; Boyiadzis, M; Foon, KA; Luong, TM; McHayleh, W; Natale, J; Raptis, A; Redner, RL; Schlesselman, JJ; Sehgal, R | 1 |
| Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Mano, H; Miyawaki, S; Tanaka, M; Tsunoda, S; Yazawa, Y | 1 |
| Burnett, AK; Duncombe, A; Gibson, B; Goldstone, AH; Hills, RK; McMullin, MF; Milligan, DW; Prentice, AG; Wheatley, K | 1 |
| Dessalvi, P; Di Tucci, AA; Emanuele, A; Pettinau, M; Romani, C | 1 |
| Arceci, RJ; Bernstein, M; Buck, S; Chang, MN; Dahl, GV; Kshirsagar, S; Lacayo, NJ; Lum, BL; O'Brien, MM; Ravindranath, Y; Sikic, BI; Weinstein, H | 1 |
| Ângelo, S; Moreira, JN; Pinto, AC; Simões, S | 1 |
| Ali-Osman, F; Beaven, A; Chao, NJ; Chute, J; Crout, CA; Davis, P; Decastro, C; Diehl, L; Edwards, J; Gasparetto, C; Gockerman, JP; Horwitz, M; Koh, LP; Long, GD; Moore, JO; Morris, A; Niedzwiecki, D; Prosnitz, L; Rizzieri, DA | 1 |
| Leo, E; Marchand, C; Pommier, Y; Zhang, H | 1 |
| Barraco, F; Cannas, G; Chelghoum, Y; Derbel, O; Elhamri, M; Le, QH; Michallet, M; Nicolas-Virelizier, E; Nicolini, F; Thomas, X; Troncy, J | 1 |
| Gill, D; Ho, AD; Kuhnt, E; Loeffler, M; Österborg, A; Pettengell, R; Pfreundschuh, M; Rieger, M; Walewski, J; White, D | 1 |
| Agha, M; Boyiadzis, M; Foon, KA; Hou, JZ; Raptis, A; Redner, RL | 1 |
| Alizadeh, AA; Berube, C; Coutre, S; Gotlib, J; Ho, M; Kohrt, HE; Liedtke, M; Majeti, R; Medeiros, BC; Owen, T; Patel, S; Pollyea, DA | 1 |
| Brantly, ML; Campos, MA; Chapman, KR; Kueppers, F; Sandhaus, RA; Stocks, JM; Strange, C; Turino, G; Wang-Smith, L | 1 |
| Briel, J; Gocke, CD; Hess, AD; Kanakry, CG; Karp, JE; Kos, F; Levitsky, H; Luznik, L; Meyer, C; Smith, BD; Thoburn, C | 1 |
| Argnani, L; Baccarani, M; Broccoli, A; Derenzini, E; Fanti, S; Gandolfi, L; Pellegrini, C; Quirini, F; Stefoni, V; Zinzani, PL | 1 |
| Teh, TC; Wei, A | 1 |
| Berthou, C; Deconinck, E; Delwail, V; François, S; Gastinne, T; Gyan, E; Milpied, N; Monjanel, H; Moreau, A; Perrodeau, E | 1 |
| Fernandez, HF; George, TJ; Ho, VQ; Kharfan-Dabaja, MA; Komrokji, RS; Lancet, JE; List, AF; Pinilla-Ibarz, J; Price, SL; Wetzstein, GA | 1 |
| Ancliff, P; Darbyshire, P; Goulden, N; Green, N; Hancock, J; Leighton, C; Love, S; Masurekar, A; Moorman, AV; Morgan, M; Parker, C; Révész, T; Saha, V; Sutton, R; Waters, R | 1 |
| Guan, XQ; Huang, LB; Ke, ZY; Luo, XQ; Xu, L; Zhang, XL; Zhang, YC | 1 |
| Agha, M; Boyiadzis, M; Duggal, S; Foon, KA; Hou, JZ; Luong, TM; Mehta, DR; Raptis, A; Redner, RL; Schlesselman, JJ | 1 |
| Pham, XH; Tran, NQ; Tuteja, N; Tuteja, R | 1 |
| Czarnik-Matusewicz, H; Ganczarski, G; Gąsiorowski, J; Głowacka, K; Kuliczkowski, K; Orzechowska-Juzwenko, K; Wiela-Hojeńska, A; Wołowiec, D; Łapiński, Ł | 1 |
| Camus, M; Guillet, G; Hainaut-Wierzbicka, E; Levillain, P; Lopez, L; Saulnier, JP | 1 |
| Hägglund, H; Karbach, H; Klimkowska, M; Machaczka, M; Nahi, H | 1 |
| Belinka, BA; Gupta, A; Kachlany, SC; Le, A | 1 |
| Agostinelli, C; Broccoli, A; Faccioli, L; Pastore Trossello, M; Spinardi, L; Stefoni, V; Zinzani, PL | 1 |
| De Graaf, SS; Gibson, BE; Harrison, CJ; Howman, AJ; Webb, DK; Wheatley, K | 1 |
| Bargetzi, M; Cornelissen, JJ; Ferrant, A; Fey, MF; Gratwohl, A; Graux, C; Huijgens, PC; Löwenberg, B; Maertens, J; Ossenkoppele, GJ; Schaafsma, R; Schanz, U; Schouten, HC; Theobald, M; van Putten, W; Vellenga, E; Verdonck, LF | 1 |
| Kamoto, A; Kawashima, A; Nakai, Y; Nakayama, M; Nishimura, K; Nonomura, N; Ono, Y; Takada, T; Takayama, H; Tanigawa, G; Tsujimura, A; Ujike, T; Yamaguchi, Y | 1 |
| Darzynkiewicz, Z; Dobrucki, J; Rybak, P; Traganos, F; Zhao, H | 1 |
| Carroll, M; Kasner, MT; Luger, SM; Perl, AE; Shank, D | 1 |
| Altman, J; Carlson-Leuer, K; Coyle, K; Frankfurt, O; Mehta, J; Newman, D; Rademaker, AW; Tallman, MS; Trifilio, SM | 1 |
| Arima, N; Furukawa, T; Hachiman, M; Hamada, T; Kofune, H; Kozako, T; Matsushita, K; Nakashima, M; Suzuki, S; Uozumi, K; White, Y; Yoshimitsu, M | 1 |
| Atenafu, EG; Brandwein, JM; Gupta, V; Minden, MD; Murray, C; Nixon, S; Saini, L; Schimmer, AD; Schuh, AC; Yee, KW | 1 |
| Fukushima, T; Haba, T; Morinaga, K; Nakao, S; Origasa, H; Sugiyama, T; Ueda, M; Ueda, T; Umehara, H; Urasaki, Y; Yamaguchi, M | 1 |
| Levis, M | 1 |
| Abboud, CN; Cashen, AF; DiPersio, JF; Hladnik, LM; Kulkarni, S; McFarland, K; Motabi, IH; Rettig, MP; Stockerl-Goldstein, KE; Trinkaus, KM; Uy, GL; Vij, R; Westervelt, P | 1 |
| Bartolesi, AM; Fanci, R; Pecile, P; Pini, G | 1 |
| Appelbaum, FR; Geraghty, DE; Godwin, JE; Ho, PA; Kutny, M; Meshinchi, S; Ostronoff, F; Othus, M; Petersdorf, SH; Radich, JP; Stirewalt, DL; Willman, CL | 1 |
| Hamamoto, K; Hasegawa, D; Kikuchi, A; Kojima, S; Manabe, A; Nakahata, T; Ohtsuka, Y; Okamura, J | 1 |
| Bozkurt, C; Dogru, M; Kocaoglu, AC; Ozmen, S | 1 |
| Austin, CA; Cowell, IG | 1 |
| Dirnhofer, S; Girsberger, S; Karow, A; Lehmann, T; Lundberg, P; Passweg, JR; Rovó, A; Skoda, R; Tichelli, A | 1 |
| Agha, M; Boyiadzis, M; Duggal, S; Hou, JZ; Im, A; Lin, Y; McLaughlin, B; Raptis, A; Redner, R; Smith, C | 1 |
| Abrahamsson, J; Forestier, E; Gustafsson, B; Ha, SY; Hasle, H; Heilmann, C; Heldrup, J; Jahnukainen, K; Jónsson, ÓG; Lausen, B; Palle, J; Wareham, NE; Zeller, B | 1 |
| Atenafu, EG; Brandwein, JM; Gupta, V; Hassanein, M; Minden, MD; Schimmer, AD; Schuh, AC; Yee, KW | 1 |
| Chen, TL; Estey, EH; Gardner, KM; Markle, LJ; Othus, M; Walter, RB | 1 |
| Cho, BS; Cho, SG; Eom, KS; Kim, DW; Kim, HJ; Kim, JH; Kim, YJ; Lee, JW; Lee, S; Lee, SE; Min, CK; Min, WS; Park, CW; Shin, SH; Yahng, SA; Yoon, JH | 1 |
| Cantor, R; Demeure, O; Eskin, E; Ghazalpour, A; Hormozdiari, F; Lagarrigue, S; Lusis, AJ; Martin, L; Pan, C; Roux, PF; van Nas, A | 1 |
| Cunningham, D; Linch, DC; Lowry, L; Smith, P | 1 |
| Amadori, S; Berneman, Z; De Fabritiis, P; de Witte, T; Falzetti, F; Fazi, P; Guimaraes, JE; Halkes, CJ; Ho, AD; Karrasch, M; Latagliata, R; Lübbert, M; Magro, D; Marie, JP; Muus, P; Salih, HR; Selleslag, D; Specchia, G; Stasi, R; Suciu, S; Thomas, X; Venditti, A; Vignetti, M; Willemze, R | 1 |
| Bompas, E; Clarisse, B; Cojocarasu, O; Delva, R; Eymard, JC; Guillot, A; Houede, N; Joly, F; Leconte, A; Lheureux, S; Linassier, C; Mourey, L; Oudard, S; Ravaud, A; Ringensen, F; Sevin, E; Tubiana-Mathieu, N; Valenza, B; Vedrine, L | 1 |
| Bastide, C; Beuzeboc, P; Brenot-Rossi, I; Bruyère, F; Guy, L; Karsenty, G; Mongiat-Artus, P | 1 |
| Brito-Ramirez, AS; Cantú-Rodríguez, OG; Gomez-Almaguer, D; Gutiérrez-Aguirre, H; Herrera-Garza, JL; Jaime-Pérez, JC; Pinzon-Uresti, MA | 1 |
| Audisio, E; Boccadoro, M; Bruno, B; Crisà, E; Ferrero, D; Festuccia, M; Frairia, C; Gatti, T; Giai, V; Marmont, F; Passera, R; Riera, L | 1 |
| Iland, HJ; Seymour, JF; Wei, A | 1 |
| Adachi, S; Hamamoto, K; Hanada, R; Hayashi, Y; Horibe, K; Imaizumi, M; Kobayashi, R; Kudo, K; Miyamura, T; Morimoto, A; Moritake, H; Nakayama, H; Shimada, A; Tabuchi, K; Taga, T; Tawa, A; Tomizawa, D; Tsuchida, M; Tsukimoto, I; Yabe, H | 1 |
| Abbi, KK; Claxton, DF; Ehmann, WC; Rybka, W | 1 |
| Ahn, JS; Chung, JS; Jo, DY; Joo, YD; Jung, SH; Kim, DY; Kim, I; Lee, JJ; Lee, KH; Moon, JH; Park, S; Shin, HJ; Sohn, SK; Song, IC; Yang, DH | 1 |
| Avvisati, G; Breccia, M; Carmosino, I; Chisini, M; Cimino, G; Colafigli, G; Finsinger, P; Foà, R; Girmenia, C; Latagliata, R; Lo-Coco, F; Minotti, C; Montagna, C; Petti, MC; Romano, A; Volpicelli, P; Vozella, F | 1 |
| Cortes, JE; Feldman, EJ; Goldberg, SL; Hogge, DE; Kantarjian, H; Kolitz, JE; Larson, M; Louie, AC; Pigneux, A; Recher, C; Rizzeri, DA; Schiller, G; Warzocha, K | 1 |
| Acab, A; Chailangkarn, T; Dietrich, A; Fernandez, TV; Griesi-Oliveira, K; Gu, X; Gupta, AR; Haddad, G; Ji, W; Lifton, RP; Marchetto, MC; Ming, GL; Muotri, AR; Murdoch, JD; Nicol, X; Nunez, Y; Passos-Bueno, MR; Pradhan, D; Sanders, SJ; Song, H; Spitzer, N; State, MW; Sunaga, DY; Vadasz, E; Walker, MF | 1 |
| Berube, C; Coutré, SE; Dinner, S; Dunn, T; Gotlib, J; Liedtke, M; Medeiros, B; Patel, S | 1 |
| Baruchel, A; Bertrand, Y; Brethon, B; Cave, H; Galambrun, C; Gandemer, V; Leverger, G; Nelken, B; Plat, G; Rohrlich, P; Schmitt, C; Thomas, C; Vérité, C | 1 |
| Boyd, JD; Brightsmith, DJ; Hoppes, SM | 1 |
| Ai, X; Ding, M; Ding, S; Gu, X; Huang, G; Li, X; Lv, L; Pang, L; Song, X; Zhao, J | 1 |
| Amorim, S; Brice, P; Fleury, I; Harel, S; Mounier, N; Thieblemont, C | 1 |
| Bhatnagar, B; Blum, W; Canning, R; Devine, SM; Garzon, R; Geyer, S; Klisovic, R; Marcucci, G; Vasu, S; Walker, AR; Walsh, K; Wang, H; Wu, YZ | 1 |
| Austin, CA; Bramley, RL; Cowell, IG; Jackson, GH; Lee, KC | 1 |
| Bochennek, K; Creutzig, U; Gilfert, J; Hassler, A; Lehrnbecher, T; Perner, C; Reinhardt, D; Schöning, S | 1 |
| Ashizawa, M; Fujiwara, S; Hatano, K; Ito, S; Kanda, Y; Kawasaki, Y; Mashima, K; Minakata, D; Muroi, K; Nakano, H; Oh, I; Ohmine, K; Okazuka, K; Sato, K; Sugimoto, M; Suzuki, T; Umino, K; Yamamoto, C; Yamasaki, R | 1 |
| Diao, W; Jiang, X; Yu, P | 1 |
| Agha, M; Amjad, A; Boyiadzis, M; Dorritie, KA; Duggal, S; Farah, R; Hou, JZ; Im, A; Lim, S; McLaughlin, B; Raptis, A; Redner, RL; Sehgal, A; Shuai, Y | 1 |
| Bernas, T; Berniak, K; Bujnowicz, L; Darzynkiewicz, Z; Dobrucki, J; Hoang, A; Rybak, P; Zarębski, M | 1 |
| Atwal, M; Austin, CA; Cowell, IG; Lishman, EL | 1 |
| Abdalla, B; Alfaar, AS; Awad, M; Rashed, WM; Taha, H; Zekri, W | 1 |
| Adachi, S; Goto, H; Hasegawa, D; Hayashi, Y; Horibe, K; Iwamoto, S; Miyamura, T; Mizutani, S; Moritake, H; Nakayama, H; Saito, A; Shiba, N; Shimada, A; Taga, T; Tanaka, S; Terui, K; Tomizawa, D | 1 |
| Abboud, CN; Andreeff, M; DiPersio, JF; Eades, W; Fletcher, TR; Jacoby, MA; Konopleva, MY; McFarland, K; Reineck, T; Rettig, MP; Shannon, W; Stockerl-Goldstein, K; Stone, RM; Uy, GL; Westervelt, P | 1 |
| Becker, PS; Buckley, SA; Chen, TL; Estey, EH; Halpern, AB; Hendrie, PC; Huebner, EM; Orlowski, KF; Othus, M; Percival, MM; Pogosova-Agadjanyan, EL; Scott, BL; Stirewalt, DL; Walter, RB | 1 |
| Alexander, TB; Inaba, H; Pounds, S; Pui, CH; Ribeiro, RC; Rubnitz, JE; Triplett, BM; Wang, L | 1 |
| Ali, AM; Cooley, SA; DiPersio, JF; Miller, JS; Rashidi, A; Romee, R; Shanley, R; Ustun, C; Vij, KR; Weisdorf, DJ; Westervelt, P | 1 |
| Amrein, PC; Attar, EC; Avigan, D; Ballen, KK; Brunner, AM; DeAngelo, DJ; Ebert, BL; Fathi, AT; Hobbs, GS; Luptakova, K; McMasters, M; Rosenblatt, J; Sperling, AS; Steensma, DP; Stone, RM; Stroopinsky, D; Wadleigh, M; Washington, A; Werner, L | 1 |
| Bocchia, M; Cencini, E; Fabbri, A; Gentili, F; Mazzei, MA; Schiattone, L | 1 |
| Carabasi, M; Carroll, M; Filicko-O'Hara, J; Flomenberg, N; Frey, NV; Hexner, EO; Jeschke, GR; Kasner, MT; Loren, AW; Luger, SM; Mangan, JK; Mick, R; Perl, AE; Wagner, JL; Weiss, M | 1 |
| Borel, P; Buffière, C; Caris-Veyrat, C; Goupy, P; Halimi, C; Margier, M; Reboul, E; Remond, D | 1 |
| Huang, Y; Liu, DD; Lv, TT; Xu, J; Yuan, GL; Zhou, XF | 1 |
| Altman, JK; Broun, ER; Carroll, MP; Karp, JE; Kaufmann, SH; Ketterling, RP; Lazarus, HM; Litzow, MR; Luger, SM; Paietta, EM; Pratz, KW; Rowe, JM; Rybka, WB; Tallman, MS; Tun, HW; Wang, XV; Zhang, Y | 1 |
| Advani, AS; Caimi, P; Carew, J; Carraway, H; Chan, R; Cooper, B; de Lima, M; Elson, P; Gerds, A; Hamilton, B; Kalaycio, M; Little, J; Maciejewski, J; Malek, E; Miron, A; Mukherjee, S; Nazha, A; Pink, J; Sekeres, MA; Sobecks, R; Tomlinson, B; Unger, A; Visconte, V; Wei, W | 1 |
| Ballerini, F; Cagnetta, A; Cea, M; Clavio, M; Colombo, N; Gobbi, M; Guolo, F; Lemoli, RM; Marcolin, R; Miglino, M; Minetto, P; Todiere, A | 1 |
| Armstrong, L; Atwal, M; Austin, CA; Cowell, IG; Lee, DC; Lee, KC; Rowe, C; Swan, RL | 1 |
| Chang, WH; Cheng, NM; Wang, PH | 1 |
| Cheng, M; Lee, NR; Wang, PH | 1 |
| Kankanala, J; Kiselev, E; Pommier, Y; Ravji, A; Wang, Z; Xie, J | 1 |
| Ballen, K; Bhatt, S; Brunner, A; Burgess, M; Carr, SA; DeAngelo, DJ; Ebert, BL; Fell, G; Garcia, JS; Keshishian, H; Letai, A; Medeiros, BC; Neuberg, D; Sperling, AS; Stone, RM; Yilma, B | 1 |
| Amrein, PC; Attar, E; Ballen, KK; Behnan, T; Bergeron, MK; Bertoli, C; Blonquist, TM; Brunner, AM; Burke, M; Chen, YB; Connolly, C; Duong, VH; Emadi, A; Fathi, AT; Foster, JE; Graubert, TA; Hasserjian, RP; Hobbs, G; Hock, H; Lescinskas, C; Lesho, P; Macrae, M; Mann, ML; McAfee, SL; McGregor, K; Moran, JA; Narayan, R; Neuberg, DS; Preffer, FI; Rae, J; Ramos, AY; Som, TT; Story, JL; Vartanian, MK; Wey, MC | 1 |
| Abbenante, MC; Arpinati, M; Baccarani, M; Baldazzi, C; Bertamini, L; Bochicchio, MT; Bonifazi, F; Caso, L; Cavo, M; Cristiano, G; Curti, A; de Polo, S; Fontana, MC; Marconi, G; Martinelli, G; Nanni, J; Olivi, M; Ottaviani, E; Paolini, S; Papayannidis, C; Parisi, S; Ragaini, S; Sartor, C; Sessa, M; Talami, A; Testoni, N | 1 |
| Czauderna, C; Galle, PR; Heil, E; Heinrich, B; Heinrich, S; Kloeckner, R; Koch, S; Marquardt, JU; Philippe P Diggs, L; Schmidtmann, I; Sprinzl, M; Weinmann, A; Wörns, MA | 1 |
| Agrawal, V; Arain, S; Cahill, K; Calip, GS; Christian, S; Esen, A; Griffin, S; Khan, I; Konig, H; Odenike, O; Patel, P; Quigley, JG; Shergill, A; Stock, W; Sweiss, K | 1 |
| Berkowitz, RS; Elias, KM; Goldstein, DP; Horowitz, NS; Jareemit, N | 1 |
| Bin, T; Chen, S; Chen, X; Cheng, J; Liao, Y; OUYang, J; Zou, W | 1 |
| Aramaki, K; Ikeda, N; Kosono, S; Shiozaki, Y | 1 |
| Liu, Y; Wang, S; Ye, H; Zhang, L; Zhou, Y | 1 |
| Chen, XJ; Chen, YM; Guo, Y; Liu, F; Liu, LP; Liu, TF; Liu, XM; Quan Qi, B; Ruan, M; Yang, WY; Zhang, AL; Zhang, L; Zhu, XF; Zou, Y | 1 |
| Akkurt, DM; Cinli, TA; Demir, I; Durusoy, SS; Gunes, AK; Ince, I; Ozkan, G; Pehlivan, M; Sarifakiogullari, S; Serin, I | 1 |
| Aotsuka, N; Doki, N; Fujisawa, S; Fujiwara, SI; Gotoh, M; Ishizaki, T; Kanamori, H; Kanda, J; Kanda, Y; Kimura, SI; Miyazaki, T; Mori, T; Najima, Y; Okamoto, S; Onizuka, M; Saito, T; Sakaida, E; Shono, K; Tachibana, T; Takahashi, S; Tanaka, M; Watanabe, R | 1 |
| Advani, AS; Becker, PS; Bixby, DL; DeAngelo, DJ; Feldman, EJ; Jonas, BA; Liesveld, JL; Magnani, JL; Marlton, P; O'Dwyer, ME; Thackray, HM | 1 |
| Abgral, R; Berthou, C; Guillerm, G; Ianotto, JC; LE Roux, PY; Lombion, N; Robin, P; Salaün, PY; Schick, U; Tempescul, A | 1 |
| García-Ramos, A | 1 |
41 review(s) available for etoposide and mitoxantrone
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Cytotoxic treatment of metastatic breast cancer. Which drugs and drug combinations to use?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Dactinomycin; Doxorubicin; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Melphalan; Methotrexate; Mitomycin; Mitoxantrone; Neoplasm Metastasis; Vincristine | 1992 |
New agents in the treatment of acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Daunorubicin; Drug Evaluation; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Remission Induction; Tretinoin | 1991 |
Treatment of relapsed and refractory acute myeloid leukemia in adults.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance; Etoposide; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Remission Induction | 1989 |
Etoposide: fifteen years experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Hodgkin Disease; Humans; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Lomustine; Melphalan; Mitoxantrone | 1989 |
Chemotherapy of malignant disease: an update.
Topics: Amsacrine; Antineoplastic Agents; Cisplatin; Coformycin; Etoposide; Female; Humans; Ifosfamide; Male; Mitoxantrone; Neoplasms; Pentostatin; Pregnancy | 1988 |
Treatment of acute leukemia--advances in chemotherapy, immunotherapy, and bone marrow transplantation.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Age Factors; Aminoacridines; Amsacrine; Anthraquinones; Antibodies, Monoclonal; Azacitidine; Bone Marrow Transplantation; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Immunotherapy; Infant; Interferons; Leukemia; Leukemia, Lymphoid; Liposomes; Middle Aged; Mitoxantrone; Naphthacenes; Prognosis; Teniposide; Transplantation, Homologous; Transplantation, Isogeneic; Vinblastine; Vindesine | 1983 |
New agents in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Alkylating Agents; Animals; Anthraquinones; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Indazoles; Lung Neoplasms; Male; Mice; Mitoxantrone; Triazines; Vinblastine; Vindesine | 1984 |
Therapy-related acute leukemia associated with t(11q23) after primary acute myeloid leukemia with t(8;21): a report of two cases.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cell Lineage; Child; Child, Preschool; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Enzyme Inhibitors; Etoposide; Fatal Outcome; Female; Humans; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Mitoxantrone; Neoplasms, Second Primary; Oncogenes; Topoisomerase II Inhibitors; Translocation, Genetic | 1995 |
A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carboplatin; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 8; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Eosinophilia; Etoposide; Fatal Outcome; Female; Humans; Hydroxyurea; Hyperplasia; Ifosfamide; Leukemia, Myeloid; Lymph Nodes; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Pregnancy; Pregnancy Complications, Neoplastic; Remission Induction; Syndrome; Translocation, Genetic; Vincristine | 1995 |
Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all transretinoic acid (ATRA) combined with chemotherapy: The European experience. European APL Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cell Differentiation; China; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Europe; Humans; Immunologic Factors; Leukemia, Promyelocytic, Acute; Leukocytosis; Life Tables; Middle Aged; Mitoxantrone; New York; Pilot Projects; Remission Induction; Survival Rate; Treatment Outcome; Tretinoin | 1995 |
Prednisone, oral etoposide, and novantrone for treatment of non-Hodgkin's lymphoma: a preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Prospective Studies | 1994 |
High dose versus standard dose chemotherapy for the treatment of breast cancer. A review of current concepts.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carboplatin; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Paclitaxel; Taxoids; Thiotepa | 1995 |
[Chemotherapy of relapsed AML and ALL].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mechlorethamine; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prednisone; Procarbazine; Recurrence; Remission Induction; Vinblastine | 1996 |
Factors that influence prognosis of intermediate-grade lymphomas at relapse.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Cisplatin; Cytarabine; Etoposide; Humans; Ifosfamide; L-Lactate Dehydrogenase; Lymphoma, Non-Hodgkin; Mesna; Methylprednisolone; Middle Aged; Mitoxantrone; Outcome Assessment, Health Care; Prognosis | 1996 |
Mitoxantrone in the treatment of acute myelogenous leukemia: a review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Genes, MDR; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Randomized Controlled Trials as Topic | 1997 |
Defining the role of novel high-dose chemotherapy regimens for the treatment of high-risk breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials as Topic; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Mitoxantrone; Neoplasm Staging; Paclitaxel; Taxoids; Thiotepa | 1998 |
[Treatment of lymphoma in the aged].
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Middle Aged; Mitoxantrone; Palliative Care; Prednimustine; Prednisolone; Prednisone; Prognosis; Vincristine | 1998 |
Etoposide: four decades of development of a topoisomerase II inhibitor.
Topics: Administration, Oral; Anthracyclines; Antineoplastic Agents, Phytogenic; Etoposide; Humans; Mitoxantrone; Neoplasms; Technology, Pharmaceutical; Teniposide; Topoisomerase II Inhibitors | 1998 |
Long-term third chronic phase of chronic myelogenous leukemia maintained by interferon-alpha and methotrexate.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Etoposide; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Methotrexate; Mitoxantrone; Remission Induction; Time; Treatment Outcome | 1999 |
DNA topoisomerase II inhibitors.
Topics: Amsacrine; Antineoplastic Agents; Carcinogens; Disease Models, Animal; Etoposide; Evidence-Based Medicine; Humans; Intestinal Absorption; Mitoxantrone; Neoplasms; Nucleic Acid Synthesis Inhibitors; Research Design; Risk Factors; Teniposide; Tissue Distribution; Topoisomerase II Inhibitors | 2000 |
Induction therapy of adult acute lymphocytic leukemia without the use of vincristine or prednisone.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Controlled Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Dactinomycin; Doxorubicin; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Mercaptopurine; Methotrexate; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Neutropenia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prospective Studies; Randomized Controlled Trials as Topic; Recombinant Proteins; Remission Induction; Survival Analysis; Treatment Outcome; Vincristine | 2001 |
The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Deletion; Chromosome Inversion; Chromosomes, Human; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hepatomegaly; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Remission Induction; Retrospective Studies; Splenomegaly; Survival Analysis; Translocation, Genetic; Treatment Outcome | 2001 |
Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 11; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytarabine; Disease Progression; Disease-Free Survival; Enzyme Inhibitors; Etoposide; Female; Humans; Idarubicin; Incidence; Karyotyping; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm Proteins; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Topoisomerase II Inhibitors; Treatment Outcome; Tretinoin | 2001 |
A systematic overview of chemotherapy effects in acute myeloid leukaemia.
Topics: Acute Disease; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2001 |
Paclitaxel and docetaxel in prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estramustine; Etoposide; Genes, bcl-2; Humans; Hydrocortisone; Male; Microtubules; Mitosis; Mitoxantrone; Multicenter Studies as Topic; Neoplasm Proteins; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Palliative Care; Prostatic Neoplasms; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Survival Analysis; Taxoids; Treatment Outcome; Tubulin | 2001 |
[Combination chemotherapy with VP-16 in the treatment of lung cancer and malignant lymphoma].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase II as Topic; Cytarabine; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Lymphoma; Mesna; Methylprednisolone; Mitoxantrone | 2001 |
Unrelated cord blood transplantation for an infant with chemotherapy-resistant progressive Langerhans cell histiocytosis.
Topics: Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Drug Resistance; Drug Therapy, Combination; Etoposide; Fetal Blood; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histiocytosis, Langerhans-Cell; Humans; Infant; Male; Mercaptopurine; Methotrexate; Methylprednisolone; Mitoxantrone; Prednisolone; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Vincristine | 2001 |
Treatment of large cell lymphoma in elderly patients with a mitoxantrone, cyclophosphamide, etoposide, and prednisone regimen: long-term follow-up results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lymph Nodes; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mitoxantrone; Prednisone; Remission Induction; Survival Rate; Treatment Outcome | 2003 |
[Current and new therapeutic strategies in acute myeloid leukemia].
Topics: Acute Disease; Aminoglycosides; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cytarabine; Disease-Free Survival; Etoposide; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Indoles; Leukemia, Myeloid; Mice; Middle Aged; Mitoxantrone; Piperazines; Prognosis; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases; Vidarabine | 2005 |
Toxicity of the topoisomerase II inhibitors.
Topics: Antineoplastic Agents; Cardiovascular Diseases; Daunorubicin; Doxorubicin; Enzyme Inhibitors; Epirubicin; Etoposide; Humans; Idarubicin; Leukemia; Middle Aged; Mitoxantrone; Mucositis; Podophyllotoxin; Teniposide; Topoisomerase II Inhibitors; Vascular Diseases | 2005 |
Severe toxicity following induction chemotherapy for acute myelogenous leukemia in a patient with Werner's syndrome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; DNA Helicases; Etoposide; Exodeoxyribonucleases; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; RecQ Helicases; Werner Syndrome; Werner Syndrome Helicase | 2005 |
Pulmonary complications of novel antineoplastic agents for solid tumors.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Deoxycytidine; Doxorubicin; Epirubicin; Etoposide; Everolimus; Gemcitabine; Humans; Lung; Lung Diseases; Mitoxantrone; Neoplasms; Pneumonia; Pyrimidines; Risk Factors; Sirolimus; Teniposide; Trastuzumab | 2008 |
Treatment of relapsed acute myeloid leukaemia.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colony-Stimulating Factors; Cytarabine; Etoposide; Humans; Immunity, Innate; Immunologic Factors; Leukemia, Myeloid, Acute; Mitoxantrone; Randomized Controlled Trials as Topic; Secondary Prevention | 2006 |
The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia.
Topics: Adenine Nucleotides; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation; Etoposide; Fatal Outcome; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Male; Mitoxantrone; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Recurrence; Remission Induction; Reoperation; Salvage Therapy; Vidarabine; Vincristine; Young Adult | 2009 |
DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Camptothecin; DNA Topoisomerases; Doxorubicin; Enzyme Inhibitors; Etoposide; Humans; Mitoxantrone; Quinolones; Topoisomerase Inhibitors | 2010 |
Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Drug Administration Schedule; Erdheim-Chester Disease; Etoposide; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Mitoxantrone; Prednisone; Treatment Outcome; Vincristine | 2012 |
[The non-hormonal treatment of metastatic prostate cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Cisplatin; Denosumab; Docetaxel; Etoposide; Humans; Male; Mitoxantrone; Organometallic Compounds; Organophosphorus Compounds; Osteoporosis; Prostatic Neoplasms; Radiation Protection; Radioisotopes; Radium; RANK Ligand; Strontium; Strontium Radioisotopes; Taxoids | 2013 |
Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.
Topics: Adult; Age Factors; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blood Coagulation Factors; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Hydroxyurea; Idarubicin; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Oxides; Platelet Transfusion; Practice Guidelines as Topic; Remission Induction; Risk Assessment; Thioguanine; Treatment Outcome; Tretinoin | 2014 |
Allogeneic hematopoietic cell transplantation in morphologic leukemia-free aplastic state.
Topics: Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cladribine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Filgrastim; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Transplantation Conditioning; Treatment Outcome; Young Adult | 2017 |
214 trial(s) available for etoposide and mitoxantrone
| Article | Year |
|---|---|
Treatment of acute nonlymphocytic leukemia by combination of recombinant human granulocyte colony-stimulating factor and cytotoxic agents: a report of six cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cytarabine; Daunorubicin; Drug Evaluation; Drug Resistance; Drug Synergism; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Recombinant Proteins; Remission Induction | 1992 |
Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Survival Analysis; Time Factors | 1992 |
Excessive toxicity of mitoxantrone combined with etoposide in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Evaluation; Etoposide; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Mitoxantrone | 1991 |
Remission induction and postremission therapy in acute myelogenous leukemia: British MRC Study.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Doxorubicin; Drug Combinations; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Nimustine; Prednisone; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Thioguanine; United Kingdom; Vincristine | 1990 |
A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Prednimustine; Prognosis; Prospective Studies; Survival Analysis; Treatment Outcome | 1992 |
New agents in the treatment of acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Daunorubicin; Drug Evaluation; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Remission Induction; Tretinoin | 1991 |
Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV2) in relapsed and refractory lymphomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Etoposide; Hodgkin Disease; Humans; Lymphoma; Middle Aged; Mitoguazone; Mitoxantrone; Prognosis; Prospective Studies; Recurrence; Remission Induction; Vinblastine | 1991 |
Chemotherapy for invasive thymoma. A 13-year experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasm Staging; Remission Induction; Survival Rate; Thymoma; Thymus Neoplasms; Vincristine | 1991 |
Combination of mitoxantrone and etoposide in patients aged over 60 years with untreated acute myelogenous leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Etoposide; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Mitoxantrone; Multicenter Studies as Topic | 1990 |
Mitoxantrone, cytosine arabinoside, and VP-16 in 36 patients with relapsed and refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Germany, West; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Remission Induction; Survival Rate | 1990 |
Mitoxantrone and etoposide in patients with relapsed and refractory acute nonlymphocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Etoposide; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Mitoxantrone; Multicenter Studies as Topic; Remission Induction; Survival Rate; United States | 1990 |
Mitoxantrone and constant infusion etoposide for relapsed and refractory acute myelocytic leukemia.
Topics: Adult; Aged; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction | 1990 |
Intracavitary chemotherapy.
Topics: Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Catheters, Indwelling; Cisplatin; Clinical Trials as Topic; Cytarabine; Doxorubicin; Etoposide; Fluorouracil; Humans; Immunotherapy; Infusions, Parenteral; Melphalan; Methotrexate; Mitomycins; Mitoxantrone; Neoplasms; Organoplatinum Compounds | 1986 |
Mitoxantrone and VP-16 in refractory acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction | 1987 |
New agents in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Alkylating Agents; Animals; Anthraquinones; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Indazoles; Lung Neoplasms; Male; Mice; Mitoxantrone; Triazines; Vinblastine; Vindesine | 1984 |
Intensive conventional-dose chemotherapy for stage IV low-grade lymphoma: high remission rates and reversion to negative of peripheral blood bcl-2 rearrangement.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Biomarkers, Tumor; Bleomycin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Life Tables; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Neoplasm Staging; Oncogenes; Polymerase Chain Reaction; Prednisone; Procarbazine; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Remission Induction; Treatment Outcome; Vincristine | 1994 |
Effect of granulocyte colony-stimulating factor in patients with diffuse large cell lymphoma treated with intensive chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Leucovorin; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Methotrexate; Methylprednisolone; Middle Aged; Mitoxantrone; Prednisone; Procarbazine; Prospective Studies; Treatment Outcome; Vincristine | 1994 |
Delayed commencement of granulocyte colony-stimulating factor following autologous bone marrow transplantation accelerates neutrophil recovery and is cost-effective.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Mitoxantrone; Neoplasms; Neutrophils; Pilot Projects | 1994 |
CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study.
Topics: Actuarial Analysis; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chi-Square Distribution; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Etoposide; Female; Humans; Ifosfamide; Karnofsky Performance Status; L-Lactate Dehydrogenase; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Pilot Projects; Prednisone; Prognosis; Prospective Studies; Remission Induction; Survival Rate; Treatment Failure; Vincristine | 1995 |
[Comparison of low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor to intermediate-dose cytosine arabinoside and mitoxantrone with or without etoposide in the treatment of relapsed acute myeloid leukemia
Topics: Aclarubicin; Adolescent; Adult; Aged; Cytarabine; Drug Administration Schedule; Drug Therapy, Combination; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence | 1995 |
High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Confidence Intervals; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Heart Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Mitoxantrone; Neutropenia; Pilot Projects; Platelet Count; Remission Induction; Survival Rate; Vincristine | 1995 |
Mitoxantrone, etoposide and ara-C vs doxorubicin-DNA, ara-C, thioguanine, vincristine and prednisolone in the treatment of patients with acute myelocytic leukaemia. A randomized comparison.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; DNA Adducts; Doxorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prednisolone; Recurrence; Survival Analysis; Thioguanine; Vincristine | 1995 |
[NEO-MACOP-B chemotherapy for the treatment of advanced-stage aggressive non-Hodgkin's lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Methotrexate; Middle Aged; Mitoxantrone; Prednisolone; Remission Induction; Vincristine | 1993 |
Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte).
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; France; Humans; Lymphoma, Non-Hodgkin; Methotrexate; Methylprednisolone; Middle Aged; Mitoxantrone; Prednisolone; Prognosis; Remission Induction; Survival Rate; Transplantation, Autologous; Vindesine | 1993 |
Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Feasibility Studies; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Neutropenia; Remission Induction; Thrombocytopenia; Vincristine | 1995 |
Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all transretinoic acid (ATRA) combined with chemotherapy: The European experience. European APL Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cell Differentiation; China; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Europe; Humans; Immunologic Factors; Leukemia, Promyelocytic, Acute; Leukocytosis; Life Tables; Middle Aged; Mitoxantrone; New York; Pilot Projects; Remission Induction; Survival Rate; Treatment Outcome; Tretinoin | 1995 |
A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Over Studies; Cytarabine; Etoposide; Female; Humans; Ifosfamide; Lymphoma; Male; Mesna; Methylprednisolone; Methylprednisolone Hemisuccinate; Middle Aged; Mitoxantrone; Prednisone; Salvage Therapy | 1994 |
Results of a salvage regimen in refractory or relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Cytarabine; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; L-Lactate Dehydrogenase; Life Tables; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Prognosis; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Vindesine | 1994 |
[Role of double induction in the treatment of acute myeloblastic leukemia in the adult: intermediate results of protocol LAM90].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cytarabine; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Remission Induction | 1994 |
Mitoxantrone in combination with etoposide and prednimustine in patients older than 70 years with unfavorable non-Hodgkin's lymphoma: a prospective study in 52 patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Prednimustine; Prospective Studies; Remission Induction | 1994 |
Prednisone, oral etoposide, and novantrone for treatment of non-Hodgkin's lymphoma: a preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Prospective Studies | 1994 |
Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia (AL).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Cyclosporine; Etoposide; Female; Humans; Leukemia; Male; Membrane Glycoproteins; Middle Aged; Mitoxantrone | 1993 |
An Eastern Cooperative Oncology Group phase II study of single agent DHAD, VP-16, aclacinomycin, or spirogermanium in metastatic pancreatic cancer.
Topics: Aclarubicin; Adenocarcinoma; Adjuvants, Immunologic; Antineoplastic Agents; Etoposide; Female; Humans; Male; Mitoxantrone; Organometallic Compounds; Pancreatic Neoplasms; Spiro Compounds; Survival Rate | 1994 |
All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Drug Administration Schedule; Etoposide; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Salvage Therapy; Tretinoin | 1994 |
Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Immunotherapy; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Stem Cell Transplantation; Survival Analysis; Thiotepa | 1993 |
NOPE for relapsed aggressive diffuse non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Heart Failure; Humans; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Prednisolone; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Vincristine | 1993 |
Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Etoposide; Female; Humans; Lymphoma; Male; Middle Aged; Mitoxantrone | 1994 |
Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON).
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction | 1994 |
Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Recombinant Proteins; Remission Induction; Survival Analysis | 1993 |
[A combination chemotherapy of mitoxantrone, etoposide, carboplatin, and prednisolone (MECP) in recurrent or refractory non-Hodgkin's lymphomas].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisolone; Remission Induction | 1994 |
Phase II study of etoposide, ifosfamide, and mitoxantrone for the treatment of resistant adult acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Ifosfamide; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Salvage Therapy | 1993 |
[Study on the inhibitory effect of oral granisetron against nausea/vomiting induced by cytosine arabinoside containing chemotherapy for tumors in the hematopoietic organs].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Granisetron; Humans; Indazoles; Lymphoma; Male; Middle Aged; Mitoxantrone; Nausea; Vomiting | 1993 |
Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cytarabine; Drug Administration Schedule; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Pilot Projects; Recombinant Proteins | 1993 |
A phase II trial of a chemotherapy combination in elderly patients with aggressive lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Neutropenia; Prednisone; Remission Induction | 1993 |
Mitoxantrone, etoposide and intermediate-dose Ara-C (MEC): an effective regimen for poor risk acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Male; Middle Aged; Mitoxantrone; Risk; Treatment Outcome | 1993 |
The rationale of therapy with mitoxantrone in non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Co-operative Study Group, (NHLCSG) Italy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Gastrointestinal Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Vincristine | 1993 |
Mitoxantrone-containing regimen for treatment of childhood acute leukemia (AML) and analysis of prognostic factors: results of the EORTC Children Leukemia Cooperative Study 58872.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Etoposide; Feasibility Studies; Female; Heart; Heart Function Tests; Humans; Infant; Leukemia, Myeloid; Male; Mitoxantrone; Prognosis; Thioguanine; Vincristine | 1996 |
Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neutropenia; Pilot Projects; Remission Induction; Survival Rate | 1996 |
A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Ifosfamide; Lymphoma; Male; Mesna; Middle Aged; Mitoxantrone; Platinum; Prospective Studies; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Treatment Failure | 1995 |
A phase II trial of prednisone, oral etoposide, and novantrone (PEN) as initial treatment of non-Hodgkin's lymphoma in elderly patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Neoplasm Staging; Prednisone | 1995 |
MEC (mitoxantrone, etoposide and intermediate dose cytarabine): an effective induction regimen for previously untreated acute non-lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Life Tables; Male; Middle Aged; Mitoxantrone; Remission Induction; Salvage Therapy; Survival Rate | 1995 |
Post-remission intensive consolidation with high-dose cytarabine-based chemotherapy and granulocyte colony-stimulatory factor in adults with acute myelogenous leukemia: a preliminary report.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neutropenia; Remission Induction | 1995 |
[Response-oriented salvage chemotherapy with mitoxantrone, etoposide and enocitabine for previously treated acute myeloid leukemia. Tohoku Leukemia Study Group].
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Recurrence; Salvage Therapy | 1995 |
High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow Diseases; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Life Tables; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Recombinant Proteins; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 1996 |
Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma: evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; HIV Infections; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednimustine; Prognosis; Prospective Studies; Recurrence; Survival Rate | 1996 |
Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide.
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Intestinal Mucosa; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Quality of Life; Remission Induction; Survival Analysis; Treatment Outcome | 1996 |
An intensive chemotherapy of adult T-cell leukemia/lymphoma: CHOP followed by etoposide, vindesine, ranimustine, and mitoxantrone with granulocyte colony-stimulating factor support.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow; Cyclophosphamide; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Mitoxantrone; Nitrosourea Compounds; Prednisone; Vincristine; Vindesine | 1996 |
[An intensive chemotherapy of adult T-cell leukemia/lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Mitoxantrone; Nitrosourea Compounds; Prednisolone; Proportional Hazards Models; Remission Induction; Survival Rate; Vincristine; Vindesine | 1996 |
A new protocol (MiCEP) for the treatment of intermediate or high-grade non-Hodgkin's lymphoma in the elderly.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Etoposide; Feasibility Studies; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Life Tables; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Prednisone; Remission Induction; Survival Analysis; Treatment Outcome | 1996 |
Phase II trial of tamoxifen, etoposide, mitoxantrone, and cisplatin in patients with metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Etoposide; Female; Humans; Middle Aged; Mitoxantrone; Tamoxifen | 1996 |
[Treatment results for unselected patients with acute myelogenous leukemia. During a 10-year period, August 1984 to July 1994].
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Patient Selection; Prednisolone; Remission Induction; Retrospective Studies; Treatment Outcome | 1996 |
Timed sequential chemotherapy for advanced acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone | 1996 |
Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Mitoxantrone; Survival Analysis; Treatment Outcome | 1996 |
Etoposide and mitoxantrone as a second cycle of consolidation therapy following high dose cytosine arabinoside and daunorubicin in patients with acute non-lymphocytic leukemia in remission: a pilot study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Etoposide; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxantrone; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Remission Induction; Salvage Therapy | 1996 |
Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group.
Topics: Adolescent; Adult; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Male; Middle Aged; Mitoxantrone; Netherlands; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Treatment Outcome | 1997 |
[Short-term intensive treatment for acute myelogenous leukemia (excluding M3 subtype) in adults].
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Middle Aged; Mitoxantrone; Time Factors; Vinblastine; Vincristine | 1997 |
[Chemotherapy schedules and bacteremia in adult patients with acute leukemia].
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Cytarabine; Daunorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Leukemia; Male; Mitoxantrone; Neutropenia; Risk Factors | 1996 |
Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Drug Resistance, Neoplasm; Etoposide; Genes, MDR; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Recurrence | 1997 |
Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Mitoxantrone; Prednisone; Treatment Outcome; Vincristine | 1997 |
Outcome of a multicenter treatment program including autologous or allogeneic bone marrow transplantation for de novo acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cause of Death; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Mitoxantrone; Probability; Remission Induction; Survival Rate; Transplantation, Autologous; Transplantation, Homologous | 1997 |
Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Leukocyte Count; Life Tables; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Proportional Hazards Models; Prospective Studies; Remission Induction; Treatment Outcome | 1997 |
Weekly chemotherapy using PMitCEBO in the palliation of recurrent non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Palliative Care; Prednisolone; Recurrence; Vincristine | 1997 |
CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Lymphoma, Non-Hodgkin; Mitoxantrone; Prednimustine; Prednisone; Vincristine | 1998 |
An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: results of 8722, a randomized phase II study conducted by Cancer and Leukemia Group B.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone | 1998 |
Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.
Topics: Acute Disease; Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Mitoxantrone; Patient Compliance; Recurrence; Remission Induction; Survival Rate; Thioguanine; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 1998 |
[Preliminary treatment results of relapsed or refractory acute leukemia using two and three drug regimens].
Topics: Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Idarubicin; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction | 1998 |
Alternating triple therapy for the treatment of intermediate grade and immunoblastic lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Male; Mesna; Methotrexate; Methylprednisolone Hemisuccinate; Middle Aged; Mitoxantrone; Prednisone; Prognosis; Vincristine | 1998 |
Phase II trial of MINE as a front-line therapeutic modality in intermediate- and high-grade non-Hodgkin's lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Mitoxantrone; Prospective Studies; Treatment Outcome | 1998 |
[Chemotherapy of resistant and recurrent lymphoma based on a combination of ifosfamide and etoposide. Antitumor effects, toxicity and stimulation of peripheral stem cells].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Leukapheresis; Lymphoma, Non-Hodgkin; Male; Mesna; Methotrexate; Middle Aged; Mitoxantrone; Recurrence; Salvage Therapy; Transplantation Conditioning | 1998 |
Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis | 1998 |
High single dose of mitoxantrone and cytarabine in acute non-lymphocytic leukemia: a pharmacokinetic and clinical study.
Topics: Adult; Aged; Amsacrine; Chromatography, High Pressure Liquid; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neutropenia; Time Factors | 1998 |
Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow; Cardiovascular Diseases; Cohort Studies; Cyclosporins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Infections; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Recombinant Proteins; Remission Induction; Treatment Outcome | 1999 |
Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Methylprednisolone; Middle Aged; Mitoxantrone; Paclitaxel; Prospective Studies; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 1998 |
Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Combined Modality Therapy; Cytarabine; Diarrhea; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Infections; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Neutropenia; Remission Induction; Salvage Therapy; Treatment Outcome | 1999 |
Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with
Topics: Acute Disease; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Double-Blind Method; Etoposide; Feasibility Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Pilot Projects; Transplantation, Autologous | 1999 |
Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Prednisone; Remission Induction; Survival Analysis; Vincristine | 1999 |
Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cytarabine; Disease-Free Survival; Drug Synergism; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Humans; Leukemia, Myeloid; Male; Mitoxantrone; Recurrence | 1999 |
Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC).
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; Cytarabine; Etoposide; Genes, MDR; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Prognosis; Remission Induction; Salvage Therapy | 1999 |
Myeloprotective effect of a non-toxic indigenous preparation Rasayana in cancer patients receiving chemotherapy and radiation therapy. A pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Bone Marrow; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Fluorouracil; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; India; Leukocyte Count; Leukopenia; Lipid Peroxidation; Male; Mitoxantrone; Neoplasms; Pharmaceutical Preparations; Pilot Projects; Plant Extracts; Radiation Injuries; Radiotherapy | 1999 |
Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: results of ECOG 5282.
Topics: Aclarubicin; Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Etoposide; Female; Humans; Male; Mitoxantrone; Organometallic Compounds; Spiro Compounds; Stomach Neoplasms | 1999 |
Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hospitalization; Humans; Length of Stay; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neutropenia; Recombinant Proteins; Remission Induction; Treatment Outcome | 2000 |
A phase II study of two cycles of high-dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Liver Neoplasms; Middle Aged; Mitoxantrone; Platelet Count; Soft Tissue Neoplasms; Survival Rate; Tamoxifen; Thiotepa; Transplantation, Autologous | 2000 |
Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclosporine; Drug Resistance, Multiple; Etoposide; Female; Flow Cytometry; Genes, MDR; Humans; Immunosuppressive Agents; Infant; Infant, Newborn; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2000 |
Phase II evaluation of a high-dose mitoxantrone based induction regimen in untreated adults with acute myeloid leukemia.
Topics: Actuarial Analysis; Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Conjunctivitis; Cytarabine; Disease-Free Survival; Etoposide; Female; Gastrointestinal Diseases; Humans; Hyperbilirubinemia; Leukemia, Myeloid; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Remission Induction; Risk; Stomatitis; Stroke Volume; Survival Analysis; Survival Rate; Treatment Outcome; Tretinoin; Ventricular Dysfunction, Left | 2000 |
A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Survival Analysis; Treatment Outcome | 2000 |
Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Predictive Value of Tests; Recurrence; Risk; Thioguanine; Tretinoin | 2000 |
Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Diseases; Disease Progression; Disease-Free Survival; Etoposide; Female; Humans; L-Lactate Dehydrogenase; Life Tables; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Prednisone; Prognosis; Safety; Salvage Therapy; Survival Analysis; Treatment Outcome | 2000 |
High-dose chemotherapy with tandem autologous transplantation as part of the initial therapy for aggressive non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Feasibility Studies; Female; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Humans; Life Tables; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mitoxantrone; Remission Induction; Salvage Therapy; Survival Analysis; Survival Rate; Treatment Outcome | 2000 |
Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Patient Selection; Recurrence; Ventricular Function, Left | 2000 |
Treatment of childhood acute myelogenous leukemia with allogeneic and autologous stem cell transplantation during the first remission: a report from the Kyushu-Yamaguchi Children's Cancer Study group in Japan.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Prognosis; Remission Induction; Transplantation, Autologous; Transplantation, Homologous | 2000 |
Mitoxantrone, etoposide, carboplatinum and ara-C combination therapy (MECA) in refractory and relapsed acute leukemia.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Recurrence; Risk Factors; Salvage Therapy; Treatment Outcome | 2000 |
Cemp, a mitoxantrone containing combination, in the treatment of intermediate and high grade non-hodgkin's lymphoma: an effective and non toxic therapeutic alternative for adult and elderly patients.
Topics: Actuarial Analysis; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Survival Rate; Treatment Outcome | 2001 |
Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisolone; Prospective Studies; Remission Induction; Survival Rate; Vincristine | 2001 |
Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; Cytarabine; Drug Resistance, Multiple; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone | 2001 |
Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Ifosfamide; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Non-Hodgkin; Mesna; Methylprednisolone Hemisuccinate; Middle Aged; Mitoxantrone; Prednisone; Retrospective Studies; Salvage Therapy; Vincristine | 2001 |
Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Male; Mitoxantrone; Remission Induction; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2001 |
Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Kinetics; Lymphoma; Male; Mesna; Methotrexate; Middle Aged; Mitoxantrone; Prognosis; Salvage Therapy; Treatment Outcome | 2001 |
Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Leukapheresis; Lymphoma, B-Cell; Male; Middle Aged; Mitoxantrone; Recombinant Proteins; Remission Induction; Rituximab; Transplantation, Autologous | 2001 |
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunologic Factors; Interferon-alpha; Lenograstim; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prednisone; Recombinant Proteins; Remission Induction; Survival Analysis; Thioguanine; Treatment Outcome; United Kingdom; Vincristine | 2001 |
Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Remission Induction; Survival Rate; Time Factors; Transplantation, Autologous; Transplantation, Homologous | 2001 |
Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Epirubicin; Epithelial Cells; Etoposide; Female; Fluorouracil; Humans; Infusions, Intravenous; Infusions, Parenteral; Laparotomy; Middle Aged; Mitoxantrone; Ovarian Neoplasms; Postoperative Care; Second-Look Surgery | 2001 |
Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group.
Topics: Aclarubicin; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 11; Cytarabine; Disease-Free Survival; DNA-Binding Proteins; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Histone-Lysine N-Methyltransferase; Humans; Immunophenotyping; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Myeloid-Lymphoid Leukemia Protein; Prognosis; Proto-Oncogenes; Remission Induction; Survival Rate; Transcription Factors; Translocation, Genetic; Treatment Outcome; Vincristine | 2001 |
Efficacy of carboplatin with an MEP (mitoxantrone, etoposide and prednisone) regimen for relapsed and CHOP-resistant diffuse large B-cell lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Resistance, Multiple; Etoposide; Female; Follow-Up Studies; Humans; Leucovorin; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisone; Recurrence; Survival Rate; Time Factors; Vincristine | 2002 |
Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Mitoxantrone; Prednisone; Prospective Studies; Remission Induction; Survival Analysis; Treatment Outcome; Vindesine | 2001 |
High-dose chemotherapy in poor-prognosis adult small round-cell tumors: clinical and molecular results from a prospective study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cyclophosphamide; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Melphalan; Middle Aged; Mitoxantrone; Neuroectodermal Tumors, Primitive, Peripheral; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Rhabdomyosarcoma; Survival Analysis; Thiotepa; Vincristine | 2002 |
Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Child; Child, Preschool; Chromatography, High Pressure Liquid; Cyclosporine; Drug Interactions; Drug Resistance, Multiple; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Male; Metabolic Clearance Rate; Mitoxantrone | 2002 |
Timed sequential chemotherapy with concomitant granulocyte colony-stimulating factor for high-risk acute myelogenous leukemia: a single arm clinical trial.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Cytarabine; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neutrophils; Platelet Count; Risk Factors; Survival Rate; Time Factors; Treatment Outcome | 2002 |
Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clone Cells; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; DNA, Neoplasm; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Mitoxantrone; Multiple Myeloma; Remission Induction; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2002 |
ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cytarabine; Dacarbazine; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Male; Mechlorethamine; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Prednisone; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vincristine | 2002 |
Flexible low-intensity combination chemotherapy for elderly patients with acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Survival Analysis; Treatment Outcome | 2002 |
Phase III trial of a humanized anti-CD33 antibody (HuM195) in patients with relapsed or refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Fever; Humans; Hypotension; Infections; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Survival Rate; Treatment Outcome | 2002 |
Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; DNA Fragmentation; DNA Topoisomerases, Type II; Enzyme Induction; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Topotecan | 2002 |
Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chemical and Drug Induced Liver Injury; Cytarabine; Disease-Free Survival; Etoposide; Female; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neutropenia; Remission Induction; Survival Analysis; Treatment Outcome | 2002 |
Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Italy; Logistic Models; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisone; Probability; Prognosis; Proportional Hazards Models; Survival Rate; Treatment Outcome; Vincristine | 2002 |
Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitoxantrone; Prognosis; Remission Induction; Statistics, Nonparametric; Stem Cell Transplantation; Survival Rate | 2002 |
Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Female; Humans; Male; Melphalan; Middle Aged; Mitoxantrone; Multiple Myeloma; Prednisone; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Rate; Time Factors; Treatment Outcome | 2002 |
Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation.
Topics: Adolescent; Age of Onset; Bone Marrow Transplantation; Child; Cytarabine; Dexamethasone; Drug Therapy, Combination; Etoposide; Female; Follow-Up Studies; Histiocytosis, Non-Langerhans-Cell; Humans; Immunosuppressive Agents; Male; Mitoxantrone; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Time Factors | 2002 |
Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis; Survival Rate; Treatment Outcome | 2002 |
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Prednisone; Procarbazine; Prognosis; Remission Induction; Survival Rate; Vidarabine; Vincristine | 2002 |
Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Etoposide; Female; Humans; Ifosfamide; Lymphoma; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Mitoxantrone; Polymerase Chain Reaction; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Stem Cells; Time Factors | 2002 |
The treatment of acute myeloid leukemia with mitoxantrone, etoposide and low-dose cytarabine in elderly patients - a report of Polish Acute Leukemia Group (PALG) phase II study.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Poland; Prognosis; Prospective Studies; Remission Induction; Survival Rate | 2002 |
A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT).
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Etoposide; Female; Humans; Ifosfamide; Lymphoma, B-Cell; Male; Middle Aged; Mitoxantrone; Rituximab; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous | 2003 |
First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Neoplasm Staging; Prednisone; Prognosis; Rituximab; Survival Rate; Time Factors; Treatment Outcome; Vincristine | 2003 |
Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Prognosis; Survival Rate; Treatment Outcome | 2003 |
Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Salvage Therapy; Survival Rate | 2003 |
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; Female; Humans; Idarubicin; Immunophenotyping; Leukemia, Myeloid; Leukocyte Count; Longitudinal Studies; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Predictive Value of Tests; Probability; Recurrence; Risk Assessment; Stem Cell Transplantation; Survival Analysis; Time Factors; Transplantation, Autologous; Treatment Outcome | 2003 |
Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neutropenia; Opportunistic Infections; Remission Induction; Survival Analysis | 2004 |
Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Disease-Free Survival; Etoposide; Female; Genes, MDR; Humans; Logistic Models; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Myelodysplastic Syndromes; Survival Analysis; United States | 2004 |
Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol.
Topics: Acute Disease; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid; Logistic Models; Male; Middle Aged; Mitoxantrone; Proportional Hazards Models; Remission Induction; Transplantation, Autologous | 2004 |
Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: a randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Regression Analysis; Survival Analysis; Treatment Outcome | 2004 |
Phase II study of PEND chemotherapy in patients with refractory/relapsed Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Male; Mitoxantrone; Prednisone; Remission Induction; Salvage Therapy; Survival Analysis | 2004 |
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Karyotyping; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Splenomegaly; Survival Analysis; Treatment Outcome | 2005 |
Induction chemotherapy for acute myelogenous leukemia.
Topics: Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis; Treatment Outcome | 2005 |
Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Humans; Infusions, Intravenous; Middle Aged; Mitoxantrone; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Quality of Life; Survival Analysis; Treatment Outcome | 2005 |
[VNCOP-B (etoposide, mitoxantrone, cyclophosphamide, vincristine, predonisolone, bleomycin) therapy in elderly patients with aggressive non-Hodgkin lymphoma--a study of efficacy and safety, final report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neutropenia; Prednisone; Remission Induction; Survival Rate; Treatment Outcome; Vincristine | 2005 |
Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Transplantation, Autologous | 2005 |
Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncolo
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Prognosis; Remission Induction; Risk Factors; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Treatment Outcome; Vincristine | 2005 |
High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin; Cohort Studies; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Liver Neoplasms; Lung Neoplasms; Middle Aged; Mitoxantrone; Organ Specificity; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Survival Analysis; Thiotepa; Transplantation, Autologous; Treatment Outcome | 2005 |
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Proportional Hazards Models; Recurrence; Survival Analysis; Treatment Outcome | 2005 |
Severe toxicity following induction chemotherapy for acute myelogenous leukemia in a patient with Werner's syndrome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; DNA Helicases; Etoposide; Exodeoxyribonucleases; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; RecQ Helicases; Werner Syndrome; Werner Syndrome Helicase | 2005 |
Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Prospective Studies; Salvage Therapy | 2006 |
Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Epirubicin; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Neutropenia; Prednisone; Prospective Studies; Pyruvaldehyde; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vincristine | 2005 |
A prospective randomized study to compare the molecular response rates between central lymphatic irradiation and intensive alternating triple chemotherapy in the treatment of stage I-III follicular lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Genes, bcl-2; Humans; Lymphoma, Follicular; Methylprednisolone; Middle Aged; Mitoxantrone; Polymerase Chain Reaction; Prednisone; Procarbazine; Prospective Studies; Translocation, Genetic; Vincristine | 2005 |
Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials.
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Cytogenetic Analysis; Daunorubicin; Down Syndrome; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Leukocyte Count; Male; Mitoxantrone; Thioguanine; Treatment Outcome; United Kingdom | 2006 |
A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progression; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Survival Analysis; Treatment Outcome; Vincristine | 2006 |
Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Time Factors | 2006 |
Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Topics: Acute Disease; Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Down Syndrome; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrocortisone; Infant; Infections; Japan; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Methotrexate; Mitoxantrone; Remission Induction; Survival Analysis; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Tretinoin; Vincristine | 2007 |
Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Infusions, Intravenous; Length of Stay; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Pancytopenia; Patient Compliance; Risk Factors | 2006 |
High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lymphoma; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Mitoxantrone; Peripheral Blood Stem Cell Transplantation; Prognosis; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation, Autologous | 2006 |
Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas--results of a randomized comparison by the German Low-Grade Lymphoma Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chlorambucil; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Germany; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Melphalan; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Prospective Studies; Survival Rate; Treatment Outcome; Vincristine | 2007 |
Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Promyelocytic, Acute; Liposomes; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Oncogene Proteins, Fusion; Prognosis; Recurrence; Remission Induction; Salvage Therapy; Survival Analysis; Time Factors; Treatment Outcome; Tretinoin | 2007 |
Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Combined Modality Therapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Haplotypes; Histocompatibility; HLA Antigens; Humans; Imatinib Mesylate; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia; Lymphocyte Transfusion; Male; Methotrexate; Mitoxantrone; Pancytopenia; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Recurrence; Remission Induction; Salvage Therapy; Tissue Donors; Treatment Outcome | 2007 |
Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cytarabine; Etoposide; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitoxantrone; Piperazines; Pyrimidines; Survival Analysis; Treatment Outcome | 2007 |
Flexible low-intensity combination chemotherapy for elderly patients with acute myeloid leukaemia: a multicentre, phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Treatment Outcome | 2007 |
Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma: Japan Clinical Oncology Group Study 9004.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Mercaptopurine; Methotrexate; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Stem Cell Transplantation; Transplantation, Autologous | 2007 |
VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mitoxantrone; Prednisone; Rituximab; Survival Analysis; Treatment Outcome; Vincristine | 2007 |
Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP r
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Humans; Infusions, Intravenous; Injections; Leukocyte Count; Lymphatic Metastasis; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Platelet Count; Prednisone; Survival Analysis | 2008 |
Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cohort Studies; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction | 2008 |
Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Salvage Therapy; Treatment Outcome | 2009 |
CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy.
Topics: 3' Untranslated Regions; Acute Disease; Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; CTLA-4 Antigen; Cytarabine; Disease-Free Survival; Etoposide; Female; Genotype; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Incidence; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Polymorphism, Single Nucleotide; Proportional Hazards Models; Recurrence; Remission Induction; Young Adult | 2009 |
Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in Non-Hodgkin Lymphoma (NHL) patients--analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cohort Studies; Cyclophosphamide; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Recombinant Proteins; Treatment Outcome; Vincristine | 2009 |
Effect and prognostic analysis of treatment for acute myeloid leukemia using Chinese drugs combined with chemotherapy.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Child; Chromosome Aberrations; Cytarabine; Daunorubicin; Drugs, Chinese Herbal; Etoposide; Female; Humans; Immunophenotyping; Integrative Medicine; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Treatment Outcome; Young Adult | 2009 |
Citrulline as a marker for chemotherapy induced mucosal barrier injury in pediatric patients.
Topics: Acute Disease; Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carbohydrates; Cell Death; Child; Child, Preschool; Citrulline; Cytarabine; Daunorubicin; DNA; Enterocytes; Etoposide; Feces; Female; Humans; Infant; Interleukin-8; Intestinal Absorption; Leukemia, Myeloid; Leukocyte L1 Antigen Complex; Male; Mitoxantrone; Models, Biological; Mucositis; Stomatitis | 2009 |
Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fever; Follow-Up Studies; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Mitoxantrone; Peripheral Nervous System Diseases; Prednisolone; Prospective Studies; Radiotherapy, Adjuvant; Remission Induction; Treatment Outcome; Vincristine | 2010 |
Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Pharmacokinetic-pharmacodynamic modeling of manganese after a single intravenous infusion of mangafodipir in patients with acute alcoholic hepatitis.
Topics: Acute Disease; Adolescent; Adult; Aged; Anesthetics, Local; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Interactions; Edetic Acid; Etoposide; Hepatitis, Alcoholic; Humans; Infusions, Intravenous; Male; Manganese; Metabolic Clearance Rate; Middle Aged; Mitoxantrone; Prednisone; Pyridoxal Phosphate; Vincristine; Young Adult | 2009 |
Mitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neutropenia; Prognosis; Remission Induction; Retrospective Studies; Survival Analysis; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate; Thioguanine; Treatment Outcome; Tretinoin; Young Adult | 2010 |
Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Child; Child, Preschool; Cyclosporins; Drug Resistance, Multiple; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Salvage Therapy; Young Adult | 2010 |
Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Gene Frequency; Glutathione S-Transferase pi; Glutathione Transferase; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Peripheral Blood Stem Cell Transplantation; Polymorphism, Genetic; Survival Analysis; Time Factors; Treatment Outcome | 2010 |
Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Kaplan-Meier Estimate; Leucovorin; Lymphoma, B-Cell; Male; Mediastinal Neoplasms; Methotrexate; Middle Aged; Mitoxantrone; Multivariate Analysis; Prednisolone; Prednisone; Proportional Hazards Models; Prospective Studies; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2011 |
Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy.
Topics: Adult; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cohort Studies; Drug Recalls; Drug Resistance, Neoplasm; Etoposide; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Withholding Treatment | 2011 |
Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study.
Topics: alpha 1-Antitrypsin; alpha 1-Antitrypsin Deficiency; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Etoposide; Female; HIV Infections; Humans; Male; Malnutrition; Mitoxantrone; Prednisone; Protease Inhibitors; Vincristine | 2010 |
Long-term follow-up of tandem high-dose therapy with autologous stem cell support for adults with high-risk age-adjusted international prognostic index aggressive non-Hodgkin Lymphomas: a GOELAMS pilot study.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Peripheral Blood Stem Cell Transplantation; Pilot Projects; Quality of Life; Remission Induction; Risk Factors; Rituximab; Transplantation, Autologous | 2011 |
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Humans; Idarubicin; Infant; Kaplan-Meier Estimate; Leukocyte Count; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Polyethylene Glycols; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Assessment; Treatment Outcome; United Kingdom; Vidarabine; Vincristine | 2010 |
Influence of anticancer therapy on oxidation phenotype and acetylation phenotype in patients with acute myeloblastic leukemia.
Topics: Acetylation; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytochrome P-450 CYP2D6; Daunorubicin; Drug Interactions; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Oxidation-Reduction; Phenotype; Young Adult | 2011 |
Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Induction Chemotherapy; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Prognosis; Survival Analysis; Thioguanine; Treatment Outcome | 2011 |
Autologous peripheral blood stem cell transplantation for acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Prognosis; Prospective Studies; Remission Induction; Transplantation, Autologous; Treatment Outcome; Young Adult | 2011 |
Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Phosphorylation; Pilot Projects; Ribosomal Protein S6; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2012 |
A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Prospective Studies; Remission Induction; Vinblastine; Vincristine; Young Adult | 2012 |
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Flow Cytometry; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Prognosis; Receptors, CXCR4; Remission Induction; Salvage Therapy; Survival Rate; Young Adult | 2012 |
Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Etoposide; Exons; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Mutation; Neoplasm Staging; Prognosis; Survival Rate | 2013 |
Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cytarabine; Etoposide; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Karyotype; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Recurrence; Remission Induction; Salvage Therapy; Vidarabine | 2012 |
High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Retrospective Studies; Risk Factors; Survival Rate | 2013 |
Cyclosporine modulation of multidrug resistance in combination with pravastatin, mitoxantrone and etoposide for adult patients with relapsed/refractory acute myeloid leukemia: a phase 1/2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Pravastatin; Treatment Outcome | 2013 |
Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).
Topics: Acute Disease; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Febrile Neutropenia; Female; Follow-Up Studies; Gemtuzumab; Humans; Induction Chemotherapy; Infections; Leukemia, Myeloid; Liver; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis; Treatment Outcome | 2013 |
Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Etoposide; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Palliative Care; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Vinblastine; Vinorelbine | 2015 |
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Proportional Hazards Models; Remission Induction; Risk; Survival Analysis; Topotecan; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2014 |
Phase I/II study of clofarabine, etoposide, and mitoxantrone in patients with refractory or relapsed acute leukemia.
Topics: Adenine Nucleotides; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Recurrence; Remission Induction; Treatment Outcome | 2015 |
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
Topics: Adult; Aged; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Humans; Injections; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Risk Assessment; Salvage Therapy; Treatment Outcome; Vidarabine | 2015 |
Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Retrospective Studies; Salvage Therapy | 2014 |
A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee).
Topics: Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Asparaginase; Child; Child, Preschool; Clofarabine; Dexamethasone; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Male; Maximum Tolerated Dose; Mitoxantrone; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy; Young Adult | 2016 |
Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Mass Index; Cholesterol; Drug Administration Schedule; Etoposide; Female; Humans; Hyperprolactinemia; Lipoproteins, HDL; Male; Mitoxantrone; Prednisone; Prolactin; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Treatment Outcome; Triglycerides; Vincristine | 2015 |
Infectious Complications in Children With Acute Myeloid Leukemia and Down Syndrome: Analysis of the Prospective Multicenter Trial AML-BFM 2004.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Down Syndrome; Etoposide; Female; Humans; Idarubicin; Infant; Infections; Leukemia, Myeloid, Acute; Male; Mitoxantrone | 2016 |
A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Benzylamines; Cyclams; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Stem Cell Transplantation | 2017 |
Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers; Cytarabine; Decitabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Recurrence; Treatment Outcome; Young Adult | 2017 |
Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cladribine; Clinical Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neoplasm, Residual; Recurrence; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Young Adult | 2017 |
A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Mitoxantrone; Remission Induction; Salvage Therapy; Survival Analysis | 2018 |
Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Mechanistic Target of Rapamycin Complex 1; Middle Aged; Mitoxantrone; Phosphorylation; Pilot Projects; Remission Induction; Signal Transduction; Sirolimus | 2018 |
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Flavonoids; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Recurrence; Remission Induction; Salvage Therapy; Sirolimus; Topotecan; Tumor Lysis Syndrome | 2019 |
A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Glycine; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Patient Safety; Remission Induction; Salvage Therapy; Treatment Outcome | 2019 |
Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cytarabine; Etoposide; Female; Humans; Induction Chemotherapy; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitochondria; Mitoxantrone | 2020 |
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Immunoconjugates; Induction Chemotherapy; Ki-1 Antigen; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Recurrence; Young Adult | 2020 |
Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Glycolipids; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Survival Rate | 2022 |
343 other study(ies) available for etoposide and mitoxantrone
| Article | Year |
|---|---|
Bis(bioreductive) alkylating agents: synthesis and biological activity in a nude mouse human carcinoma model.
Topics: Animals; Antineoplastic Agents; Benzoquinones; Burkitt Lymphoma; Cell Line; Cisplatin; Drug Resistance; Humans; Methotrexate; Mice; Mice, Nude; Nasopharyngeal Neoplasms; Quinones; Tumor Stem Cell Assay; Vinblastine | 1983 |
Topoisomerase II-mediated DNA cleavage by adocia- and xestoquinones from the Philippine sponge Xestospongia sp.
Topics: Animals; Antineoplastic Agents; Crystallography, X-Ray; DNA; Drug Screening Assays, Antitumor; Humans; Intercalating Agents; Magnetic Resonance Spectroscopy; Molecular Structure; Philippines; Porifera; Quinones; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1995 |
Inhibition of topoisomerase II catalytic activity by pyridoacridine alkaloids from a Cystodytes sp. ascidian: a mechanism for the apparent intercalator-induced inhibition of topoisomerase II.
Topics: Acridines; Alkaloids; Animals; Catalysis; Cell Survival; CHO Cells; Cricetinae; DNA; Humans; Intercalating Agents; Magnetic Resonance Spectroscopy; Pyridones; RNA; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Urochordata | 1994 |
Design of antineoplastic agents on the basis of the "2-phenylnaphthalene-type" structural pattern. 2. Synthesis and biological activity studies of benzo]b]naphtho[2,3-d]furan-6,11-dione derivatives.
Topics: Antineoplastic Agents; Carcinoma, Small Cell; Cisplatin; DNA Topoisomerases, Type II; Furans; Humans; Leukemia, Promyelocytic, Acute; Naphthoquinones; Structure-Activity Relationship; Tumor Cells, Cultured | 1993 |
Cell-based screen for identification of inhibitors of tubulin polymerization.
Topics: Animals; Brain Neoplasms; Bucladesine; Cell Differentiation; Drug Screening Assays, Antitumor; Formazans; Glioma; Rats; Tubulin; Tumor Cells, Cultured | 1996 |
Design and synthesis of modified quinolones as antitumoral acridones.
Topics: Acridines; Animals; Anti-Infective Agents; Antineoplastic Agents; Cricetinae; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Humans; Mice; Quinolones; Structure-Activity Relationship; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1999 |
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; CD4-Positive T-Lymphocytes; Cells, Cultured; Doxorubicin; Drug Resistance, Neoplasm; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Indoles; Lamivudine; Microbial Sensitivity Tests; Neoplasm Proteins; Reverse Transcriptase Inhibitors; Zidovudine | 2003 |
Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.
Topics: Animals; Antineoplastic Agents; Cell Division; Drug Screening Assays, Antitumor; Humans; Mice; Naphthyridines; Neoplasm Transplantation; Neoplasms, Experimental; Structure-Activity Relationship; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; Biological Transport; Cell Line; Dogs; Drug Resistance, Neoplasm; Etoposide; Male; Mice; Mice, Knockout; Neoplasm Proteins | 2003 |
Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Biological Transport; Cell Membrane; Drug Resistance, Microbial; Drug Resistance, Multiple; Ligands; Models, Molecular | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Synthesis, DNA binding, and cytotoxicity of 1,4-bis(2-amino-ethylamino)anthraquinone-amino acid conjugates.
Topics: Amino Acid Sequence; Amino Acids; Anthraquinones; Antineoplastic Agents; Combinatorial Chemistry Techniques; DNA; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Stereoisomerism; Structure-Activity Relationship | 2008 |
Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells.
Topics: Acetylcysteine; Antineoplastic Agents, Phytogenic; Antioxidants; Curcumin; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Humans; K562 Cells; Microscopy, Fluorescence; Molecular Structure; Reactive Oxygen Species; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2007 |
The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds.
Topics: Anthracyclines; Antigens, Neoplasm; Antineoplastic Agents; Cell Line; Cell Survival; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Design; Enzyme Inhibitors; Humans; Models, Molecular; Molecular Structure; Neoplasms; Nucleic Acid Denaturation; Plasmids; Protein Binding; Quantitative Structure-Activity Relationship; Temperature; Topoisomerase II Inhibitors | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties of novel indeno[2,1-c]quinolin-7-one and indeno[1,2-c]isoquinolin-5,11-dione derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; DNA; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorescence; Humans; Indenes; Isoquinolines; Mitoxantrone; Nucleic Acid Denaturation; Quinolines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
Topics: Candida albicans; Membrane Transport Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Substrate Specificity | 2010 |
Indeno[1,2-c]isoquinolin-5,11-diones conjugated to amino acids: Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties.
Topics: Amino Acids; Antineoplastic Agents; Arginine; Cell Line, Tumor; DNA; DNA Topoisomerases, Type II; Humans; Indenes; Isoquinolines; Mutation; Structure-Activity Relationship; Topoisomerase II Inhibitors; Transition Temperature | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
Synthesis, cytotoxicity and topoisomerase inhibition properties of multifarious aminoalkylated indeno[1,2-c]isoquinolin-5,11-diones.
Topics: Antineoplastic Agents; Cell Line, Tumor; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Humans; Isoquinolines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Transition Temperature | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzopyrans; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Proto-Oncogene Proteins c-bcl-2; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Structure-Activity Relationship | 2012 |
Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Humans; Liver-Specific Organic Anion Transporter 1; Molecular Structure; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Peptides; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2015 |
Structure-activity relationship of novel acridone derivatives as antiproliferative agents.
Topics: Acridones; Antineoplastic Agents; Cell Proliferation; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Structure-Activity Relationship; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2021 |
A combination of mitoxantrone, etoposide and prednisone in elderly patients with non-Hodgkin's lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone | 1992 |
Inhibitors of topoisomerases do not block the passage of human lymphocyte chromosomes through mitosis.
Topics: Amsacrine; Camptothecin; Chromosome Aberrations; Chromosomes, Human; Daunorubicin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Ellipticines; Ethidium; Etoposide; Humans; In Vitro Techniques; Lymphocytes; Mitosis; Mitoxantrone; Nalidixic Acid; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1992 |
Dissociation of cytotoxicity and DNA cleavage activity induced by topoisomerase II-reactive intercalating agents in hamster-human somatic cell hybrids.
Topics: Animals; CHO Cells; Chromosome Mapping; Chromosomes, Human, Pair 17; Colony-Forming Units Assay; Cricetinae; Daunorubicin; DNA Damage; DNA Topoisomerases, Type II; DNA, Single-Stranded; Doxorubicin; Etoposide; Genes; Humans; Hybrid Cells; Mitoxantrone | 1992 |
Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells.
Topics: Adenosine Triphosphate; Antibodies; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Breast Neoplasms; Cell Membrane Permeability; Cross Reactions; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance; Etoposide; Gene Expression; Humans; Intracellular Fluid; Membrane Glycoproteins; Membrane Proteins; Mitoxantrone; Tumor Cells, Cultured; Verapamil | 1992 |
[A case of diffuse large cell lymphoma treated with combination chemotherapy of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) and BEMP (bleomycin, etoposide, mitoxantrone, procarbazine) with complete remission].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Infusions, Intravenous; Lymphoma, Large B-Cell, Diffuse; Male; Mitoxantrone; Prednisone; Procarbazine; Remission Induction; Vincristine | 1992 |
High cell density-dependent resistance and P-glycoprotein-mediated multidrug resistance in mitoxantrone-selected Chinese hamster cells.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Line; Cell Survival; Clone Cells; Cricetinae; Cricetulus; DNA; Doxorubicin; Drug Resistance; Etoposide; Gene Amplification; Membrane Glycoproteins; Mitoxantrone; RNA; Vincristine | 1992 |
Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy.
Topics: alpha-Fetoproteins; Analysis of Variance; Antineoplastic Agents; Ascites; Bilirubin; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; Etoposide; Female; Fluorouracil; Follow-Up Studies; Humans; Interferon-gamma; Liver Neoplasms; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Prognosis; Regression Analysis; Risk Factors; Serum Albumin; Tegafur; Time Factors | 1992 |
[Treatment of elderly patients with hematological malignancies].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Hodgkin Disease; Humans; Leucovorin; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Methotrexate; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prednisone; Vincristine | 1992 |
Non-Hodgkin's lymphomas: a review of the M.D. Anderson experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Mesna; Methylprednisolone; Middle Aged; Mitoxantrone; Prednisone; Salvage Therapy; Texas; Vincristine | 1992 |
Effective treatment of relapsed acute myeloid leukaemia with drugs chosen by DiSC assay.
Topics: Acute Disease; Antineoplastic Agents; Cytotoxicity Tests, Immunologic; Drug Hypersensitivity; Etoposide; Female; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Recurrence; Vidarabine | 1992 |
Serial changes of the serum macrophage colony-stimulating factor level after cytoreductive chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Enzyme-Linked Immunosorbent Assay; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Leukopenia; Macrophage Colony-Stimulating Factor; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Predictive Value of Tests; Prednisone; Remission Induction; Vindesine | 1992 |
High-dose mitoxantrone and etoposide conditioning in autologous bone marrow transplantation for relapsed Hodgkin's disease.
Topics: Adult; Bone Marrow Transplantation; Etoposide; Female; Heart Diseases; Hodgkin Disease; Humans; Male; Mitoxantrone; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy | 1992 |
[Combination chemotherapy with mitoxantrone, etoposide, vindesine and prednisolone for relapsed or refractory malignant lymphoma: presence of cross-resistance to CHOP therapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Resistance; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Recurrence; Vincristine; Vindesine | 1992 |
Impact of laparotomy finding of significant intraabdominal adhesions on the surgically defined complete response rate to subsequent salvage intraperitoneal chemotherapy.
Topics: Abdomen; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Female; Humans; Infusions, Parenteral; Laparotomy; Mitoxantrone; Ovarian Neoplasms; Retrospective Studies; Tissue Adhesions | 1992 |
Chemical compatibility of mitoxantrone and etoposide (VP-16).
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Stability; Etoposide; Mitoxantrone | 1991 |
Intensive individualized induction therapy with behenoyl cytarabine, daunorubicin and 6-mercaptopurine followed by intensive consolidation including intermediate-dose continuous cytarabine, mitoxantron, etoposide and vinca alkaloids in acute myeloid leuke
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Mitoxantrone; Vinca Alkaloids | 1991 |
Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Drug Stability; Epirubicin; Etoposide; Feasibility Studies; Female; Humans; Ifosfamide; Infusion Pumps, Implantable; Infusions, Intravenous; Male; Mesna; Middle Aged; Mitoxantrone; Neoplasms | 1991 |
Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia.
Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; DNA Topoisomerases, Type II; Drug Resistance; Drug Synergism; Etoposide; Leukemia P388; Mice; Mice, Inbred Strains; Mitoxantrone | 1991 |
[Intensification chemotherapy followed by allogenieic and autologous bone marrow transplantation in acute non-lymphoblastic leukemia in children].
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Evaluation Studies as Topic; Female; Humans; Infant; Leukemia, Myeloid, Acute; Life Tables; Male; Methotrexate; Mitoxantrone; Remission Induction; Survival Rate; Thioguanine; Transplantation, Autologous; Transplantation, Homologous | 1991 |
Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Rate | 1991 |
Experience with salvage regimens at M.D. Anderson Hospital.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Evaluation; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Lymphoma; Lymphoma, Non-Hodgkin; Mesna; Methotrexate; Methylprednisolone; Methylprednisolone Hemisuccinate; Mitoguazone; Mitoxantrone; Remission Induction; Survival Rate | 1991 |
[Acute myeloblastic leukemia 5q-. Clinical and cytogenetic remission by means of intensive chemotherapy].
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Megakaryoblastic, Acute; Male; Middle Aged; Mitoxantrone; Mosaicism; Remission Induction | 1991 |
Granulocyte-macrophage colony-stimulating factor in acute non-lymphocytic leukemia before and after chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Remission Induction; Time Factors | 1991 |
Combination therapy with mitoxantrone and etoposide in adult acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Evaluation; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Remission Induction | 1990 |
Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non-Hodgkin lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHL.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Vincristine | 1991 |
Dysmegakaryopoiesis resembling acute megakaryoblastic leukemia in treated acute myeloid leukemia.
Topics: Acute Disease; Antigens, CD; Bone Marrow; Cytarabine; Daunorubicin; Diagnosis, Differential; Doxorubicin; Etoposide; Humans; Hyperplasia; Immunophenotyping; Leukemia, Megakaryoblastic, Acute; Leukemia, Myeloid; Megakaryocytes; Mitoxantrone; Myelodysplastic Syndromes; Prognosis; Time Factors | 1991 |
Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Etoposide; Humans; L-Lactate Dehydrogenase; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Remission Induction | 1991 |
Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Survival Rate | 1991 |
A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Combined Modality Therapy; Drug Evaluation; Etoposide; Female; Humans; Infusions, Intravenous; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Rate; Thiotepa; Transplantation, Autologous | 1990 |
VIM-D salvage chemotherapy in Hodgkin's disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Dexamethasone; Etoposide; Female; Hodgkin Disease; Humans; Ifosfamide; Male; Middle Aged; Mitoxantrone | 1990 |
Mitoxantrone, etoposide and cytarabine in the treatment of acute nonlymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone | 1990 |
Acute megakaryoblastic leukemia (FAB-M7) in an infant presenting with orbital chloroma and meningeal involvement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Etoposide; Exophthalmos; Humans; Infant; Leukemia, Megakaryoblastic, Acute; Male; Meningeal Neoplasms; Mitoxantrone; Orbital Neoplasms; Prednisone; Thioguanine; Vincristine | 1990 |
Treatment of relapsed or refractory acute leukemia: comparison of two different regimens.
Topics: Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Leukemia; Mitoxantrone; Neoplasm Recurrence, Local | 1990 |
Continuous infusion mitoxantrone in relapsed acute nonlymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow; Etoposide; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Remission Induction | 1990 |
Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Recurrence; Remission Induction; Survival Rate | 1990 |
[Multi-agent combination chemotherapy for adult acute lymphoblastic leukemia--individualized chemotherapy].
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Remission Induction; Survival Rate; Vindesine | 1990 |
Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin.
Topics: Animals; Antibodies, Monoclonal; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; Cell Line; Colchicine; Daunorubicin; Doxorubicin; Drug Resistance; Enzyme-Linked Immunosorbent Assay; Epirubicin; Etoposide; Glycoproteins; Gramicidin; Humans; Immunosorbent Techniques; Isoxazoles; Lung Neoplasms; Menogaril; Mice; Mice, Inbred BALB C; Mitoxantrone; Nogalamycin; Phenotype; Vinblastine; Vincristine | 1987 |
The value of intensive combination chemotherapy for juvenile chronic myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Male; Mercaptopurine; Mitoxantrone; Thioguanine | 1987 |
Isolation of two Chinese hamster ovary cell mutants hypersensitive to topoisomerase II inhibitors and cross-resistant to peroxides.
Topics: Amsacrine; Animals; Cell Line; Cell Survival; Cricetinae; Dactinomycin; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance; Etoposide; Female; Mitoxantrone; Mutation; Ovary; Teniposide; Topoisomerase II Inhibitors | 1989 |
Expression of protein-associated DNA damage in the alkaline elution assay in the absence of enzymatic deproteinization.
Topics: Animals; Cell Line; DNA Damage; DNA Replication; DNA Topoisomerases, Type II; DNA, Neoplasm; Endopeptidase K; Etoposide; Humans; Hydrogen-Ion Concentration; Leukemia L1210; Liver Neoplasms, Experimental; Mice; Mitoxantrone; Podophyllotoxin; Protein Binding; Rats; Serine Endopeptidases; Teniposide; Tumor Cells, Cultured | 1989 |
Multidrug resistance in cultured human leukemia and lymphoma cell lines detected by a monoclonal antibody, MRK16.
Topics: Antibodies, Monoclonal; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dactinomycin; Daunorubicin; Doxorubicin; Drug Resistance; Etoposide; Gene Expression; Humans; Leukemia; Lymphoma; Membrane Glycoproteins; Mitoxantrone; RNA, Messenger; Tumor Cells, Cultured; Vinblastine; Vincristine; Vindesine | 1989 |
[Treatment of acute leukemia with "MB-triple V" therapy--a comparative study of "MB-triple V" therapy and B-triple V therapy].
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Female; Humans; Leukemia; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Remission Induction; Vinblastine; Vincristine; Vindesine | 1989 |
[Chemotherapy of adult ANLL].
Topics: Aclarubicin; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Drug Evaluation; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Prednisolone; Remission Induction; Survival Rate; Vincristine | 1989 |
Intraperitoneal chemotherapy as treatment for ovarian carcinoma and gastrointestinal malignancies: the Memorial Sloan-Kettering Cancer Center experience).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Etoposide; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Parenteral; Mitoxantrone; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms | 1989 |
Mitoxantrone and etoposide: an effective regimen for refractory or relapsed acute myelogenous leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood; Drug Evaluation; Etoposide; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Recurrence; Remission Induction; Time Factors | 1989 |
Differential increases in glutathione S-transferase activities in a range of multidrug-resistant human tumor cell lines.
Topics: Antineoplastic Agents; Blotting, Northern; Blotting, Western; Breast Neoplasms; Doxorubicin; Drug Resistance; Etoposide; Glutathione; Glutathione Peroxidase; Glutathione Transferase; Humans; In Vitro Techniques; Mitoxantrone; Tumor Cells, Cultured; Vincristine | 1989 |
Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs.
Topics: Amsacrine; Breast Neoplasms; Cell Survival; DNA Damage; DNA Repair; DNA Topoisomerases, Type II; Doxorubicin; Drug Synergism; Estrogens; Etoposide; Female; Humans; Mitoxantrone; Tumor Cells, Cultured | 1988 |
Resistant multiple myeloma treated with mitozantrone in combination with vincristine and dexamethasone (MOD)
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexamethasone; Doxorubicin; Drug Administration Schedule; Drug Resistance; Etoposide; Humans; Immunoglobulin G; Middle Aged; Mitoxantrone; Multiple Myeloma; Vincristine | 1989 |
[A case of chronic adult T-cell leukemia benefited by small doses of MEPP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cisplatin; Drug Administration Schedule; Etoposide; Humans; Leukemia, T-Cell; Male; Middle Aged; Mitoxantrone; Prednisolone; Skin | 1988 |
Sequential pilot studies of intensive postremission chemotherapy for acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Pilot Projects; Thioguanine | 1987 |
Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction | 1988 |
Combination therapy with mitoxantrone and etoposide in refractory acute myelogenous leukemia.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone | 1986 |
Mitoxantrone and VP-16 in refractory acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Drug Resistance; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone | 1986 |
Salvage chemotherapy for non-Hodgkin's lymphoma with a combination of mitoxantrone, etoposide, cisplatin, and prednisolone.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisolone | 1987 |
[A new drug and current strategy in the treatment of acute non-lymphocytic leukemia in adults].
Topics: Acute Disease; Adult; Aminoacridines; Amsacrine; Anthraquinones; Antineoplastic Agents; Cytarabine; Drug Administration Schedule; Etoposide; Humans; Leukemia; Mitoxantrone | 1986 |
Transient protection of cultured human cells against antitumor agents by 12-O-tetradecanoylphorbol-13-acetate.
Topics: Antineoplastic Agents; Cell Division; Cell Survival; Cells, Cultured; Diglycerides; Dose-Response Relationship, Drug; Etoposide; Humans; Methotrexate; Mitoxantrone; Nasopharyngeal Neoplasms; Tetradecanoylphorbol Acetate; Time Factors; Type C Phospholipases; Verapamil; Vincristine | 1987 |
[Salvage chemotherapy of non-Hodgkin's lymphoma with a four-drug combination of mitoxantrone, etoposide, cisplatin and prednisolone (MEPP)].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisolone | 1987 |
[Mitoxantrone in the treatment of relapsed and refractory malignant lymphoma].
Topics: Adult; Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Evaluation; Drug Resistance; Etoposide; Female; Humans; Lymphoma; Male; Middle Aged; Mitoxantrone; Prednisolone; Recurrence | 1985 |
[Current clinical status of new anticancer drugs].
Topics: Altretamine; Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Epirubicin; Etoposide; Humans; Mitoxantrone; Neoplasms | 1983 |
Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP) combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematuria; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Mitoxantrone; Neutropenia; Prednisone; Prospective Studies; Recurrence; Survival Rate; Vincristine | 1995 |
Pharmacokinetics of mitoxantrone, etoposide and cytosine arabinoside in leukemic cells during treatment of acute myelogenous leukemia--relationship to treatment outcome and bone marrow toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Treatment Outcome | 1995 |
Serum levels of interleukin-10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Enzyme-Linked Immunosorbent Assay; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Interleukin-10; Life Tables; Lymphoma, Large B-Cell, Diffuse; Male; Mesna; Methotrexate; Methylprednisolone Hemisuccinate; Middle Aged; Mitoxantrone; Neoplasm Proteins; Prognosis; Risk Factors; Sensitivity and Specificity; Severity of Illness Index; Survival Analysis; Treatment Outcome; Vincristine | 1995 |
High-dose chemotherapy and autologous peripheral stem cell transplantation in patients with relapsing malignant lymphomas--first experience in the Slovak Republic.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lymphoma; Mitoxantrone; Salvage Therapy; Slovakia | 1995 |
A marrow harvest procedure under local anesthesia.
Topics: Anesthesia, Local; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Carmustine; Combined Modality Therapy; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Lung Neoplasms; Mitoxantrone; Outpatients; Pain Measurement; Thiotepa; Tissue Preservation; Transplantation, Autologous | 1995 |
Characteristics of the inhibitory effect of mitoxantrone and pirarubicin on lung metastases of colon carcinoma 26.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Division; Colonic Neoplasms; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Endothelium, Vascular; Etoposide; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Inbred Strains; Mitoxantrone; Neoplasm Transplantation; Neovascularization, Pathologic; Rats | 1995 |
Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Methylprednisolone; Middle Aged; Mitoxantrone; Prednisolone; Prospective Studies; Recurrence; Salvage Therapy; Vincristine | 1995 |
Therapy-related acute myelomonocytic leukemia following successful treatment for acute promyelocytic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cytarabine; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Mercaptopurine; Methotrexate; Mitoxantrone; Neoplasms, Second Primary; Remission Induction; Thioguanine; Translocation, Genetic | 1995 |
Granulocyte colony-stimulating factor (CSF), macrophage-CSF, granulocyte-macrophage CSF, interleukin-3, and interleukin-6 levels in sera from children undergoing blood stem cell autografts.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Child; Cytarabine; Daunorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Interleukin-6; Leukemia, Myeloid, Acute; Leukocyte Count; Lymphoma, Non-Hodgkin; Macrophage Colony-Stimulating Factor; Male; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Stem Cell Transplantation; Time Factors; Transplantation, Autologous | 1993 |
Alternating chemotherapy of CHOP-Bleo and POEM-Bleo for diffuse large-cell lymphoma: a single-institutional study with a long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Remission Induction; Vincristine | 1993 |
"Atypical" multidrug resistance in human ovarian cancer cell line A2780 selected for resistance to doxorubicin (A2780 DX3).
Topics: Antineoplastic Agents; Catalysis; Cell Survival; DNA Damage; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance, Multiple; Etoposide; Female; Humans; Mitoxantrone; Ovarian Neoplasms; Tumor Cells, Cultured | 1995 |
Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autolog
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Cell Survival; Colony-Forming Units Assay; Combined Modality Therapy; Cyclophosphamide; Daunorubicin; Diploidy; Etoposide; Female; Genetic Markers; Hematopoietic Stem Cells; Humans; Idarubicin; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Philadelphia Chromosome; Remission Induction; Survival Rate; Vidarabine; Whole-Body Irradiation | 1995 |
Prolonged impairment of hematopoiesis after high-dose therapy followed by autologous bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Busulfan; Carmustine; Cell Count; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoiesis; Hematopoietic Cell Growth Factors; Humans; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplasms; Prognosis; Radiation Injuries; Treatment Outcome; Vincristine; Whole-Body Irradiation | 1995 |
Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Remission Induction; Treatment Outcome | 1995 |
Mitoxantrone and etoposide in breast milk.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Leukemia, Promyelocytic, Acute; Milk, Human; Mitoxantrone; Pregnancy; Pregnancy Complications, Neoplastic | 1995 |
Interactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Agents; Cladribine; Cytarabine; Daunorubicin; Drug Interactions; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Fluoresceins; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Tumor Cells, Cultured | 1994 |
Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; DNA Damage; DNA, Neoplasm; DNA, Single-Stranded; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Humans; Mitoxantrone; Ovarian Neoplasms; Recombinant Proteins; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1993 |
Experience with implanted subcutaneous ports for intraperitoneal chemotherapy in ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Catheters, Indwelling; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Parenteral; Middle Aged; Mitoxantrone; Ovarian Neoplasms; Postoperative Complications; Reoperation; Retrospective Studies | 1994 |
MINE-ESHAP salvage therapy for recurrent and refractory lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Humans; Ifosfamide; Lymphoma; Mesna; Methylprednisolone Hemisuccinate; Mitoxantrone; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate | 1994 |
Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in refractory lymphoma patients undergoing autologous bone marrow transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Chemotherapy, Adjuvant; Cyclophosphamide; Etoposide; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Mitoxantrone | 1994 |
Circumvention of atypical multidrug resistance with tumor necrosis factor.
Topics: DNA Damage; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance; Drug Synergism; Etoposide; Female; Humans; Mitoxantrone; Ovarian Neoplasms; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1994 |
Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes | 1994 |
Differential induction of chromosomal aberrations by topoisomerase inhibitors in cultured Chinese hamster cells.
Topics: Aclarubicin; Animals; Camptothecin; Cells, Cultured; Chromosome Aberrations; Cricetinae; Cricetulus; Doxorubicin; Etoposide; Fibroblasts; Lung; Mitoxantrone; Sister Chromatid Exchange; Topoisomerase I Inhibitors | 1994 |
[The current chemotherapy of acute myeloid leukemias in adults].
Topics: Aclarubicin; Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Mitoxantrone; Prognosis; Remission Induction; Time Factors | 1993 |
In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Blood Proteins; Cytarabine; Etoposide; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Protein Binding; Serum Albumin; Topoisomerase II Inhibitors | 1993 |
[Short-term intensive consolidation chemotherapy in the treatment of acute nonlymphocytic leukemia].
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Survival Rate; Vinblastine; Vincristine | 1994 |
Hemolytic uremic syndrome developing during remission of acute myelomonocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Hemolytic-Uremic Syndrome; Humans; Leukemia, Myelomonocytic, Acute; Middle Aged; Mitoxantrone; Plasma Exchange; Platelet Aggregation Inhibitors; Prednisolone; Remission Induction; Zinostatin | 1993 |
Dipyridamole enhancement of drug sensitivity in acute lymphoblastic leukemia cells.
Topics: Administration, Oral; Antineoplastic Agents; Bone Marrow; Child; Dipyridamole; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Drug Synergism; Etoposide; Female; Humans; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tumor Cells, Cultured; Vincristine | 1993 |
Treatment of relapsing and refractory adult acute myeloid leukemia according to in vitro clonogenic leukemic cell drug sensitivity.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Pilot Projects; Prospective Studies; Recurrence; Salvage Therapy; Tumor Stem Cell Assay | 1993 |
Induction therapy for acute myelogenous leukemia in patients over 60 years with intermediate-dose cytosine arabinoside, mitoxantrone and etoposide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction | 1993 |
Double mutations of the N-ras gene in a patient with acute myelomonocytic leukemia.
Topics: Aclarubicin; Alleles; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 9; Codon; Cytarabine; Daunorubicin; Disease Progression; Doxorubicin; Etoposide; Fatal Outcome; Genes, ras; Genetic Vectors; Humans; Karyotyping; Leukemia, Myelomonocytic, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Point Mutation; Prednisolone; Vinblastine; Vincristine | 1995 |
Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Fungemia; Fungi; Humans; Intestinal Mucosa; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Mycoses; Remission Induction; Retrospective Studies | 1995 |
Selective discharge of patients with acute myeloid leukemia during chemotherapy-induced neutropenia.
Topics: Acute Disease; Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Catheterization, Central Venous; Cross Infection; Cytarabine; Daunorubicin; Disease Susceptibility; Etoposide; Female; Fever; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neutropenia; Patient Discharge; Safety; Treatment Outcome | 1996 |
Factors influencing prognosis after dose-intensive therapy for recurrent or refractory Hodgkin's disease. Results of sequential trials: a case for treating patients with resistant disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Carmustine; Clinical Trials as Topic; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Resistance; Etoposide; Female; Hodgkin Disease; Humans; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Survival Rate; Thiotepa; Treatment Outcome; Vinblastine | 1995 |
Pneumocystis carinii pneumonia in adults with acute leukaemia: is there a need for primary chemoprophylaxis?
Topics: Aclarubicin; Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Finland; Humans; Immunocompromised Host; Incidence; Leukemia; Male; Mercaptopurine; Methotrexate; Middle Aged; Mitoxantrone; Pneumonia, Pneumocystis; Prednisone; Premedication; Retrospective Studies; Thioguanine; Trimethoprim, Sulfamethoxazole Drug Combination; Vincristine | 1996 |
Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Thiotepa | 1995 |
Intensive induction and consolidation chemotherapy in a young woman with acute myeloid leukemia and severe chronic renal failure.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Contraindications; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Kidney Failure, Chronic; Leukemia, Myeloid, Acute; Mitoxantrone | 1996 |
The distribution of topoisomerase II on mammalian chromosomes.
Topics: Amsacrine; Animals; Cells, Cultured; CHO Cells; Cricetinae; DNA Topoisomerases, Type II; Etoposide; Fibroblasts; Fluorescent Antibody Technique; Humans; L Cells; Lymphocytes; Mice; Mitosis; Mitoxantrone; Muridae; Rats; Topoisomerase II Inhibitors | 1996 |
Late relapse after autologous BMT.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cytarabine; Etoposide; Female; Humans; Idarubicin; Leukemia, Myelomonocytic, Acute; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Time Factors | 1996 |
Intensive remission induction therapy for chronic myeloid leukemia in blast phase with a goal of post-remission bone marrow transplant--a pilot study.
Topics: Adolescent; Adult; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Etoposide; Female; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Pilot Projects; Remission Induction; Survival Rate; Vincristine | 1996 |
In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antigens, CD34; Antineoplastic Agents; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Recurrence; Risk Factors; Treatment Outcome | 1996 |
Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein.
Topics: Amides; Antineoplastic Agents; Aspartic Acid; Blotting, Western; Breast Neoplasms; Cell Cycle; Clone Cells; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Female; Flow Cytometry; Gene Expression; Genes, p53; Humans; Immunohistochemistry; Melphalan; Mitoxantrone; Neoplasm Proteins; Nuclear Proteins; Phosphonoacetic Acid; Polymerase Chain Reaction; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Pyrazoles; Ribonucleosides; Ribose; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1996 |
[CD7, HLA-DR, CD38 positive acute undifferentiated leukemia with subcutaneous tumor and thymoma].
Topics: Acute Disease; ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Antigens, CD; Antigens, CD7; Antigens, Differentiation; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Etoposide; Gene Rearrangement; HLA-DR Antigens; Humans; Immunoglobulin Heavy Chains; Immunophenotyping; Leukemia; Membrane Glycoproteins; Mitoxantrone; N-Glycosyl Hydrolases; Prednisolone; Receptors, Antigen, T-Cell, gamma-delta; Remission Induction; Skin Neoplasms; Thymoma; Thymus Neoplasms | 1996 |
Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Cells; Bone Marrow; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Etoposide; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Life Tables; Middle Aged; Mitoxantrone; Recombinant Proteins; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Thioguanine; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Whole-Body Irradiation | 1996 |
Effective autologous peripheral blood stem cell transplantation in plasma cell leukemia followed by T-large granular lymphocyte expansion: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Plasma Cell; Lymphocyte Count; Male; Melphalan; Mitoxantrone; Prednisone; Remission Induction; T-Lymphocyte Subsets; Transplantation Conditioning; Vincristine; Whole-Body Irradiation | 1996 |
Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspases; Cysteine Endopeptidases; Cytarabine; Enzyme Induction; Etoposide; HL-60 Cells; Humans; Mitoxantrone; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger | 1996 |
Acute leukemia during pregnancy: obstetric management and perinatal outcome of two cases.
Topics: Abnormalities, Drug-Induced; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Etoposide; Fatal Outcome; Female; Humans; Leukemia, Promyelocytic, Acute; Mitoxantrone; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Recurrence; Thioguanine | 1995 |
11q23 aberration is an additional chromosomal change in de novo acute leukemia after treatment with etoposide and mitoxantrone.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 11; DNA Topoisomerases, Type II; Enzyme Inhibitors; Etoposide; Fatal Outcome; Female; Humans; Karyotyping; Leukemia, Monocytic, Acute; Mitoxantrone; Neoplasm Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Topoisomerase II Inhibitors | 1996 |
Mobilized peripheral blood progenitor cells (PBPC) in support of tandem cycles of high-dose chemotherapy (HDC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Carboplatin; Cyclophosphamide; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Male; Melphalan; Middle Aged; Mitoxantrone; Neoplasms; Patient Acceptance of Health Care; Remission Induction; Salvage Therapy; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 1996 |
Cytotoxic efficacy with combinations of topoisomerase I and topoisomerase II inhibitors in sensitive and multidrug-resistant L1210 mouse leukemia cells.
Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Multiple; Drug Synergism; Enzyme Inhibitors; Etoposide; Leukemia L1210; Mice; Mitoxantrone; Topoisomerase I Inhibitors; Topotecan | 1996 |
Granulocyte-colony stimulating factor fails to prevent leucopenia caused by CEMP in elderly patients with aggressive lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Lymphoma, Non-Hodgkin; Mitoxantrone; Prednisone; Recombinant Proteins | 1996 |
[The detection of minimal residual disease by DEK/CAN chimeric m-RNA in a case of AML M2 with translocation t(6;9) (p23;q34) after chemotherapy and peripheral blood stem cell transplantation].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 6; Chromosomes, Human, Pair 9; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Mitoxantrone; Neoplasm, Residual; Oncogene Proteins; Oncogene Proteins, Fusion; Polymerase Chain Reaction; Prednisolone; Recombinant Fusion Proteins; RNA, Messenger; Translocation, Genetic | 1997 |
Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leucovorin; Leukapheresis; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Pilot Projects; Prednisone; Risk; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vincristine | 1997 |
In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
Topics: Aclarubicin; Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bleomycin; Bone Marrow; Cell Survival; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Follow-Up Studies; Humans; Infant; Infant, Newborn; Life Tables; Melphalan; Methotrexate; Mitomycin; Mitoxantrone; Neoplastic Stem Cells; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Recurrence; Remission Induction; Tumor Cells, Cultured; Vincristine | 1997 |
[Combination chemotherapy with BH-AC, mitoxantrone, etoposide, and prednisolone to refractory or relapsed malignant lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Male; Middle Aged; Mitoxantrone; Prednisolone | 1997 |
Salvage treatment after failure or relapse following initial chemotherapy for follicular non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxorubicin; Etoposide; Female; Humans; Life Tables; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Procarbazine; Prognosis; Proportional Hazards Models; Remission Induction; Salvage Therapy; Survival Analysis; Vincristine | 1997 |
Salvage intraperitoneal therapy of advanced epithelial ovarian cancer: impact of retroperitoneal nodal disease.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carboplatin; Carcinoma; Cisplatin; Combined Modality Therapy; Cytarabine; Etoposide; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Laparotomy; Lymphatic Metastasis; Middle Aged; Mitoxantrone; Neoplasm Staging; Ovarian Neoplasms; Retroperitoneal Space; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 1997 |
Pharmacokinetic monitoring of anticancer drugs at King Faisal Specialist Hospital, Riyadh, Saudi Arabia.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Doxorubicin; Etoposide; Fluorouracil; Humans; Methotrexate; Mitoxantrone; Reference Values; Saudi Arabia | 1997 |
Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Disease-Free Survival; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Life Tables; Lymphoma, Non-Hodgkin; Mesna; Methylprednisolone; Methylprednisolone Hemisuccinate; Mitoxantrone; Prognosis; Salvage Therapy; Texas; Treatment Outcome | 1997 |
Salvage therapy for relapsed or refractory childhood acute lymphocytic leukemia by alternative administration a lymphoid- and myeloid-directed chemotherapeutic regimen consisting of dual modulation of ara-C, hydroxyurea, and etoposide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Fever; Gastrointestinal Diseases; Humans; Hydrocortisone; Hydroxyurea; Leucovorin; Male; Methotrexate; Mitoxantrone; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Treatment Outcome | 1997 |
Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Survival; Coloring Agents; Cyclosporine; Cyclosporins; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1997 |
Administration of MINE protocol in untreated patients with intermediate and high grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Middle Aged; Mitoxantrone; Remission Induction; Survival Rate; Treatment Outcome | 1997 |
MDR1 gene expression and drug resistance of AML cells.
Topics: Aclarubicin; Acute Disease; Antineoplastic Agents; Cytarabine; Daunorubicin; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Gene Expression; Genes, MDR; Humans; Lethal Dose 50; Leukemia, Myeloid; Mitoxantrone; Tumor Cells, Cultured | 1998 |
Leukemic cells with 11q23 translocations express granulocyte colony-stimulating factor (G-CSF) receptor and their proliferation is stimulated with G-CSF.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Blast Crisis; Cell Division; Cell Line; Chromosome Mapping; Chromosomes, Human, Pair 11; Cytarabine; DNA Replication; Etoposide; Granulocyte Colony-Stimulating Factor; Granulocytes; Humans; Immunophenotyping; Infant; Male; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Granulocyte Colony-Stimulating Factor; Tumor Cells, Cultured | 1998 |
Intracellular glutathione content of urothelial cancer in correlation to chemotherapy response.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Glutathione; Humans; Male; Middle Aged; Mitoxantrone; Ureteral Neoplasms; Urinary Bladder Neoplasms | 1997 |
Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors?
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chromosome Inversion; Chromosomes, Human, Pair 16; Etoposide; Female; Gene Rearrangement; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Oncogene Proteins, Fusion; Topoisomerase I Inhibitors | 1998 |
The role of intensive AML-specific therapy in treatment of children with RAEB and RAEB-t.
Topics: Adolescent; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cell Transformation, Neoplastic; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Infant; Male; Mitoxantrone; Remission Induction | 1998 |
Levels of proteins C and S do not decline subsequent to first line chemotherapy in lymphoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; alpha-2-Antiplasmin; Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; Bleomycin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Fibrin Fibrinogen Degradation Products; Hodgkin Disease; Humans; Leucovorin; Lymphoma; Lymphoma, Non-Hodgkin; Male; Mechlorethamine; Methotrexate; Middle Aged; Mitoxantrone; Partial Thromboplastin Time; Plasminogen; Prednisone; Procarbazine; Protein C; Protein S; Thrombophilia; Time Factors; Vinblastine; Vincristine | 1997 |
A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with DNA-topoisomerase II inhibitors, etoposide and mitoxantrone, and the alkylating agent, cyclophosphamide.
Topics: Alkylating Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Southern; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 21; Cosmids; Cyclophosphamide; DNA Probes; DNA Topoisomerases, Type II; Etoposide; Female; Gene Deletion; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Leukemia, Radiation-Induced; Middle Aged; Mitoxantrone; Prednisone; Topoisomerase II Inhibitors; Translocation, Genetic | 1998 |
Case 17: Essential thrombocythaemia with inversion 3 terminating in acute leukaemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 3; Cytarabine; Etoposide; Fatal Outcome; Female; Humans; Karyotyping; Leukemia; Middle Aged; Mitoxantrone; Thrombocythemia, Essential | 1998 |
[Low-dose oral etoposide and subcutaneous injection of low-dose cytosine arabinoside (Et-A non i.v.) with or without minimum anthracycline for refractory acute non-lymphoblastic leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Vindesine | 1998 |
Management of acute promyelocytic leukemia relapse in the ATRA era.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Salvage Therapy; Thioguanine; Treatment Outcome; Tretinoin | 1998 |
Secondary acute myeloid leukemia following treatment with VP16-containing regimens for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Doxorubicin; Enzyme Inhibitors; Etoposide; Fatal Outcome; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Leukemia, Monocytic, Acute; Leukemia, Myelomonocytic, Acute; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Male; Methotrexate; Mitoxantrone; Neoplasm Proteins; Neoplasms, Second Primary; Prednisone; Topoisomerase II Inhibitors; Vincristine | 1998 |
Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Biological Transport; Cytarabine; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Etoposide; Humans; KB Cells; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Multidrug Resistance-Associated Proteins; Phenotype; Prognosis; Treatment Outcome; Tumor Cells, Cultured | 1995 |
Evidence against a direct role for the induction of c-jun expression in the mediation of drug-induced apoptosis in human acute leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cisplatin; Cytarabine; Etoposide; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Genes, jun; HL-60 Cells; Humans; Leukemia, B-Cell; Mitoxantrone; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-jun; Recombinant Proteins; Transfection; Tumor Cells, Cultured | 1995 |
P-glycoprotein expression and prognostic value in acute myeloid leukemia.
Topics: Actuarial Analysis; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Child; Cohort Studies; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Genes, MDR; Humans; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neoplastic Stem Cells; Prognosis; Remission Induction | 1998 |
Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Chromatography, High Pressure Liquid; Cytarabine; Etoposide; Female; Humans; Infant; Infusions, Intravenous; Leukemia, Myeloid; Male; Mitoxantrone; Recurrence; Remission Induction | 1998 |
Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Hemorrhage; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Pancytopenia; Platelet Count; Platelet Transfusion; Retrospective Studies; Spain; Thrombocytopenia | 1998 |
High-dose sequential chemotherapy with autologous blood stem cell rescue for relapsed or resistant lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Stem Cells | 1998 |
Induction of diplochromosomes in mammalian cells by inhibitors of topoisomerase II.
Topics: Amsacrine; Animals; CHO Cells; Chromatids; Chromosome Aberrations; Chromosome Segregation; Cricetinae; Demecolcine; DNA Topoisomerases, Type II; Enzyme Inhibitors; Etoposide; Interphase; Metaphase; Mitoxantrone; Nucleic Acid Synthesis Inhibitors; Topoisomerase II Inhibitors | 1998 |
Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Cytarabine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Leukemia, Myeloid; Leukopenia; Liver; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 1999 |
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Leukemia, Myeloid; Male; Mechlorethamine; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Neoplastic Stem Cells; Pilot Projects; Platelet Transfusion; Recurrence; Remission Induction; Risk; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine | 1999 |
A single apheresis to achieve a high number of peripheral blood CD34+ cells in a lithium-treated patient with acute myeloid leukaemia.
Topics: Adult; Antigens, CD34; Antimanic Agents; Antineoplastic Combined Chemotherapy Protocols; Bipolar Disorder; Blood Cell Count; Cytarabine; Daunorubicin; Drug Synergism; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Idarubicin; Leukapheresis; Leukemia, Monocytic, Acute; Lithium Carbonate; Mitoxantrone; Recombinant Proteins; Remission Induction; Thioguanine | 1999 |
Downbeat nystagmus caused by thiamine deficiency: an unusual presentation of CNS localization of large cell anaplastic CD 30-positive non-Hodgkin's lymphoma.
Topics: Adult; Anisocoria; Antineoplastic Combined Chemotherapy Protocols; Aphasia; Bleomycin; Brain Neoplasms; Cyclophosphamide; Cytarabine; Dizziness; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hemiplegia; Humans; Lymphoma, Large-Cell, Anaplastic; Methotrexate; Mitoxantrone; Neoplastic Stem Cells; Nystagmus, Pathologic; Prednisone; Remission Induction; Thiamine; Vincristine; Vomiting; Wernicke Encephalopathy | 1999 |
Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisone; Prognosis; Risk Factors; Severity of Illness Index; Survival Analysis; Vincristine | 1999 |
Cryptic insertion (15;17) in a case of acute promyelocytic leukemia detected by fluorescence in situ hybridization.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cytarabine; Etoposide; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Male; Mitoxantrone; Neoplasm Proteins; Oncogene Proteins, Fusion; Reverse Transcriptase Polymerase Chain Reaction; Translocation, Genetic; Tretinoin | 1999 |
Trisomy 21 associated transient neonatal myeloproliferation in the absence of Down's syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 6; Cytarabine; Down Syndrome; Etoposide; Female; Hematopoietic Stem Cells; Humans; In Situ Hybridization, Fluorescence; Infant, Newborn; Karyotyping; Male; Mitoxantrone; Myeloproliferative Disorders; Time Factors | 1998 |
Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Etoposide; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Mitoxantrone; Recurrence; Time Factors; Tissue Donors; Transplantation Chimera; Transplantation, Homologous | 1999 |
A new PCR MIMIC strategy to quantify low mdr1 mRNA levels in drug resistant cell lines and AML blast samples.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Chromosome Banding; Cytarabine; Daunorubicin; DNA, Complementary; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Leukemic; Genes, MDR; Humans; K562 Cells; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neoplastic Stem Cells; Oligonucleotide Probes; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sensitivity and Specificity; Tumor Cells, Cultured | 1999 |
Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
Topics: Acute Disease; Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Marrow Transplantation; Clinical Protocols; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Evaluation Studies as Topic; Feasibility Studies; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukapheresis; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Remission Induction; Time Factors; Transplantation, Autologous; Treatment Outcome | 1999 |
[The value of intracellular CD41 antigen detection to the diagnosis of acute megakaryoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Infant; Leukemia, Megakaryoblastic, Acute; Male; Megakaryocytes; Mitoxantrone; Platelet Glycoprotein GPIIb-IIIa Complex; Remission Induction | 1999 |
Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation.
Topics: Acridines; Amsacrine; Animals; Antigens, Neoplasm; Antineoplastic Agents; Cell Survival; Cells, Cultured; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Isoenzymes; Mice; Mice, Transgenic; Mitoxantrone; Topoisomerase II Inhibitors | 1999 |
Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals.
Topics: Androstadienes; Antineoplastic Agents; Apigenin; Apoptosis; bcl-Associated Death Protein; bcl-X Protein; Camptothecin; Carrier Proteins; Cell Survival; Chromones; Cycloheximide; Dactinomycin; Dimerization; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Flavonoids; Genes, bcl-2; HL-60 Cells; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Mitoxantrone; Morpholines; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Sirolimus; Wortmannin | 2000 |
Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis; Treatment Outcome; Vincristine | 2000 |
Acute myeloblastic leukemia secondary to myelodysplasia (MDS-AML): a comparison of remission induction with three drugs versus standard two-drugs induction.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Remission Induction | 2000 |
Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs.
Topics: Amsacrine; Animals; Antineoplastic Agents; Blood Proteins; Carcinoma, Lewis Lung; Cattle; Doxorubicin; Etoposide; Humans; Mice; Mitoxantrone; Orosomucoid; Protein Binding; Serum Albumin; Vincristine | 2000 |
High-dose chemotherapy and stem cell transplantation for patients with stage IV breast cancer without clinically evident disease: correlation of CD34+ selection to clinical outcome.
Topics: Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Separation; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Mitoxantrone; Survival Analysis; Thiotepa; Treatment Outcome | 2000 |
Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Tretinoin | 2000 |
Deletion of the multidrug resistance-associated protein (MRP1) gene in acute myeloid leukemia with inversion of chromosome 16 has no prognostic impact.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair 16; Cytarabine; DNA-Binding Proteins; Etoposide; Gene Deletion; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Leukemia, Myeloid; Mitoxantrone; Multidrug Resistance-Associated Proteins; MutS Homolog 3 Protein; Prognosis; Prospective Studies; Recurrence; Remission Induction | 2000 |
In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents; Asparaginase; Bone Marrow Cells; Child; Child, Preschool; Cytarabine; Daunorubicin; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Ifosfamide; Infant; Leukemia, Prolymphocytic; Leukemia, T-Cell; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Statistics, Nonparametric; Teniposide; Thioguanine; Vincristine | 2000 |
Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma.
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Purging; Cardiomyopathies; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cyclophosphamide; Cystitis; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hemorrhage; Humans; Infections; Leucovorin; Life Tables; Lymphoma, Non-Hodgkin; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Pilot Projects; Salvage Therapy; Survival Analysis; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine | 2000 |
Chemotherapy and marrow transplantation for congenital leukaemia.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Infant, Newborn; Leukemia; Methotrexate; Mitoxantrone; Prednisolone; Treatment Outcome; Vincristine | 2001 |
[Is it useful to perform a (67)gallium scintigraphy in the follow-up of patients with gastric lymphoma?].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Fatal Outcome; Follow-Up Studies; Gallium Radioisotopes; Gastrectomy; Gastroscopy; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Male; Mesna; Methylprednisolone; Mitoxantrone; Neoplasm Recurrence, Local; Paclitaxel; Prednisone; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy, Adjuvant; Stomach Neoplasms; Stomach Ulcer; Tomography, X-Ray Computed; Vincristine | 2001 |
Action of topoisomerase targeting drugs on non-Hodgkin's lymphoma and leukemia. Correlation of clinical and cell culture studies.
Topics: Acute Disease; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Cytarabine; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Isoenzymes; Leukemia; Leukocytes; Lymphoma, Non-Hodgkin; Mitoxantrone; Polymerase Chain Reaction; RNA, Messenger; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan | 2000 |
Herbimycin A enhances apoptotic effect of chemotherapeutic drugs on K562 cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Etoposide; HL-60 Cells; Humans; K562 Cells; Lactams, Macrocyclic; Mitoxantrone; Protein-Tyrosine Kinases; Quinones; Rifabutin; Teniposide | 1998 |
Atp-bound topoisomerase ii as a target for antitumor drugs.
Topics: Adenosine Triphosphate; Amino Acid Substitution; Amsacrine; Animals; Antineoplastic Agents; Cattle; DNA Topoisomerases, Type II; Doxorubicin; Etoposide; Kinetics; Mitoxantrone; Mutagenesis, Site-Directed; Recombinant Proteins; Teniposide; Thymus Gland | 2001 |
Neutrophilic eccrine hidradenitis in two neutropaenic patients.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Hidradenitis; Humans; Leukemia, Myeloid; Mitoxantrone | 2001 |
Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Prognosis; Remission Induction; Survival Analysis; Thioguanine; Treatment Outcome; Tumor Cells, Cultured | 2001 |
Detection of human herpesvirus 6 and JC virus in progressive multifocal leukoencephalopathy complicating follicular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brain; Cyclophosphamide; DNA, Viral; Doxorubicin; Etoposide; Fatal Outcome; Female; Herpesviridae Infections; Herpesvirus 6, Human; Humans; Immunity, Cellular; Immunocompromised Host; JC Virus; Leukoencephalopathy, Progressive Multifocal; Lymphoma, Follicular; Magnetic Resonance Imaging; Mitoxantrone; Nitrosourea Compounds; Papillomavirus Infections; Piperazines; Polymerase Chain Reaction; Prednisolone; Recurrence; Salvage Therapy; Vincristine; Vindesine; Virus Activation | 2001 |
Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Arthroplasty, Replacement, Hip; Asparaginase; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Femur Head Necrosis; Humans; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Osteonecrosis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Risk Factors; Treatment Outcome; Vincristine | 2001 |
Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Adhesion; Cell Nucleus; Cell Survival; Comet Assay; DNA Damage; DNA Topoisomerases, Type II; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fibronectins; Humans; Integrin beta1; Mitoxantrone; Receptors, Fibronectin; Topoisomerase II Inhibitors; U937 Cells | 2001 |
University of Washington high-dose cyclophosphamide, mitoxantrone, and etoposide experience in metastatic breast cancer: unexpected cardiac toxicity.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Cyclophosphamide; Etoposide; Female; Heart Diseases; Humans; Medical Audit; Middle Aged; Mitoxantrone; Retraction of Publication as Topic; Scientific Misconduct; South Africa; Washington | 2001 |
Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Topics: Amsacrine; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Carcinoma; Clone Cells; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Induction; Enzyme Inhibitors; Etoposide; Female; Humans; Mitoxantrone; Neoplasm Proteins; Nucleic Acid Synthesis Inhibitors; RNA, Messenger; RNA, Neoplasm; Selection, Genetic; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vincristine | 2001 |
Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
Topics: Amsacrine; Anthracyclines; Antineoplastic Agents; Busulfan; Cell Survival; Child; Child, Preschool; Cytarabine; Down Syndrome; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Thioguanine; Vincristine | 2002 |
FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cohort Studies; Cytarabine; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Lipopolysaccharide Receptors; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplastic Stem Cells; Thioguanine; Treatment Outcome | 2001 |
Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Topics: Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Nucleus; Cell Survival; Comet Assay; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Etoposide; Fluorescent Antibody Technique; Humans; K562 Cells; Microscopy, Confocal; Mitoxantrone; Topotecan | 2002 |
Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Base Sequence; Cell Division; Cell Survival; Cell-Free System; Cisplatin; Daunorubicin; Drug Resistance, Neoplasm; Etoposide; Flow Cytometry; Humans; Mitoxantrone; Molecular Sequence Data; Neoplasm Proteins; Peptides; Phenotype; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; RNA, Catalytic; RNA, Messenger; Stomach Neoplasms; Time Factors; Transfection; Tumor Cells, Cultured | 2002 |
Conjunctival chloroma (granulocytic sarcoma).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Conjunctival Neoplasms; Etoposide; Humans; Leukemia, Myeloid; Male; Mitoxantrone; Sarcoma, Myeloid | 2002 |
Overexpression of the atypical protein kinase C zeta reduces topoisomerase II catalytic activity, cleavable complexes formation, and drug-induced cytotoxicity in monocytic U937 leukemia cells.
Topics: Antineoplastic Agents; Cell Survival; DNA Topoisomerases, Type II; DNA, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Kinetics; Mitochondria; Mitoxantrone; Neoplasm Proteins; Protein Kinase C; Recombinant Proteins; Topoisomerase II Inhibitors; U937 Cells | 2002 |
Lactic acid based PEU/HA and PEU/BCP composites: Dynamic mechanical characterization of hydrolysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Substitutes; Cisplatin; Composite Resins; Etoposide; Gamma Rays; Hydrolysis; Lactic Acid; Materials Testing; Mechanics; Mitoxantrone; Polyesters; Polyurethanes; Sodium Chloride; Sterilization; Tamoxifen | 2002 |
CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia treated with idarubicin and cytosine arabinoside.
Topics: Acute Disease; Aged; Antigens, CD; Antigens, CD7; Antigens, Differentiation, Myelomonocytic; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; CD56 Antigen; Cytarabine; Daunorubicin; Diagnosis, Differential; Etoposide; Fatal Outcome; Humans; Idarubicin; Killer Cells, Natural; Leukemia, Myeloid; Leukemic Infiltration; Lymphoma, Non-Hodgkin; Male; Mercaptopurine; Mitoxantrone; Myeloid Cells; Neoplastic Stem Cells; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sarcoma, Myeloid; Sialic Acid Binding Ig-like Lectin 3 | 2002 |
Acute myocardial infarction as the presenting symptom of acute myeloblastic leukemia with extreme hyperleukocytosis.
Topics: Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Confusion; Cytarabine; Etoposide; Fatal Outcome; Female; Gemtuzumab; Humans; Idarubicin; Immunotherapy; Leukapheresis; Leukemia, Myeloid, Acute; Leukocytosis; Middle Aged; Mitoxantrone; Myocardial Infarction; Recurrence; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Therapeutics; Vidarabine | 2002 |
A relapsed non-Hodgkin lymphoma presenting as panhypopituitarism successfully treated by chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Etoposide; Female; Humans; Hypopituitarism; Lymphoma, Non-Hodgkin; Magnetic Resonance Imaging; Mitoxantrone; Neoplasm Recurrence, Local; Prednisone; Treatment Outcome; Vincristine | 2002 |
Blast crisis of chronic myeloid leukemia: diagnosis prompted by T(8;9).
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Child, Preschool; Chromosomes, Human, Pair 8; Chromosomes, Human, Pair 9; Combined Modality Therapy; Cytarabine; Daunorubicin; Ethmoid Sinus; Etoposide; Fusion Proteins, bcr-abl; Humans; Karyotyping; Leukemia, Myeloid, Accelerated Phase; Male; Meninges; Mitoxantrone; Remission Induction; Sacrococcygeal Region; Sarcoma, Myeloid; Thioguanine; Translocation, Genetic | 2002 |
Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
Topics: Adult; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Betamethasone; Biomarkers, Tumor; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Humans; Imatinib Mesylate; Immunosuppressive Agents; Mitoxantrone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Homologous; Vincristine | 2002 |
Waldenstrom's macroglobulinemia: is there a place and time for a cease-fire?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Case Management; Chlorambucil; Cladribine; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Immunoglobulin M; Male; Middle Aged; Mitoxantrone; Plasmapheresis; Prednisone; Rituximab; Severity of Illness Index; Thalidomide; Vidarabine; Vinblastine; Vincristine; Vinorelbine; Waldenstrom Macroglobulinemia | 2003 |
The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells.
Topics: Animals; Antineoplastic Agents; BRCA1 Protein; Busulfan; Camptothecin; Cell Division; Cell Line; Doxorubicin; Etoposide; Fibroblasts; Gene Deletion; Genes, BRCA1; Mice; Mitoxantrone; Topotecan; Tumor Suppressor Protein p53 | 2003 |
Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Palliative Care; Remission Induction; Risk Factors; Survival Rate; Time Factors; Treatment Outcome | 2003 |
High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Prognosis; Transplantation, Autologous; Treatment Outcome | 2003 |
[The fairies in A la Recherche du Temps Perdu; introduction the Proustian myths].
Topics: Etoposide; Famous Persons; History, 19th Century; History, 20th Century; Mitoxantrone; Psychoanalysis; Psychotherapy | 1952 |
An evaluation of the Maes leg amputation.
Topics: Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Gangrene; Leg; Mitoxantrone | 1953 |
[On the influence of quinine, papaverine and temper ature reduction on the mechanical and electrical activity of the isolated rat uterus].
Topics: Animals; Etoposide; Female; Humans; Mitoxantrone; Nervous System Physiological Phenomena; Papaverine; Quinine; Rats; Temperature; Uterus | 1959 |
Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Topics: Amsacrine; Animals; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Etoposide; Fibroblasts; Fluorescein-5-isothiocyanate; Fluorescent Antibody Technique; Fluorescent Dyes; Half-Life; Isoenzymes; Kinetics; Mice; Mitoxantrone | 2004 |
Rituximab in heavily pretreated cutaneous B-cell lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Leucovorin; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Mitoxantrone; Orchiectomy; Prednisone; Recurrence; Remission Induction; Rituximab; Skin Neoplasms; Testis; Vincristine | 2003 |
Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bacteria; Child; Child, Preschool; Clinical Trials as Topic; Cytarabine; Down Syndrome; Etoposide; Female; Fever; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Mitoxantrone; Neutropenia; Prospective Studies; Retrospective Studies; Thioguanine | 2004 |
VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study.
Topics: Age Distribution; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Comorbidity; Cyclophosphamide; Etoposide; Female; Hodgkin Disease; Humans; Italy; Male; Mitoxantrone; Procarbazine; Prognosis; Prospective Studies; Vinblastine | 2004 |
MLL/AF-1p fusion in therapy-related early pre-B acute lymphoblastic leukemia with t(1;11)(p32;q23) translocation developing in the relapse phase of acute promyelocytic leukemia.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 11; Cytarabine; Daunorubicin; Enzyme Inhibitors; Etoposide; Fatal Outcome; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Mitoxantrone; Myeloid-Lymphoid Leukemia Protein; Neoplasm Proteins; Neoplasms, Second Primary; Oncogene Proteins, Fusion; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Topoisomerase II Inhibitors; Translocation, Genetic; Tretinoin | 2003 |
[The fairies in A la Recherche du Temps Perdu; introduction to the Proustian myths].
Topics: Cisplatin; Etoposide; History, 19th Century; History, 20th Century; Mitoxantrone; Psychoanalysis; Psychotherapy | 1952 |
Successful treatment of disseminated nasal T-cell lymphoma using high-dose chemotherapy and autologus peripheral blood stem cell transplantation: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Follow-Up Studies; Humans; Lymphoma, T-Cell; Male; Mitoxantrone; Nasal Cavity; Nose Neoplasms; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Salvage Therapy; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome; Vincristine | 2004 |
The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blotting, Western; Cell Line, Tumor; Cell Nucleus; Comet Assay; Cytoplasm; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Etoposide; Fatty Acids, Unsaturated; Flow Cytometry; HL-60 Cells; Humans; Microscopy, Fluorescence; Mitoxantrone; Multiple Myeloma; Plasmacytoma; Protein Transport; Subcellular Fractions | 2004 |
[Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Lineage; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Remission Induction | 2004 |
[Bad temper of the surgeon].
Topics: Cisplatin; Etoposide; General Surgery; Humans; Mitoxantrone; Physicians; Surgeons | 1952 |
Topoisomerase II inhibitors, irrespective of their chemical composition, ameliorate experimental arthritis.
Topics: Animals; Antibody Formation; Arthritis, Experimental; Arthritis, Rheumatoid; Collagen Type II; Dose-Response Relationship, Drug; Down-Regulation; Etoposide; Immunization; Immunosuppressive Agents; Interleukin-6; Male; Mice; Mice, Inbred DBA; Mitoxantrone; Nucleic Acid Synthesis Inhibitors; Topoisomerase II Inhibitors | 2005 |
Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Chi-Square Distribution; Child; Child, Preschool; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Incidence; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Logistic Models; Male; Mitoxantrone; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Survival Rate | 2004 |
Acute myeloid leukemia in the elderly: etoposide when anthracyclins are contraindicated.
Topics: Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Contraindications; Cytarabine; Daunorubicin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Retrospective Studies; Survival Analysis | 2005 |
Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Mitoxantrone; Survival Rate; Vincristine | 2005 |
DNA topoisomerase II in therapy-related acute promyelocytic leukemia.
Topics: Antineoplastic Agents; DNA Damage; DNA Repair; DNA Topoisomerases, Type II; DNA, Neoplasm; Doxorubicin; Etoposide; Humans; In Vitro Techniques; Leukemia, Promyelocytic, Acute; Mitoxantrone; Neoplasms, Second Primary; Polymerase Chain Reaction; Sequence Analysis, DNA; Topoisomerase II Inhibitors; Translocation, Genetic | 2005 |
Use of MLL/GRAF fusion mRNA for measurement of minimal residual disease during chemotherapy in an infant with acute monoblastic leukemia (AML-M5).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; DNA-Binding Proteins; Etoposide; GTPase-Activating Proteins; Histone-Lysine N-Methyltransferase; Humans; Idarubicin; In Situ Hybridization, Fluorescence; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Myeloid-Lymphoid Leukemia Protein; Neoplasm, Residual; Oncogene Proteins, Fusion; Proto-Oncogenes; RNA, Messenger; Transcription Factors | 2005 |
Knee arthritis as a rare inaugural manifestation of adult leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arthritis; Cytarabine; Diagnosis, Differential; Dose-Response Relationship, Drug; Etoposide; Humans; Knee Joint; Leukemia; Magnetic Resonance Imaging; Male; Mitoxantrone; Radiography; Remission Induction; Treatment Outcome | 2005 |
Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2005 |
Granulocytic sarcoma of the heart: extramedullary relapse of acute myeloblastic leukemia after allogeneic stem cell transplantation successfully treated by chemotherapy alone.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Heart Neoplasms; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Remission Induction; Sarcoma, Myeloid; Transplantation, Homologous | 2005 |
Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators.
Topics: Antineoplastic Agents; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Estrogen Receptor beta; Etoposide; Female; Humans; Mitoxantrone; Ovarian Neoplasms; Pyrrolidines; RNA Splicing; RNA Splicing Factors; RNA-Binding Proteins; RNA, Catalytic; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes; Transfection | 2005 |
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Benzoquinones; Chromosome Aberrations; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Prognosis; Proportional Hazards Models; Prospective Studies; Remission Induction; Statistics, Nonparametric; Survival Analysis | 2005 |
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Epirubicin; Etoposide; Female; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mitoxantrone; Multiple Myeloma; Odds Ratio; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Recurrence; Remission Induction; Salvage Therapy; Time Factors; Transplantation Conditioning; Treatment Outcome | 2005 |
Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.
Topics: Acute Disease; Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Oligospermia; Sperm Motility; Spermatozoa | 2005 |
The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 9; Cohort Studies; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Myeloid-Lymphoid Leukemia Protein; Neoplasm, Residual; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Polymerase Chain Reaction; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Survival Analysis; Translocation, Genetic; Treatment Outcome; Tretinoin | 2005 |
Digitoxin, at concentrations commonly found in the plasma of cardiac patients, antagonizes etoposide and idarubicin activity in K562 leukemia cells.
Topics: Amsacrine; Antineoplastic Agents; Digitoxin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Etoposide; Humans; Idarubicin; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitoxantrone; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2006 |
Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.
Topics: Acute Disease; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Cytarabine; Daunorubicin; Developing Countries; Disease-Free Survival; Drug Evaluation; Etoposide; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Infant; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Prednisone; Remission Induction; Retrospective Studies; Singapore; Survival Analysis; Thioguanine; Treatment Outcome; Vincristine | 2007 |
[Development of acute type, CD 8 positive adult T-cell leukemia in a carrier of hepatitis B virus--possible therapeutic effect of lamivudine combined with chemotherapy].
Topics: Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carrier State; CD8-Positive T-Lymphocytes; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Hepatitis B; HTLV-I Antibodies; Humans; Irinotecan; Lamivudine; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Mitoxantrone; Nitrosourea Compounds; Pentostatin; Prednisone; Vincristine | 2006 |
[A case of secondary malignant lymphoma of the urinary bladder].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Mesna; Middle Aged; Mitoxantrone; Prednisone; Urinary Bladder Neoplasms; Vincristine | 2006 |
Successful management of cerebral and pulmonary mucormycosis with liposomal amphotericin B in a 28-year-old woman with acute lymphoblastic leukemia.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation; Brain Abscess; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Cytomegalovirus Infections; Daunorubicin; Dexamethasone; Etoposide; Fatal Outcome; Female; Humans; Immunocompromised Host; Liposomes; Lung Diseases, Fungal; Mercaptopurine; Mitoxantrone; Mucormycosis; Pneumonia, Viral; Postoperative Complications; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Transplantation, Homologous; Vincristine | 2006 |
Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Topics: Adenosine Triphosphate; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Beryllium; Cell Line, Tumor; Chlorophyll; Curcumin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Fluoresceins; Fluorescent Dyes; Fluorides; Humans; Mitoxantrone; Molecular Structure; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Organic Anion Transporters; Rhodamine 123; Vinblastine | 2007 |
Acute myelogenous leukemia associated with Ollier disease.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 21; Cytarabine; Daunorubicin; Enchondromatosis; Etoposide; Gemtuzumab; Graft vs Host Disease; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neoplastic Syndromes, Hereditary; Translocation, Genetic | 2008 |
Long-term follow-up of autologous peripheral blood stem cell transplantation in the treatment of a patient with acute panmyelosis with myelofibrosis.
Topics: Acute Disease; Anemia, Refractory; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Erythropoietin; Etoposide; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Male; Methotrexate; Middle Aged; Mitoxantrone; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Primary Myelofibrosis; Recombinant Proteins; Transplantation Conditioning; Transplantation, Autologous; Whole-Body Irradiation | 2006 |
Induction of ATM activation, histone H2AX phosphorylation and apoptosis by etoposide: relation to cell cycle phase.
Topics: Acetylcysteine; Anthraquinones; Antineoplastic Agents, Phytogenic; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Cycle Proteins; Cell Line; DNA Damage; DNA Replication; DNA-Binding Proteins; Etoposide; Flow Cytometry; Free Radical Scavengers; G1 Phase; Histones; Humans; Immunohistochemistry; Mitoxantrone; Phosphorylation; Protein Serine-Threonine Kinases; Reactive Oxygen Species; Tumor Suppressor Proteins | 2007 |
Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Cytarabine; Doxorubicin; Etoposide; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia; Methotrexate; Mitoxantrone; Mutation; Protein Kinase C; Staurosporine | 2007 |
Requirement of Apaf-1 for mitochondrial events and the cleavage or activation of all procaspases during genotoxic stress-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptotic Protease-Activating Factor 1; Caspase 2; Caspase 9; Cells, Cultured; DNA Damage; Enzyme Activation; Etoposide; Fibroblasts; Humans; Jurkat Cells; Membrane Potentials; Mice; Mice, Knockout; Mitochondria; Mitoxantrone; RNA Interference | 2007 |
The effect of short-term intensive chemotherapy on reactivation of tuberculosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Mesna; Methylprednisolone; Middle Aged; Mitoxantrone; Mycobacterium tuberculosis; Prednisone; Retrospective Studies; Tuberculosis; Vincristine; Virus Activation | 2007 |
Paraneoplastic Sweet's syndrome and the pathergy phenomenon.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Diagnosis, Differential; Drug Eruptions; Etoposide; Female; Humans; Inflammation; Leukemia, Monocytic, Acute; Middle Aged; Mitoxantrone; Neutropenia; Paraneoplastic Syndromes; Sweet Syndrome | 2007 |
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Marrow Examination; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Flow Cytometry; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Organ Specificity; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Treatment Outcome | 2007 |
Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Camptothecin; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Etoposide; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Interferon-gamma; Irinotecan; Mitoxantrone | 2007 |
Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italian
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Feasibility Studies; Female; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Mitoxantrone; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Rituximab; Transplantation, Autologous; Treatment Outcome | 2007 |
Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs.
Topics: Amsacrine; Animals; Antineoplastic Agents; Cell Line, Tumor; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Ellipticines; Etoposide; Humans; Immunoblotting; Mice; Microscopy, Confocal; Mitoxantrone; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Proto-Oncogene Proteins c-mdm2; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) therapy.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lymphoma, Large-Cell, Anaplastic; Male; Mitoxantrone; Neoplasm Recurrence, Local; Prednisone; Skin Neoplasms; Treatment Outcome; Vincristine | 2007 |
[A case of recurrent renal cell carcinoma which recurred after fourth surgical resection and survived for about 2 years by medroxyporgesterone acetate administration].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Etoposide; Humans; Interferon-alpha; Interferon-gamma; Male; Medroxyprogesterone Acetate; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nephrectomy; Thiotepa | 2007 |
[A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Evidence-Based Medicine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Prednisolone; Prednisone; Quality of Life; Retrospective Studies; Survival Rate; Vincristine | 2007 |
Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Astrocytoma; Carmustine; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Drug Synergism; Etoposide; Glioblastoma; Humans; Mitoxantrone; Valproic Acid | 2007 |
Genotoxic stress-induced expression of p53 and apoptosis in leukemic clam hemocytes with cytoplasmically sequestered p53.
Topics: Amino Acid Sequence; Animals; Apoptosis; DNA Damage; Etoposide; Fatty Acids, Unsaturated; Hemocytes; Humans; Leukemia; Mitoxantrone; Molecular Sequence Data; Mya; Topoisomerase II Inhibitors; Tumor Suppressor Protein p53 | 2008 |
Assessment of DNA double-strand breaks and gammaH2AX induced by the topoisomerase II poisons etoposide and mitoxantrone.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Comet Assay; Cricetinae; Cricetulus; DNA Breaks, Double-Stranded; Etoposide; Fibroblasts; Flow Cytometry; Histones; Immunoenzyme Techniques; Lung; Mitoxantrone; Phosphorylation; Topoisomerase II Inhibitors | 2008 |
Comment on: 'Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome'.
Topics: Administration, Oral; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Mitoxantrone; Multicenter Studies as Topic; Neoplasm Staging; Neutropenia; Prednisone; Remission Induction; Survival Analysis; Thrombocytopenia; Time Factors; Treatment Outcome; Vincristine | 2008 |
Clinical investigations in aggressive non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lymphoma, Non-Hodgkin; Mitoxantrone; Prednisolone; Prednisone; Rituximab; Vincristine | 2008 |
Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Kallikreins; Male; Mitoxantrone; Necrosis; Prostatic Neoplasms; RNA, Messenger; Serine Endopeptidases; Time Factors | 2009 |
Future research directions for the treatment of AML.
Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin | 2008 |
Successfully conservative treatment of large cervical choriocarcinoma with profuse vaginal bleeding.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cytarabine; Diagnosis, Differential; Embolization, Therapeutic; Etoposide; Female; Humans; Mitoxantrone; Pregnancy; Pregnancy Complications, Neoplastic; Ultrasonography, Doppler, Color; Uterine Neoplasms | 2009 |
Additional chromosomal abnormalities and their prognostic significance in adult Philadelphia-positive acute lymphoblastic leukemia: with or without imatinib in chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Chromosome Aberrations; Cyclophosphamide; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Mercaptopurine; Methotrexate; Middle Aged; Mitoxantrone; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Prognosis; Pyrimidines; Salvage Therapy; Vincristine; Vindesine; Young Adult | 2009 |
Incidence and outcome of patients with diffuse large B cell lymphoma with marrow involvement and preliminary experience of an adult acute lymphoblastic leukemia protocol (NEALL VI) in cyclophosphamide, doxorubicin, vincristine, and prednisolone--rituximab
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Humans; Idarubicin; Ifosfamide; Incidence; Lymphoma, Large B-Cell, Diffuse; Male; Methotrexate; Middle Aged; Mitoxantrone; Prednisolone; Prognosis; Registries; Retrospective Studies; Rituximab; Salvage Therapy; Survival Analysis; Treatment Outcome; Vincristine | 2009 |
Chemotherapy induces ATP release from tumor cells.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; Cadmium; Cell Line, Tumor; Cisplatin; Etoposide; Flow Cytometry; Fluorescent Antibody Technique; Mice; Mitomycin; Mitoxantrone; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Sphingosine; Thapsigargin | 2009 |
The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Gemtuzumab; HL-60 Cells; Humans; Idarubicin; Immunotoxins; Leukemia; Mercaptopurine; Methotrexate; Mitoxantrone; Sialic Acid Binding Ig-like Lectin 3; U937 Cells; Vincristine | 2009 |
Intrathecal chemotherapy and meningeal relapses in myelomonocytic AML. A single institution experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Injections, Spinal; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukemic Infiltration; Male; Meninges; Middle Aged; Mitoxantrone; Testis; Young Adult | 2010 |
Schedule treatment design and quantitative in vitro evaluation of chemotherapeutic combinations for metastatic prostate cancer therapy.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Antagonism; Drug Synergism; Drug Therapy, Combination; Etoposide; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Male; Mitoxantrone; Neoplasm Metastasis; Piperazines; Prostatic Neoplasms; Pyrimidines; Vinblastine | 2011 |
A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 schedule.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neutropenia; Polyethylene Glycols; Prognosis; Recombinant Proteins; Remission Induction; Survival Analysis; Treatment Outcome; Young Adult | 2010 |
Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Failure; Young Adult | 2010 |
Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Separation; Cytarabine; Cytosine; Daunorubicin; Etoposide; Female; Flavonoids; Flow Cytometry; Gene Expression Profiling; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Vidarabine; Young Adult | 2011 |
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Fluorodeoxyglucose F18; Humans; Leucovorin; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Mitoxantrone; Monitoring, Physiologic; Neoplasm Invasiveness; Neoplasm Staging; Positron-Emission Tomography; Prednisone; Retrospective Studies; Rituximab; Survival Analysis; Time Factors; Vincristine; Young Adult | 2011 |
Salvaging AML with CLAG: novel option, or more of the same?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Five Chinese pediatric patients with leukemias possibly arising from immature natural killer cells: clinical features and courses.
Topics: Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cytarabine; Etoposide; Female; Humans; Immunophenotyping; Infant; Killer Cells, Natural; Leukemia, Lymphoid; Leukemia, Myeloid; Male; Methotrexate; Mitoxantrone; Remission Induction; Treatment Outcome | 2011 |
Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2011 |
Inhibition of unwinding and ATPase activities of pea MCM6 DNA helicase by actinomycin and nogalamycin.
Topics: Adenosine Triphosphatases; Camptothecin; Cisplatin; Dactinomycin; Daunorubicin; DNA Helicases; Ellipticines; Enzyme Inhibitors; Etoposide; Intercalating Agents; Mitoxantrone; Nogalamycin; Novobiocin; Pisum sativum; Plant Proteins | 2011 |
[Severe skin reaction with mucous membrane inflammation during MINE chemotherapy].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Drug Eruptions; Edema; Etoposide; Female; Glossitis; Hodgkin Disease; Humans; Hyperalgesia; Ifosfamide; Mesna; Mitoxantrone; Mucositis; Panniculitis | 2011 |
Successful treatment of recurrent malignancy-associated hemophagocytic lymphohistiocytosis with a modified HLH-94 immunochemotherapy and allogeneic stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Dexamethasone; Drug Therapy, Combination; Etoposide; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Lymphohistiocytosis, Hemophagocytic; Lymphoma, Large-Cell, Anaplastic; Mitoxantrone; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Stem Cell Transplantation; Transplantation, Homologous; Young Adult | 2012 |
In vitro synergism between LFA-1 targeting leukotoxin (Leukothera™) and standard chemotherapeutic agents in leukemia cells.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Busulfan; Cell Line, Tumor; Daunorubicin; Drug Interactions; Drug Synergism; Etoposide; Exotoxins; Flow Cytometry; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia; Leukocytes; Lymphocyte Function-Associated Antigen-1; Membrane Potential, Mitochondrial; Mitoxantrone; Piperazines; Pyrimidines; Tumor Cells, Cultured | 2011 |
The result of adjuvant chemotherapy for localized pT3 upper urinary tract carcinoma in a multi-institutional study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cytarabine; Databases, Factual; Doxorubicin; Etoposide; Female; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Mitoxantrone; Multivariate Analysis; Nephrectomy; Prognosis; Proportional Hazards Models; Retrospective Studies; Ureteral Neoplasms; Vinblastine | 2012 |
Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin/topotecan, mitoxantrone, or etoposide.
Topics: Camptothecin; Cell Line, Tumor; DNA Damage; DNA Replication; Etoposide; Histones; Humans; Mitoxantrone; Phosphorylation; Signal Transduction; Topoisomerase Inhibitors; Topotecan | 2012 |
Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetics; Etoposide; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult | 2012 |
Novel cytotoxic isolated from Jamaican Hyptis verticillata jacq induces apoptosis and overcomes multidrug resistance.
Topics: Antineoplastic Agents; Apoptosis; Cytotoxins; Dioxolanes; DNA Damage; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Human T-lymphotropic virus 1; Humans; Hyptis; Leukemia, T-Cell; Lignans; Mitoxantrone; Plant Extracts; Poly(ADP-ribose) Polymerases; Topoisomerase Inhibitors | 2011 |
Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemia.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Etoposide; Feasibility Studies; Female; Humans; Infections; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neutropenia; Outpatients; Patient Readmission | 2012 |
Phospho-specific flow: fixating on the target.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Ribosomal Protein S6; Sirolimus; TOR Serine-Threonine Kinases | 2012 |
Refractory disseminated fusariosis by Fusarium verticillioides in a patient with acute myeloid leukaemia relapsed after allogeneic hematopoietic stem cell transplantation: a case report and literature review.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Drug Resistance, Multiple, Fungal; Etoposide; Fatal Outcome; Female; Fusariosis; Fusarium; Humans; Immunocompromised Host; Itraconazole; Leukemia, Myeloid, Acute; Mitoxantrone; Neutropenia; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Premedication; Pyrimidines; Recurrence; Salvage Therapy; Transplantation, Homologous; Triazoles; Voriconazole | 2013 |
Outcome of children with refractory anaemia with excess of blast (RAEB) and RAEB in transformation (RAEB-T) in the Japanese MDS99 study.
Topics: Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Child; Cytarabine; Etoposide; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Mitoxantrone; Remission Induction; Treatment Outcome | 2012 |
Probable cytarabine-induced acral erythema: report of 2 pediatric cases.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Etoposide; Female; Hand-Foot Syndrome; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis | 2013 |
Do transcription factories and TOP2B provide a recipe for chromosome translocations in therapy-related leukemia?
Topics: Anthracyclines; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type II; DNA-Binding Proteins; Epirubicin; Etoposide; Humans; Leukemia; Mitoxantrone; Models, Genetic; Neoplasms, Second Primary; Poly-ADP-Ribose Binding Proteins; Translocation, Genetic | 2012 |
JAK2 V617F-mutated myeloproliferative neoplasia developing five years after wild-type JAK2 acute myeloid leukemia: a case report.
Topics: Alleles; Antineoplastic Agents; Bone Marrow Neoplasms; Drug Therapy, Combination; Etoposide; Humans; Janus Kinase 2; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Mutation; Myeloproliferative Disorders; Pancreatic Neoplasms | 2013 |
Outcome of poor response paediatric AML using early SCT.
Topics: Adolescent; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Early Medical Intervention; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Idarubicin; Induction Chemotherapy; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Myeloablative Agonists; Thioguanine; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2013 |
Outcomes of elderly de novo acute myeloid leukemia treated by a risk-adapted approach based on age, comorbidity, and performance status.
Topics: Aged; Aged, 80 and over; Allografts; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Comorbidity; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Etoposide; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Risk; Severity of Illness Index; Treatment Outcome | 2013 |
Analysis of allele-specific expression in mouse liver by RNA-Seq: a comparison with Cis-eQTL identified using genetic linkage.
Topics: Alleles; Animals; Antineoplastic Combined Chemotherapy Protocols; Crosses, Genetic; Cyclophosphamide; Etoposide; Female; Gene Expression; Genetic Linkage; Genomic Imprinting; Liver; Male; Mice; Mice, Inbred C57BL; Mitoxantrone; Multigene Family; Polymorphism, Single Nucleotide; Prednisone; Quantitative Trait Loci; Sequence Analysis, RNA | 2013 |
Factors affecting survival in patients aged 60 and over with diffuse large B cell lymphoma failing first-line therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cause of Death; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Prednisolone; Prednisone; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Failure; Vincristine | 2013 |
Characteristics and clinical evolution of patients with acute myeloblastic leukemia in northeast Mexico: an eight-year experience at a university hospital.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Component Transfusion; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hospitals, University; Humans; Infant; Infusions, Intravenous; Injections, Spinal; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Methotrexate; Mexico; Middle Aged; Mitoxantrone; Proportional Hazards Models; Retrospective Studies; Risk Factors; Treatment Outcome; Young Adult | 2014 |
Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Child; Child, Preschool; Cytarabine; Etoposide; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2014 |
Clinical efficacy of mitoxantrone and Ara-C with or without etoposide salvage chemotherapy in adult patients with relapsed or refractory acute lymphoblastic leukemia: retrospective multicenter study of the Korean Adult ALL Working Party.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult | 2015 |
Acute promyelocytic leukemia in patients aged >70 years: the cure beyond the age.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Follow-Up Studies; Humans; Idarubicin; Interferon-alpha; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Mitoxantrone; Remission Induction; Survival Analysis; Time Factors; Treatment Outcome; Tretinoin | 2015 |
Modeling non-syndromic autism and the impact of TRPC6 disruption in human neurons.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autistic Disorder; Carboplatin; Cell Differentiation; Cell Line; Cell Proliferation; Cells, Cultured; Child; Disease Models, Animal; Embryo, Mammalian; Etoposide; Gene Expression Regulation; Humans; In Vitro Techniques; Induced Pluripotent Stem Cells; Inhibitory Postsynaptic Potentials; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mitoxantrone; Mutation; Neurons; Prednisolone; Signal Transduction; TRPC Cation Channels; TRPC6 Cation Channel | 2015 |
Impact of Delayed Analysis in Avian Blood Biochemical Values Measured With the Abaxis VetScan VS2.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Chemical Analysis; Blood Specimen Collection; Cisplatin; Etoposide; Mitoxantrone; Point-of-Care Systems; Psittaciformes; Tamoxifen; Time Factors | 2015 |
Consolidation therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing second-line treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Consolidation Chemotherapy; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mitoxantrone; Recurrence; Retrospective Studies; Rituximab; Stem Cell Transplantation; Treatment Outcome | 2016 |
Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chromosome Aberrations; Cytarabine; Drug Monitoring; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Retreatment; Staurosporine; Treatment Outcome; Young Adult | 2016 |
Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II.
Topics: Antigens, Neoplasm; Bortezomib; Cell Line, Tumor; Cell Proliferation; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Humans; Leupeptins; Mitoxantrone; Poly-ADP-Ribose Binding Proteins; Proteasome Inhibitors; Topoisomerase II Inhibitors | 2016 |
Dose-reduced combination of mitoxantrone, etoposide, and cytarabine (miniMEC) for relapsed and refractory acute leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retreatment; Treatment Outcome; Young Adult | 2016 |
A Successfully Treated Metastatic Choriocarcinoma Coexistent With Pregnancy: A Case Report of a 4-Year Follow-Up.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cesarean Section; Choriocarcinoma; Cyclophosphamide; Cytarabine; Etoposide; Female; Humans; Mitoxantrone; Neoplasm Metastasis; Pregnancy; Pregnancy Complications, Neoplastic; Uterine Neoplasms; Vincristine | 2016 |
Mitoxantrone and Etoposide for the Treatment of Acute Myeloid Leukemia Patients in First Relapse.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytogenetic Analysis; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Recurrence; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Low level phosphorylation of histone H2AX on serine 139 (γH2AX) is not associated with DNA double-strand breaks.
Topics: A549 Cells; Camptothecin; DNA Breaks, Double-Stranded; DNA Damage; Etoposide; Histones; Humans; Microscopy, Confocal; Mitoxantrone; Phosphorylation; Serine; Tumor Suppressor p53-Binding Protein 1 | 2016 |
Myeloperoxidase Enhances Etoposide and Mitoxantrone-Mediated DNA Damage: A Target for Myeloprotection in Cancer Chemotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Cytoprotection; DNA; DNA Damage; DNA Topoisomerases, Type II; DNA-Binding Proteins; Enzyme Inhibitors; Etoposide; Glutathione; Histones; Humans; Mitoxantrone; Myeloid Cells; Neoplasms; Peroxidase; Phosphorylation; Poly-ADP-Ribose Binding Proteins; Small Molecule Libraries | 2017 |
Nonfunctioning Adrenocortical Carcinoma in Pediatric Acute Lymphoblastic Leukemia: A Case Report of a Rare Multiple Primaries Combination.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Doxorubicin; Etoposide; Fatal Outcome; Humans; Language Development Disorders; Lung Neoplasms; Mercaptopurine; Methotrexate; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Nephrectomy; Pneumonectomy; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2017 |
Outcome of relapsed core binding factor acute myeloid leukemia in children: A result from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) AML-05R study.
Topics: Adolescent; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Core Binding Factors; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Japan; Leukemia, Myeloid, Acute; Mitoxantrone; Proto-Oncogene Proteins c-kit; Recurrence; Retrospective Studies; Surveys and Questionnaires; Treatment Outcome; Vidarabine | 2017 |
Durable response after VNCOP-B and rituximab in an elderly patient with high-grade B-cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Etoposide; Humans; Lymphoma, B-Cell; Male; Mitoxantrone; Prednisone; Rituximab; Urinary Bladder; Urinary Bladder Neoplasms; Vincristine | 2018 |
Opposite Effects of the Spinach Food Matrix on Lutein Bioaccessibility and Intestinal Uptake Lead to Unchanged Bioavailability Compared to Pure Lutein.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Caco-2 Cells; Carotenoids; Cooking; Cyclophosphamide; Etoposide; Humans; Intestinal Absorption; Lutein; Male; Mitoxantrone; Postprandial Period; Prednisone; Spinacia oleracea; Swine; Swine, Miniature | 2018 |
Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cohort Studies; Cytarabine; Daunorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Longitudinal Studies; Male; Middle Aged; Mitoxantrone; Mutation; Neoplasm Proteins; Neoplasm, Residual; Nuclear Proteins; Nucleophosmin; Recurrence; Salvage Therapy; Survival Rate | 2019 |
Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.
Topics: Anthracyclines; Cardiotoxicity; Cell Line, Tumor; Cell Survival; DNA Adducts; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Humans; Induced Pluripotent Stem Cells; K562 Cells; Mitoxantrone; Myocytes, Cardiac; Topoisomerase II Inhibitors | 2019 |
The first-line therapy for low-risk gestational trophoblastic neoplasia: Does single agent or multi-agent work?
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Gestational Trophoblastic Disease; Humans; Mitoxantrone; Prednimustine; Pregnancy | 2019 |
The use of VMP regimen as the first line chemotherapy for low-risk gestational trophoblastic neoplasia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Gestational Trophoblastic Disease; Humans; Mitoxantrone; Prednimustine; Pregnancy | 2019 |
Novel deazaflavin tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Flavins; Humans; Mitoxantrone; Molecular Docking Simulation; Molecular Structure; Mutation; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases | 2020 |
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Management; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Mitoxantrone; Preoperative Care; Prognosis; Recurrence; Treatment Outcome | 2020 |
Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carcinoma, Hepatocellular; Etoposide; Female; Germany; Humans; Ifosfamide; Kaplan-Meier Estimate; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Predictive Value of Tests; Prognosis; Retrospective Studies; Risk Assessment; ROC Curve; Tomography, X-Ray Computed; Young Adult | 2020 |
A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence; Young Adult | 2020 |
EMA vs EMACO in the treatment of gestational trophoblastic neoplasia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dactinomycin; Doxorubicin; Etoposide; Female; Gestational Trophoblastic Disease; Humans; Leucovorin; Methotrexate; Mitoxantrone; Multivariate Analysis; Neoplasm Staging; Pregnancy; Retrospective Studies; Vincristine | 2020 |
Secondary chronic myeloid leukemia following acute myeloid leukemia treated with autologous hematopoietic stem cell transplantation: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Pyrimidines; Remission Induction; Transplantation, Autologous | 2020 |
Coacervation in Cationic Polyelectrolyte Solutions with Anionic Amino Acid Surfactants.
Topics: Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Cations; Cyclophosphamide; Etoposide; Hair Preparations; Hydrophobic and Hydrophilic Interactions; Mitoxantrone; Polyelectrolytes; Prednisone; Solutions; Static Electricity; Surface Properties; Surface Tension; Surface-Active Agents; Water; X-Ray Diffraction | 2020 |
An open protocol for evaluating the accuracy of guided implant surgery by using digital casts.
Topics: Antineoplastic Combined Chemotherapy Protocols; Computer-Aided Design; Dental Implants; Etoposide; Mitoxantrone; Prednisone; Vincristine; Workflow | 2021 |
Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re-induction chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Induction Chemotherapy; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2021 |
Comparison of Mitoxantrone-Melphalan and BEAM Conditioning Regimens in Patients with Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Mitoxantrone; Transplantation Conditioning; Transplantation, Autologous | 2022 |
Pre-conditioning intervention in patients with relapsed or refractory acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter retrospective analysis.
Topics: Adolescent; Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Transplantation Conditioning; Vincristine; Young Adult | 2021 |
Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus rituximab. Comparison between Deauville 5-point scale and International Harmonization Project criteria.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Etoposide; Fluorodeoxyglucose F18; Humans; Lymphoma, Large B-Cell, Diffuse; Mitoxantrone; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prednisolone; Prognosis; Retrospective Studies; Rituximab; Vincristine | 2021 |
Optimal Minimum Velocity Threshold to Estimate the 1-Repetition Maximum: The Case of the Smith Machine Bench Press Exercise.
Topics: Etoposide; Exercise; Humans; Male; Mitoxantrone; Muscle Strength; Resistance Training; Thiotepa; Weight Lifting | 2023 |